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Abstract
Policies and public health interventions are expected to be evidence-based, 
meaning that they must rely on adequate available data supporting their need 
and cost-effectiveness. Therefore, along with the population data necessary 
for decision making, scientific research must be directed at understanding the 
causes of disease, evaluating prevention, and monitoring the impact of interven-
tions to control them.
Coronary heart disease (CHD) mortality has been decreasing in Portugal since 
the 1980s, like in most developed countries. However, the reasons for this decline 
are not clear and authors diverge about the main causes for this decline in other 
countries. Therefore, we aimed to contribute to a better understanding of the 
epidemiology of CHD in Portugal, in the last few decades. To accomplish this 
objective, six studies were performed following different designs. The next para-
graphs briefly describe the specific objective pursued in each study, as well as 
the methodology adopted and main results.  
1. To describe time trends in mortality rates, absolute number of deaths and 
years of life lost from cardiovascular diseases and cancer (Paper I)
We estimated the annual percent change in age-standardized mortality rates 
from cardiovascular diseases and cancer, in each sex. The specific contribution 
of demographic changes (due to variations in population size and age structure) 
and the variation in the age-independent “risk” of dying from the disease to the 
observed trends in the number of deaths was quantified using the tool RiskDiff. 
Years of life lost were computed using the Global Burden of Disease method.
Among men, the mortality rate from all cardiovascular diseases was more than 
two-fold higher than cancer mortality in 1980. However, three decades later mor-
tality from cancer surpassed cardiovascular diseases. After 2005, the years of 
life lost from cancer were also higher than from cardiovascular diseases. Among 
women, despite the decrease in death rates, cardiovascular diseases remained 
the leading cause of death in 2010 and their absolute burden was higher than that 
of cancers across the whole period, mainly due to more events in older women.
2. To critically summarize the evidence from studies providing data on the dis-
tribution of risk factors in adults, in order to analyze time trends in:
a) Hypertension and blood pressure (Paper II)
b) Diabetes mellitus and fasting blood glucose (Paper III)
A comprehensive systematic review was performed, using Pubmed. Reference 
screening and data extraction were conducted independently by two research-
ers. We extracted age and sex specific estimates from the original studies when-
ever available. Linear regression models with survey year, participants’ age and 
significant interaction terms as independent variables, were used to predict eco-
logical estimates of the outcomes. For hypertension prevalence and mean blood 
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pressure the models were adjusted also for sex, while for diabetes prevalence 
and mean fasting glucose the models were sex-specific.
Between 1990 and 2005, the prevalence of hypertension defined as blood pres-
sure ≥140/90 mmHg and/or drug treatment remained approximately constant in 
young adults and decreased in middle-aged and older adults, whereas the pre-
valence of self-reported hypertension increased 0.4% per year overall. Between 
1975 and 2005, mean systolic and diastolic blood pressures decreased in mid-
dle-aged and older adults, reaching a 32-mmHg decrease in systolic blood pres-
sure among women at average age 70.
Time trends of objectively defined diabetes could not be quantified due to the 
heterogeneity of the diagnostic criteria. Between 1987 and 2009, the prevalence 
of self-reported diabetes remained approximately constant in young adults, while 
it increased in middle-aged and older adults, more than two-fold among women 
and three-fold among men. In the same period, mean fasting glucose increased 
7 mg/dL among women and 8 mg/dL among men.
3. To critically summarize the evidence from studies that provide data on the 
use of pharmacological therapy for secondary prevention, during hospitaliza-
tion and prescribed at hospital discharge, following an acute coronary syn-
drome (ACS), in order to analyze time trends (Paper IV)
We searched PubMed, to identify studies reporting the proportion of ACS 
patients treated with aspirin, clopidogrel, beta-blockers, angiotensin-converting 
enzyme (ACE) inhibitors and statins. We used linear regression to quantify the 
annual variation in use of drugs, adjusting for the proportion of men in the sam-
ple and patients’ mean age, and including a quadratic term of data collection 
year when relevant.
In 25 eligible studies, including patients treated from 1993 to 2009, we observed 
an increase in the prescription of pharmacological treatments at hospital dis-
charge. Extrapolating from these data, and assuming a mean patient age of 65 
years and 70% of men, we estimate that, in 2008, 95% of patients would have 
been discharged with aspirin, 92% with clopidogrel, 82% with beta-blockers, 80% 
with ACE inhibitors and 91% with statins. Treatment during hospitalization fol-
lowed a similar pattern, except for a steeper increase in ACE inhibitors use, which 
was initially lower, but reached similar levels to those at discharge in recent years.
4. To analyze the proportion of patients receiving pharmacological therapy as 
secondary prevention after an ACS admission in a large sample of patients con-
secutively discharged from ten Portuguese hospitals, and to explore potential 
age- and sex-differences (Paper V)
We studied 747 episodes of ST segment elevation myocardial infarction (STEMI) 
and 1364 of non-ST segment elevation ACS (NSTE-ACS), within a sample of ACS 
cases consecutively discharged from ten Portuguese hospitals, in 2008-2009. 
We estimated adjusted odds ratios (OR) for the association of age and sex and 
the use of each pharmacological treatment. 
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In STEMI and NSTE-ACS patients, the proportion of patients discharged with 
aspirin was 96% and 88%, clopidogrel 91% and 78%, aspirin + clopidogrel 88% and 
71%, beta-blockers 80% and 76%, ACE-inhibitors/angiotensin receptor blockers 
(ARBs) 82% and 80%, statins 93% and 90%, 3-drug (aspirin / clopidogrel + beta-
blocker + statin) 76% and 69% and 5-drug treatment (aspirin + clopidogrel + 
beta-blocker + ACE-inhibitor / ARB + statin) 61% and 48%, respectively. Among 
STEMI patients, those aged ≥80 years were substantially less often discharged 
with clopidogrel [odds ratio (OR)=0.22, 95% confidence interval (95%CI): 0.08-
0.56], aspirin + clopidogrel (OR=0.34, 95%CI: 0.15-0.76), beta-blockers (OR=0.39, 
95%CI: 0.18-0.82), 3-drug (OR=0.41, 95%CI: 0.21-0.83) and 5-drug treatments 
(OR=0.44, 95%CI: 0.23-0.83) than those <60 years; women were less likely to 
be discharged with aspirin + clopidogrel (OR=0.52, 95%CI: 0.29-0.91). Among 
NSTE-ACS patients, those aged ≥80 years were much less likely to be discharged 
with beta-blockers (OR=0.58, 95%CI: 0.36-0.93), statins (OR=0.35, 95%CI: 0.19-
0.64) and 3-drug treatment (OR=0.47, 95%CI: 0.30-0.75); sex had no significant 
independent effect on treatment prescription.
5. To model the decline in CHD mortality, quantifying the contribution of 
changes in the use of evidence-based medical and surgical treatments, and in 
major cardiovascular risk factors (Paper VI)
The IMPACT mortality model was used to integrate data on trends in uptake of 
treatments and exposure to risk factors to explain the variation in CHD mortality.
Between 1995 and 2008, CHD mortality rates in Portugal decreased by 29% in 
men and 21% in women aged 25-84 years, corresponding to 3760 fewer deaths 
in 2008 than expected if 1995 mortality rates had persisted. Approximately 
92% of the estimated decrease in number of deaths could be explained by the 
model; the remaining 8% were attributed to changes in unmeasured factors. 
Approximately 50% of the decrease explained by the model was attributable 
to increased uptake of treatments, mainly anti-hypertensive medication (12%) 
and initial treatments after an acute myocardial infarction (10%), and 42% to 
population risk factor reductions, mainly blood pressure (27% in men and 60% 
in women), total cholesterol (14% in men and 5% in women) and smoking in men 
(11%). However, these reductions were partially offset by adverse trends in dia-
betes (18% in men and 2% in women), obesity (6% in men and 5% in women), and 
smoking in women (2%).
This thesis helped to clarify the contribution of primary and secondary CHD pre-
vention to mortality trends in Portugal. The high treatment uptake after disease 
suggests that the quality of health care in CHD secondary prevention is good. 
Healthier lifestyles have the potential to be further implemented, particularly 
since some of the observed decline in main risk factors was due to pharmacolog-
ical treatment. This thesis supports the need for a greater investment in primary 
prevention, mainly through whole population strategies, while it also provides 
objective evidence for the importance of medical treatments, particularly to fight 
against age-related inequalities.
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Resumo
As políticas de saúde e intervenções em saúde pública devem basear-se em evi-
dência adequada das necessidades das populações e do custo-benefício dessas 
medidas. Assim, além da colheita e disponibilização de dados da população, é 
necessária investigação científica dirigida à compreensão das causas de doença, 
avaliação das medidas preventivas, e monitorização do impacto das interven-
ções para a melhoria do estado de saúde.
A mortalidade por doença coronária tem diminuído em Portugal desde os anos 
1980, à semelhança da maioria dos países desenvolvidos. No entanto, as razões 
para este decréscimo não são ainda claras, e diferentes autores têm debatido 
as suas principais causas noutros países. Desde modo, foi nosso objetivo contri-
buir para um melhor conhecimento da epidemiologia da doença coronária em 
Portugal nas últimas décadas. Neste sentido, foram desenhados seis estudos dis-
tintos, cuja metodologia e principais resultados se descrevem abaixo.
1. Descrever tendências temporais na taxa de mortalidade, número de óbitos e 
anos de vida perdidos por doença cardiovascular e cancro (Artigo I)
Estimámos a variação percentual anual da taxa de mortalidade por doença car-
diovascular e cancro padronizada para a idade em cada sexo. A contribuição 
específica das variações demográficas (devidas à variação do tamanho e estru-
tura etária da população) e da variação no “risco” de morte independentemente 
da idade para a tendência temporal no número de óbitos foi quantificada usando 
a ferramenta RiskDiff. O número de anos de vida perdidos foi calculado usando 
o método do estudo Global Burden of Disease.
Nos homens, a taxa de mortalidade por doença cardiovascular foi mais do que 
duas vezes superior à mortalidade por cancro em 1980. No entanto, três décadas 
mais tarde esta tendência inverteu-se. Depois de 2005, o número de anos de vida 
perdidos por cancro foi também superior aos anos de vida perdidos por doença 
cardiovascular. Nas mulheres, apesar da diminuição na taxa de mortalidade, as 
doenças cardiovasculares mantiveram-se como principal causa de morte em 
2010, e a carga absoluta de doença foi superior à de cancro durante todo o 
período do estudo, sobretudo devido ao número de ocorrências em mulheres 
mais velhas.
2. Sumariar de forma crítica a evidência de estudos com dados de distribuição 
de fatores de risco em adultos, para analisar tendências temporais em:
a) Hipertensão e pressão arterial (Artigo II)
b) Diabetes mellitus e glicemia em jejum (Artigo III)
Foi feita uma revisão sistemática na Pubmed. A identificação das referências 
relevantes e a extração dos dados foi realizada por dois investigadores de forma 
independente. Sempre que possível, foram extraídas estimativas específicas 
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por idade e sexo. Foram usados modelos de regressão linear tomando como 
variáveis independentes o ano da colheita de dados, a idade dos participantes 
e termos de interação estatisticamente significativos entre estas variáveis, para 
calcular estimativas ecológicas ajustadas dos níveis médios de pressão arterial e 
glicemia em jejum e da prevalência de hipertensão arterial e diabetes. No caso da 
prevalência de hipertensão e pressão arterial média, os modelos foram ajustados 
para o sexo, enquanto que para a prevalência de diabetes e glicémia em jejum os 
modelos foram estratificados por sexo.
Entre 1990 e 2005, a prevalência de hipertensão definida como pressão arterial 
≥140/90 mmHg e/ou com tratamento farmacológico manteve-se aproximada-
mente constante nos jovens adultos e diminuiu em adultos de meia idade e ido-
sos, enquanto que a prevalência de hipertensão auto-declarada aumentou 0,4% 
por ano. Entre 1975 e 2005, a pressão sistólica e diastólica média diminuíram 
nos adultos de meia idade e idosos, atingindo uma diminuição de 32 mmHg na 
pressão sistólica em mulheres com idade média de 70 anos.
A tendência temporal da diabetes definida com base em medições objetivas 
não foi quantificável devido à heterogeneidade dos critérios de diagnóstico uti-
lizados nos diferentes estudos. Entre 1987 e 2009, a prevalência de diabetes 
auto-declarada manteve-se aproximadamente constante nos jovens adultos, 
aumentando no entanto em adultos de meia idade e idosos, mais de duas vezes 
nas mulheres e três vezes nos homens. No mesmo período, a glicemia em jejum 
média aumentou 7 mg/dL nas mulheres, e 8 mg/dL nos homens.
3. Sumariar de forma crítica a evidência de estudos com dados de utilização 
de terapêutica farmacológica como prevenção secundária, durante a hospitali-
zação e prescrita à data de alta, no seguimento de síndrome coronária aguda, 
para analisar tendências temporais (Artigo IV)
Foi realizada uma pesquisa na PubMed para identificar estudos que reportassem 
a proporção de doentes após síndrome coronária aguda tratados com aspirina, 
clopidogrel, bloqueadores beta e inibidores da enzima de conversão da angio-
tensina (IECAs) e estatinas. Foi utilizada uma regressão linear para quantificar a 
variação anual na utilização de fármacos, ajustando para a proporção de homens 
na amostra e idade média dos pacientes, e incluindo um termo quadrático do 
ano da colheita dos dados, quando relevante.
Em 25 estudos elegíveis, incluindo doentes tratados entre 1993 e 2009, obser-
vou-se um aumento da prescrição de terapêutica farmacológica aquando da alta. 
Destes dados, foi estimado por extrapolação que, aquando da alta, em 2008, a 
95% dos doentes foi prescrita aspirina, a 82% bloqueadores beta, a 80% IECAs e 
a 91% estatinas, assumindo uma idade média dos doentes de 65 anos e 70% de 
homens na amostra. O tratamento durante a hospitalização seguiu um padrão 
semelhante, com exceção de um aumento mais acentuado na administração de 
IECAs, que foi inicialmente mais baixo mas atingiu um nível semelhante ao pres-
crito na alta nos últimos anos.
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4. Análise da proporção de doentes com terapêutica farmacológica como pre-
venção secundária após internamento por síndrome coronária aguda numa 
amostra alargada de doentes internados consecutivamente em 10 hospitais 
portugueses, e explorar potenciais diferenças por idade e sexo (Artigo V)
Numa amostra de casos de síndrome coronária aguda com alta hospitalar em 10 
hospitais portugueses admitidos consecutivamente, foram estudados 747 episó-
dios de enfarte agudo do miocárdio com elevação do segmento ST (EAMEST) 
e 1364 de síndrome coronária aguda sem elevação do segmento ST (SCASEST).
A proporção de doentes com EAMEST e SCASEST que tiveram alta hospitalar 
com prescrição de aspirina foi 96% e 88%, com clopidogrel 91% e 78%, com aspi-
rina + clopidogrel 88% e 71%, com bloqueadores beta 80% e 76%, com IECAs ou 
antagonistas do recetor da angiotensina II (ARA II) 82% e 80%, com estatinas 
93% e 90%, com terapia tripla (aspirina / clopidogrel + bloqueador beta + esta-
tina) 76% e 69%, e terapia quíntupla (aspirina + clopidogrel + bloqueador beta 
+ IECA / ARA II + estatina) 61% e 48%, respetivamente. À data de alta, os doen-
tes com EAMEST e idade superior a 80 anos tiveram menos frequentemente 
prescrição de clopidogrel [odds ratio (OR)=0,22, intervalo de confiança a 95% 
(IC a 95%): 0,08-0,56], aspirina + clopidogrel (OR=0,34, IC a 95%: 0,15-0,76), 
bloqueadores beta (OR=0,39, IC a 95%: 0,18-0,82), terapia tripla (OR=0,41, IC 
a 95%: 0,21-0,83) e terapia quíntupla (OR=0,44, IC a 95%: 0,23-0,83) quando 
comparados com os doentes com idade inferior a 60 anos; no momento da alta 
médica, às mulheres foi menos frequentemente prescrita a associação aspirina 
+ clopidogrel (OR=0,52, IC a 95%: 0,29-0,91). Nos doentes com SCASEST com 
mais de 80 anos, foram prescritos menos frequentemente bloqueadores beta 
(OR=0,58, IC a 95%: 0,36-0,93), estatinas (OR=0,35, IC a 95%: 0,19-0,64) e tera-
pia tripla (OR=0,47, IC a 95%: 0,30-0,75); o sexo não teve efeito significativo 
independente no tratamento prescrito. 
5. Modelar o decréscimo na mortalidade por doença coronária, quantificando a 
contribuição das alterações na utilização de terapêuticas médicas e cirúrgicas 
baseadas na evidência e nos principais fatores de risco cardiovascular (Artigo VI)
Foi utilizado o modelo IMPACT para integrar os dados de tendências de utiliza-
ção de tratamentos e exposição a fatores de risco para explicar a variação na 
mortalidade por doença coronária.
Entre 1995 e 2008, a taxa de mortalidade por doença coronária em Portugal 
diminuiu cerca de 29% nos homens e 21% nas mulheres com idades compreen-
didas entre os 25 e os 84 anos, correspondendo a 3760 menos mortes em 2008 
do que seria esperado se as taxas de mortalidade de 1995 se tivessem mantido. 
Aproximadamente 92% da diminuição do número de mortes estimada foi expli-
cada por este modelo; os restantes 8% são atribuíveis a alterações em fatores 
não considerados. Cerca de 50% da diminuição explicada por este modelo foi 
atribuída ao aumento da utilização de tratamentos, sobretudo anti-hipertensores 
(12%) e ao tratamento inicial após enfarte agudo do miocárdio (10%), e 42% a 
redução de fatores de risco na população, principalmente pressão arterial (27% 
nos homens e 60% nas mulheres), colesterol total (14% nos homens e 5% nas 
mulheres) e consumo de tabaco nos homens (11%). No entanto, estas reduções 
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foram atenuadas por tendências opostas na prevalência de diabetes (18% nos 
homens e 2% nas mulheres), obesidade (6% nos homens e 5% nas mulheres), e 
consumo de tabaco nas mulheres (2%).
Este trabalho ajudou a clarificar a contribuição da prevenção primária e secun-
dária para a tendência da mortalidade em Portugal por doença coronária. A ele-
vada utilização de tratamentos médico-cirúrgicos após a doença sugere que a 
qualidade dos cuidados de saúde na prevenção secundária de doença coroná-
ria é boa. Os estilos de vida mais saudáveis deverão ser mais implementados, 
nomeadamente dado que grande parte do decréscimo observado nos principais 
fatores de risco foi devida a tratamento farmacológico. Esta tese apoia a neces-
sidade de um maior investimento na prevenção primária, principalmente atra-
vés de estratégias de base populacional, fornecendo também evidência objetiva 
relativamente à importância dos tratamentos médicos, em particular no combate 
a desigualdades relacionadas com a idade.
Introduction | 11 
1. Introduction
The common occurrence of cardiovascular diseases (CVD) in most populations 
and their impact on mortality, loss of independence, impaired quality of life, and 
social and economical costs are compelling reasons for public health concern. 
Policies and public health interventions are expected to be evidence-based, 
meaning that they must rely on adequate available data supporting their need 
and cost-effectiveness. Therefore, along with collecting and allowing access 
to the population data necessary for decision making, scientific research must 
be directed at understanding the causes of disease, evaluating prevention, and 
monitoring the impact of interventions to control them. 
1.1 Atherosclerosis
Atherosclerosis is a pathological condition that occurs in the inner lining of 
medium and large arteries throughout the body. It consists on a chronic inflam-
matory process, which develops over decades in response to the biologic effects 
of risk factors 1, 2. Atherosclerosis affects especially the heart, aorta, brain and 
lower extremities.
Figure 1 describes schematically the development of an atherosclerotic lesion. 
The process starts with changes in endothelial permeability and in the compo-
sition of the extracellular matrix below the endothelium that promote the entry 
and retention of cholesterol-containing low-density lipoprotein (LDL) particles in 
the artery wall 3. The induction of endothelial and smooth cell activation, secre-
tion of inflammatory mediators and expression of adhesion molecules leads to 
leukocyte accumulation in the sub-endothelium. This inflammatory response in 
turn can promote further oxidation of the LDL particles, resulting in the activa-
tion of macrophages that engulf the LDL particles to become “foam cells” (cells 
loaded with lipids). These activated macrophages can then further contribute 
to damage by various secreted mediators or by adding thrombogenic and anti-
genic debris to the lesion, fostering the progress of the resulting atheroscle-
rotic plaque 4. The fracture of the plaque’s fibrous cap enables blood coagulation 
components to come into contact with tissue factors in the interior of the plaque 
and can result in the occlusion of the artery and consequent symptoms due to 
impaired or obstructed blood flow to the tissues beyond 5.
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The risk factors for atherosclerosis act at several points of this pathogenic path-
way 1, 2. A change in the integrity of the endothelial cells is responsible for the 
beginning of the whole process. This could be initiated by oxidative, hemody-
namic, or biochemical stimuli (from smoking, hypertension, or dyslipidemia) and 
inflammatory factors, that change their permeability to promote the entry and 
retention of blood monocytes and LDL particles. Hypertension is a major risk 
factor for atheromata, and can increase arterial wall tension, leading to disturbed 
repair processes and aneurysm formation. Cigarette smoking and diabetes mel-
litus also affect vascular biology, but through less well understood biochemical 
mechanisms. The evidence that supports the causal role of LDL cholesterol in 
atherosclerosis is vast. A strong association between LDL cholesterol and ath-
erosclerosis was first observed in ecological studies, then tested in animal mod-
els, and confirmed in large epidemiological and intervention studies 6.
1.2. Clinical presentation and natural history of coronary 
heart disease
Coronary heart disease (CHD) or ischaemic heart disease comprises many con-
ditions that vary widely in manifestations and in public health importance, and 
together contribute to CVD mortality and morbidity 7. All CHD conditions appear 
after longstanding disease of the walls of arteries that supply the myocardium. 
The myocardial cells are dependent on a continuous supply of oxygen and nutri-
ents, and if the blood flow is interrupted and not restored within minutes, injury 
and death take place. The typical symptom is pain due to muscle ischemia, with 
or without vegetative accompanying symptoms, which subsides or resolves 
upon recovery of enough blood flow to meet oxygen needs 8-10.
Figure 2 represents the typical phases in the development of CHD from the per-
spective of its biological and clinical progression. After the silent progression 
Figure 1.
Stages in the 
development of 
atherosclerotic lesions 
(reproduced from 
Libby P et al. 5).
SMCs – smooth muscle cells
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of the atherosclerotic process over years or decades, one or more precipitating 
factors lead to the disruption of an advanced atherosclerotic lesion or plaque 12. 
Then, minor aggregation by blood platelets with spontaneous resolution of the 
resulting small clot and some enlargement of the plaque may occur. Sometimes 
a large occlusive clot produces acute events, like unstable angina, myocardial 
infarction or sudden death. If the acute event does not result in sudden death, 
other short- or long-term outcomes are possible: recovery, short-term fatality, 
later recurrence as a new episode or late coronary death. During this process 
there are several phases when the cascade can be stopped or at least post-
poned: by delaying the development of the plaque, avoiding the precipitating 
factors, or allowing a rapid access to treatments.
Stable angina is chest pain that normally occurs when the demand of blood flow-
ing through the heart arteries increases, usually when a person exercises stren-
uously 10.  Unstable angina and acute myocardial infarction (AMI) are character-
ized by a sudden worsening of angina symptoms, which become more frequent, 
more prolonged, and more severe and/or happen at a lower threshold or at rest. 
If the blood clot grows to completely obstruct the circulation causing necrosis 
of the heart muscle, the patient suffers an AMI 8, 9. Furthermore, because one of 
the main consequences of atherosclerotic obstruction is the loss of myocardial 
muscle, a common occurrence in many of these patients is the subsequent devel-
opment of heart failure, a condition with particularly high mortality, poor quality 
of life and with high consumption of healthcare resources 10.
Further details about the diagnosis of CHD and risk stratification for treatment 
decisions will be given in a subsequent subsection about management of CHD.
1.3. Burden of coronary heart disease
Characterizing the distribution of a disease is essential to its epidemiologic under-
standing. Descriptive epidemiology aims to study the distribution of disease in 
relation to persons, place, and time. One tenet of epidemiology is that patterns 
Figure 2.
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in the distribution of a disease may suggest clues to causation and possibilities 
for prevention. 
The most frequent assessment of the global burden of diseases focuses on mor-
tality data, which is often the most readily available health indicator albeit with 
important and sometimes severe limitations. Some projects, like Global Burden 
of Diseases Study 7, go beyond mortality data to estimate burdens due to disabil-
ity and premature deaths. The Global Burden of Disease Study made it clear that, 
accompanying the gratifying gains in cardiovascular health that occurred in the 
industrially developed nations towards the last decade of the twentieth century, 
there was an alarming escalation of the CVD epidemic in other and more pop-
ulous regions of the world. According to this study, CHD was the first cause of 
death worldwide in 1990 and was projected to remain in this rank 30 years later, 
in 2020. Years of life lost, the second indicator analyzed, were estimated taking 
into account predicted ages at death in relation to an assumed life expectancy 
of 82.5 years. In these computations, CHD was projected to advance from fourth 
to first rank between 1990 and 2020. In addition, when the years of life lost are 
combined with years lived with disability a new measure of burden is calculated, 
the disability-adjusted life years. The position of CHD is expected to move up 
from fifth to first rank between 1990 and 2020. It is noteworthy that CHD con-
tributes importantly to disease burden in terms not only of death but also of 
reduced life expectancy and disability. CHD is estimated to rank first among all 
heath conditions in all three measures by 2020, less than a decade from now. The 
lifetime risk of CHD estimated in the Framingham Heart Study population at age 
40 was 48.6% for men and 31.7% for women 13. 
In Europe, CHD remains the major cause of death, accounting for 1.8 million 
deaths each year, and is also a major cause of morbidity and loss of quality of life. 
Death rates from CHD are generally higher in Central and Eastern Europe than in 
Northern, Southern and Western Europe 14. Apart from being different, the CHD 
mortality rates trends decreased in most European countries, in the last 30 years 
15. Figure 3 depicted the percent changes in CHD mortality in some European 
countries in between 1990 and 2010.
Figure 3.
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The decrease in mortality rates may reflect advances in the methods for pre-
vention and treatment for CHD. In the last three decades, there was a delay in 
the onset of clinical manifestations, an improvement in the immediate disease 
outcome and an increase of life expectancy. The number of patients who survive 
a cardiovascular event, and who require subsequent medical or interventional 
therapy is increasing and the burden of CVD has shifted from the middle aged to 
the elderly, but remains high.
1.4. Major risk factors for coronary heart disease
The study of the physiopathology of CHD made clear that this group of dis-
eases is characterized by a long asymptomatic latent period, which provides 
an opportunity for early preventive interventions that change disease course. 
In the past half-century, extensive documentation was produced, not only on 
the occurrence of CHD throughout the world but also reporting the results of 
successful investigation on its underlying causes and prevention. The vast shifts 
in causes of death stimulate strong epidemiologic interest because they must 
reflect profound changes in the factors that influence health and disease 17. 
Strategies of prevention were derived from the concept of “risk factors”, intro-
duced in 1961 by researchers of the Framingham Heart Study 18. In 1978, the term 
“primordial prevention” was proposed by Strasser and introduced in the scientific 
community 19. From 1981, Rose articulated more clearly the idea of two comple-
mentary approaches to shifting adverse population distributions of risk factors 
towards more favorable ones, by a “high-risk” strategy of intensive intervention 
targeting those at the extreme of risk and a “mass” or “population-wide” strategy 
to shift the whole distribution towards lower risk 20. Throughout the years, many 
factors have been causally related to the development of arterial atherosclerosis, 
and the landmark Framingham study identified most of them 21.
The study of the role of CHD risk factors is complex and needs to consider innu-
merable connections between characteristics of individuals (e.g. age, sex, genetic 
inheritance), their lifestyles (e.g. diet, smoking, alcohol), metabolic processes (e.g. 
lipid metabolism, blood pressure) and also extrinsic social and environmental con-
ditions. Due to this complexity, it has been difficult to clearly define which are the 
major risk factors for CHD. Different authors and institutions have diverged in the 
criterion used for this selection. In 2004, Stamler and colleagues reviewed the his-
tory of research and suggested six established major risk factors: serum total cho-
lesterol, blood pressure, cigarette smoking, body mass index, diabetes and adverse 
diet has a determinant factor for all the others22. The selection of these factors was 
justified on the basis of their role in the etiology of the disease, their strong impact 
on risk and their potential for being prevented or reversed 22. The investigators of 
the INTERHEART study, which included a sample of 15152 AMI cases and 14820 
controls from 52 countries, identified nine risk factors which together explain over 
90% of the myocardial infarction risk: smoking, dyslipidemia, hypertension, diabe-
tes, obesity, unhealthy diet, physical activity, alcohol consumption, and psychoso-
cial factors 23. Regardless of the chosen criteria, some risk factors are consistently 
present in all lists of major risk factors for CHD.
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Coronary heart disease
Population attributable fraction for individual factor (%)
Risk factor High-income      
countries
Low- and middle- 
income countries
World
Burden 
(DALYs)
Mortality Burden 
(DALYs)
Mortality Burden 
(DALYs)
Mortality
High cholesterol 57 52 46 43 48 45
High blood pressure 48 49 44 47 45 47
Overweight and 
obesity
27 19 16 14 18 15
Smoking 23 15 15 11 17 12
Physical inactivity 21 19 21 20 21 19
DALYs- disability-adjusted life years
 
The Global Burden of Disease and Risk Factors incorporates a detailed assess-
ment of risk factors as well as diseases worldwide and reported estimates of the 
contribution of selected risk factors to the burden of diseases 24. The results pre-
sented in Table 1 are population attributable fractions for each risk factor, and the 
outcomes represent the percentage of burden measured as disability-adjusted 
life years and mortality. Each risk factor was considered separately, and since 
factors frequently concur to disease occurrence, the cumulative percentages 
for multiple risk factors may exceed 100%. Within the risk factors considered 
individually, high cholesterol stands out as the leading factor for CHD, followed 
by high blood pressure. If the high cholesterol distribution of the high income 
region were reduced to the theoretical minimum risk exposure (defined as bel-
low 0.6 mmol/L), the burden of CHD would be expected to be 57% lower, and 
the mortality would be reduced by 52%. In this study diabetes was considered as 
a disease and not as a risk factor.
This and other evidence suggests that there is a vast potential for prevention, 
if public health strategies are implemented and sustained to preserve low risk 
or restore the more favorable distributions of risk. Once the most important 
modifiable risks are defined, and since these risk factors together with diabetes 
account for about 75% of CHD 25, it is crucial to analyse their distribution in the 
populations. 
According to the most recent European Cardiovascular Disease Statistics from 
the European Society of Cardiology, women are now smoking nearly as much as 
men, fruit and vegetables consumption has increased in recent decades, while 
overall fat consumption has remained stable; few adults participate in adequate 
levels of physical activity, with inactivity more common among women than 
men; levels of obesity are high across Europe both in adults and children; and 
the prevalence of diabetes has increased rapidly over the last ten years, by more 
than 50% in many countries 14. 
Table 1.
Individual contributions 
of risk factors to CHD, 
world and by broad 
income group (data 
source Lopez AD et 
al.24).   
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There is relatively little comparable international data on the prevalence of 
major risk factors. Available data in European countries are usually taken from 
national health surveys and there are limitations about the comparability due to 
differences in the study designs (sampling methods, age range) and methods 
(objectively defined or reported information). Figure 4 depicts the prevalence of 
major risk factors for CHD in six European countries. Compared to Spain, Italy, 
United Kingdom, Finland and Sweden, Portugal had higher levels of hyperten-
sion, diabetes and physical inactivity in recent years 14. Some methodological 
issues need to be pointed out: the prevalence of hyperlipidemia and hyperten-
sion were quantified using the same definition in all countries and the estimates 
were age-standardized; the height and weight data in Italy was self-reported 
and there was no data for United Kingdom; and physical inactivity was defined 
as answering “no” to the question “How often do you exercise or play sport?”.
In 2011, a series of systematic reviews were published with the aim of analysing 
health examination surveys and epidemiological studies with data on cardiovas-
cular risk factors, and estimating worldwide trends for each one 26-29. According 
to this pooled analysis, the mean systolic blood pressure and serum choles-
terol decreased in Western Europe, while body mass index and fasting glucose 
increased, between 1980 and 2010. The trends varied significantly across regions 
and countries, supporting the need for specific data from each population.
Age and sex play an important role in the epidemiology of the atherosclerotic 
process, and they are considered the most important non-modifiable risk factors 
by some authors and institutions, like the World Health Organization 30, 31. However, 
differences in disease distribution by these characteristics could reflect underlying 
social or environmental factors, like social conditions, behavioral patterns or spe-
cific exposures. To this extent health patterns by age and sex may be modifiable. 
For instance, the increase of blood pressure with age has been seen as a natural or 
inevitable process, but the degree of increase differs widely between and within 
populations 32. Additionally, there is strong evidence that the old and very old 
patients would obtain a particularly large absolute benefit from pharmacological 
treatment in CHD secondary prevention 33, 34. Thus, age can be seen as a marker for 
other modifiable risk factors, and the degree of its effect can be changed.      
Mortality rates by CHD present a striking pattern of variation with age (Figure 5). 
The increase is evident across age groups. Clear patterns are also evident by sex, 
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with higher rates for men in all age categories, except in the older groups, where 
the rates are approximately the same. Until 80 years, men and women seem to 
present a lag time of ten years. Plausible explanations for these can be biological 
(e.g. chromosomal, hormonal or reproductive), social (e.g. access to education 
or different patterns on occupation), cultural, or behavioral (e.g. health informa-
tion or use of health services). 
From a public health perspective, these distributions of CHD have further impli-
cations. For instance, older age groups experience a higher disease burden 
than others, and such differences can represent inequalities, beyond the simple 
fact of variation in disease frequency 35. Explicit attention to the groups most 
affected should be made a priority for society and decision makers. In contrast 
to what would be expected, sometimes these groups are those who are under-
represented in CHD epidemiological studies 36 and those who are undertreated 
in clinical practice 37.
Risk scores for prevention and management 
Changes in the overall distribution of risk factors are important to implement 
effective strategies targeting not only the general population, but also high-risk 
groups. For that, the identification of the individuals who are at a high risk is 
essential. A physician may intuitively estimate the patient’s overall cardiovas-
cular risk, based on age, sex, tobacco use, visible obesity, blood pressure levels 
and other simple measurements. However, this clinical judgement would be very 
imprecise. Therefore, objective risk assessment using risk charts, calculators or 
computer programs is recommended. Such risk estimation does not exclude the 
need for clinical judgement as these tools do not incorporate all risk factors for 
atherosclerotic disease.  
   
The European guidelines on CVD prevention in clinical practice recommend the 
utilization of the detailed SCORE charts 39. The SCORE, as many other similar 
risk charts, facilitates the estimation of the risk in apparently healthy persons. 
This tool allows the estimation of 10-year risk of a fatal cardiovascular event 
Figure 5
Mortality rates for 
CHD by age and 
sex in Europe and 
Portugal, in 2008 (data 
source World Health 
Organization and 
Official statistics from 
Portugal 16, 38)
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(including myocardial infarction, stroke, aneurysm of the aorta, or other) based 
on the impact of combinations of five major risk factors (age, gender, smoking, 
blood pressure, and lipid levels). There are specific charts for high and low risk 
countries for CVD, and for men and women 40. Patients who have had a clinical 
event, such as an acute coronary syndrome or a stroke, are automatically eligible 
for intensive risk factor management.
1.5. Management of coronary heart disease
Given the importance of the population-based and high-risk strategies, a combi-
nation of both is likely to lead to the greatest benefits and once an individual has 
developed CVD, his/her risk of developing other CVD event must be minimized. 
Depending on the patients’ sex, age and clinical presentation, those who survive 
the acute stage of a cardiovascular event have a 1.5- to 15-fold higher likelihood of 
suffering a new event or death, compared to the general population 41. 
Historical insight
Advances in the prevention, diagnosis, and treatment of CHD have been remark-
able since the mid-20th century (Figure 6). The development of coronary angi-
ography in 1958 42 combined with left ventriculography allowed clinicians to 
understand the natural history of coronary artery disease. It became the stan-
dard diagnostic tool and provided the basis for surgical treatment using coro-
nary revascularization techniques. Additionally, the refinement of the open-heart 
surgery technique, performed for the first time in 1954 42, made emerge the field 
of invasive treatments in cardiology. Until 1961, patients with AMI who reached 
the hospital alive were placed in beds located throughout the hospital far from 
the vigilance by nurses or doctors. At that time, patients were commonly found 
dead in their beds, presumably from a fatal tachyarrhythmia. Indeed, the risk of 
death occurring in the hospital was approximately 30% 43. The development of 
coronary care units, providing continuous monitoring of the electrocardiogram, 
closed-chest cardiac resuscitation, and external defibrillation, reduced in-hospital 
mortality by a half among patients admitted with AMI 44. Despite major advances 
in treatment, by the 1970s, in-hospital mortality from AMI was approximately 
18% 45. Evidence on the efficacy of different pharmacological treatments for the 
secondary prevention after an ACS has become available gradually over the 
1980s. Aspirin and beta-blockers were the first with proven effectiveness in CHD 
patients 46, 47. In the early 1990s, the effect of angiotensin-converting-enzyme 
(ACE)  inhibitors  for secondary prevention in ACS patients was first described 
48, 49. This drug causes the dilation of blood vessels, slowing the progression of 
CVD and improving survival rates, mainly among patients with left ventricular 
dysfunction. In the mid-1990s, several large randomized clinical trials have estab-
lished the effectiveness of statins 50 in delaying death and preventing non-fatal 
coronary events, in the context of secondary prevention. Finally, it was only in the 
late 1990s that a role for clopidogrel in the management of CHD was established 
51. Meanwhile, in 1986, an Italian group showed that intravenous streptokinase 
reduced early mortality in patients with AMI, in one of the first cardiac large trials, 
involving more than 10,000 patients 52. The combination of coronary angioplasty 
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and stenting with potent platelet inhibition reduced in-hospital case-fatality to 
about 7% 53.
In the beginning of the twenty-first century, a clear investment was made at a 
different level of the clinical pathway, to decrease the time between the onset of 
symptoms and the patient’s arrival at the hospital, in order to maximize the effec-
tiveness of treatment. We have moved from a situation in which many patients 
spent long hours in small local hospitals, contributing to increasing mortality, to 
the provision of rapid transport to centers with catheterization laboratory. With 
all these improvements in treatment, in 2004 the crude in-hospital mortality was 
4.0% and at 30 days was 5.1% 54, much lower than 30 years before.
Current European guidelines
The main goal of guidelines is to help physicians to make decisions in their daily 
practice. They summarize and evaluate all available evidence on a particular 
issue, and assist the physicians in selecting the best management strategies for 
an individual patient with a given condition, taking into account the impact on 
outcome, as well as the risk-benefit ratio of particular diagnostic or therapeutic 
9. A large number of guidelines about CHD have been issued in recent years by 
the European Society of Cardiology and, in addition to define new standards of 
care, the clinical terminology used to classify the type of ACS also has undergone 
change. In 2000, the American and European cardiology societies adopted a 
new AMI diagnostic system that included testing for troponin levels, which are 
much more sensitive to myocardial necrosis than the cardiac enzymes normally 
used up until then 55, 56. Nowadays, the current international consensus definition 
states that the term ‘acute myocardial infarction’ should be used when there is 
evidence of myocardial necrosis in a clinical setting consistent with myocardial 
ischaemia 57. This new definition increased the number of non-ST elevation myo-
cardial infarction (NSTEMI) cases identified by about 30%, mainly due to patients 
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who would previously have been diagnosed with unstable angina, while the num-
ber of ST segment elevation myocardial infarction (STEMI) patients remained 
unchanged 58.
Acute coronary syndrome
The current guidelines of the European Society of Cardiology divide the rec-
ommendations for patients presenting with acute ischaemic symptoms in two: 
one for STEMI patients and other for NSTEMI and unstable angina patients 8, 9. 
Therefore, in the initial diagnosis is fundamental to decide the type of treatment 
that should be provided (Figure 7). The leading symptom of ACS is chest pain 
lasting for 20 min or more, not responding to nitroglycerine. Some patients pres-
ent with less typical symptoms, such as nausea or vomiting, shortness of breath, 
fatigue, palpitations or syncope. Since the timely diagnosis is fundamental to 
successful management, ECG monitoring should be initiated as soon as possible 
in all patients with suspected of an ACS. Blood sampling for serum markers is 
routinely carried out in the acute phase and the results are even more important 
if the ECG is inconclusive.
Figure 7 displays a diagram for in-hospital management of the invasive strat-
egies, for patients with and without ST-segment elevation ACS. In addition to 
the invasive treatments, in-hospital pharmacological treatment is a very import-
ant part of the process of care and usually includes 3 approaches: anti-isch-
aemic agents, with the objective of decreasing myocardial oxygen demand (by 
decreasing heart rate, lowering blood pressure, reducing preload, or reducing 
myocardial contractility) or increase myocardial oxygen supply (by inducing cor-
onary vasodilatation); antiplatelet agents, to decrease the platelet aggregation 
and inhibit thrombus formation; and anticoagulants agents, to inhibit thrombin 
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generation and/or activity. The decision about the drugs used and dose applied 
should be based on the risk-benefit ratio for each patient, taking into account 
several factors such as previous history (e.g. allergies or intolerance to medica-
tion), hemodynamic status at admission (e.g. hypotension or bradycardia), inva-
sive treatments performed (e.g. percutaneous coronary intervention (PCI) with 
stent) and several other indicators (e.g. risk of bleeding). For instance, STEMI 
patients undergoing primary PCI should receive a combination of dual antiplate-
let therapy with aspirin and an adenosine diphosphate receptor blocker, as early 
as possible before angiography, and an anticoagulant.
Long-term therapies are important to decrease the risk for new events and prema-
ture death. It was estimated that 20% of all patients were re-hospitalized and 18% 
of men and 23% of women over 40 years of age died during the first year after an 
ischaemic event 59. Even though long-term management will be mainly the respon-
sibility of the general practitioner in a large proportion of patients, these interven-
tions will have a higher chance of being implemented if they are initiated during 
the hospital stay 60. The combination of drug therapies and lifestyle changes need 
to be considered as fundamental for effective secondary prevention. 
The key lifestyle interventions include cessation of smoking, blood pressure con-
trol, healthy diet, weight control and the improvement of physical activity. For 
current smokers, stopping smoking is potentially the most effective of all sec-
ondary prevention measures, reducing subsequent CVD mortality by nearly 50% 
61.  The combination of drug therapy [beta-blockers and ACE-inhibitors or angio-
tensin receptor blocker (ARB)] and lifestyle modification (reduced salt intake) 
may help to achieve the systolic blood pressure between the recommended lev-
els after an ACS (≥110 mmHg and <140 mmHg) 62. A healthy diet could help to 
avoid obesity and decrease blood pressure, and should be based on an a suitable 
energy intake; increasing the consumption of fruit, vegetables, whole-grain cere-
als, fish, lean meat and low-fat dairy products; reducing total fats and salt intake 
39. Although it has not been established that weight reduction per se reduces 
mortality, the body mass index should be sustained at the optimal levels, below 
25 kg/m2, because weight loss can improve many obesity-related risk factors. 
The benefits of exercise therapy in the reduction of future cardiac events are 
well established and are related with improvement of endothelial function and 
collateralization and reduction of the progression of coronary lesions and the 
thrombogenic risk. A proper exercise training program could reduce the CVD 
mortality by 26% 63. A comprehensive, multidisciplinary and structured rehabil-
itation program has been shown to be effective in reducing all-cause mortality 
and the risk of re-infarction, as well as improving risk factors, exercise-based 
capacity and health-related quality of life after an ACS 64. However, due to the 
limited number of rehabilitation services, and partly because of a lack of ade-
quately trained professionals, only high risk patients, with multiple modifiable 
risk factors, have access to this reintegration program. 
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STEMI NSTE-ACS
Drug therapy Recommendation Class Level Class Level
Aspirin Low dose, indefinitely I A I A
Clopidogrel For those who are intolerant to
aspirin
I B I A
Dual antiplatelet 
therapy
Patients with stent I A I A
Patients without stent IIa C I A
Beta-blockers All patients IIa B IIa B
Patients with heart failure or LV 
dysfunction
I A I A
ACE-inhibitors All patients IIa A I B
Patients with heart failure or LV 
dysfunction
I A I A
ARB For those who are intolerant to ACE-
inhibitors 
I B I B
Statins With target LDL-C levels <1.8 
mmol/L 
IIa C I B
Aldosterone 
antagonist
Patients with LV dysfunction and 
either diabetes or heart failure, 
without significant renal dysfunction
I B I A
ACE – angiotensin-converting-enzyme; ARB – angiotensin receptor blockers; LV – left ventricular; NSTE-ACS – Non-ST 
elevation acute coronary syndrome; STEMI – ST segment elevation myocardial infarction
 
The main treatments with proven efficacy in secondary prevention that must be 
implemented after an ACS are described in Table 2. A patient without contrain-
dications should be discharged at least with aspirin, clopidogrel, a beta-blocker, 
a statin and an ACE-inhibitor or ARB.
Stable angina pectoris
The last guidelines on the management of stable angina pectoris of the European 
Society of Cardiology were published in 2006 10. The diagnosis of stable angina is 
mainly based on the patient’s clinical history, and on the presence of chest pain, 
pressure, or heaviness that limits exertion, situated over the sternum or in the 
left chest and left arm. It begins gradually after physical or emotional triggers 
and is relieved within 10 min of rest 10. In the majority of cases, it is possible to 
make a reliable diagnosis on the basis of the clinical history only, although phys-
ical examination and objective tests are necessary to confirm the diagnosis and 
assess the severity of underlying disease 10. To confirm the diagnosis and plan 
further management, is recommendable an initial non-invasive strategy, like an 
exercise ECG, stress echo, or myocardial perfusion scintigraphy. Coronary arte-
riography is generally undertaken for further risk stratification purposes. These 
exams allow the confirmation of the diagnosis, the assessment of the severity of 
CHD in patients with mild-to-moderate symptoms and the effective risk stratifi-
cation. Although stable angina is less severe than an ACS, there is an increased 
risk of progression to AMI and/or death.
The recommend secondary prevention after a diagnosis of stable CHD is very 
similar with the recommended after an ACS. In the absence of contraindications 
or intolerance, patients with stable angina pectoris should be treated with aspirin 
and statin therapy. A beta-blocker should be used first line or, alternatively, a 
Table 2.
Level and class of 
recommendation 
for each drug 
recommended for 
secondary prevention 
in STEMI and NSTE-
ACS patients (data 
sources Steg G et al. 
and Fox K et al. 8, 9). 
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calcium-channel blocker or long-acting nitrate may be used to provide antiangi-
nal effects. ACE-inhibition is indicated in patients with ventricular dysfunction, 
hypertension, or diabetes. The lifestyle modification should be implemented in 
addition to pharmacological intervention. 
Secondary prevention in Europe
As the diagnosis of stable angina in epidemiological studies is mainly based on 
clinical history and usually the patients are diagnosed in primary care, studies 
describing secondary prevention on CHD stable patients are rare, and the com-
parability between the few exiting is difficult since it dependents on the subjec-
tive definition used. Therefore, we are going to focus on the description of the 
implementation of secondary prevention only among ACS patients. 
Despite the recommendations, the implementation of the evidence-based treat-
ment after an acute coronary event is far from optimal and rates of surgical 
procedures and drug treatment vary widely across Europe. To compare data 
from different countries is usually very difficult because the quality and the rep-
resentativeness of data are limited and different from one country to another. 
However, according to Eurostat, reported in the European Cardiovascular 
Disease Statistics 14, among 24 European countries Portugal had the low-
est rates of coronary angioplasty (23 procedures per 100,000 inhabitants in 
2009), 20 times less than the country with highest rates, Germany. For coro-
nary artery bypass graft (CABG), rates were highest in Germany and Estonia, 
lowest in Finland and Romania. In Portugal, 40 CABG procedures per 100,000 
inhabitants were performed in 2009. However, direct comparisons between 
the number of procedures performed in each population cannot be interpreted 
as an indicator of the quality of care without considering the ACS incidence 
in each country. Portugal is a low risk country for CHD, and the number of 
patients discharged per year is approximately 3 times lower than in Germany 
(339 versus 916 patients discharged per 100,000 inhabitants in 2008), so it is 
understandable that the number of procedures is lower than some high risk 
countries 16.      
Concerning pharmacological treatment, the most comprehensive data is from 
the EUROASPIRE project 65. This study from the European Society of Cardiology 
has collected, among other data, information on drug prescriptions for patients 
with diagnosed cardiovascular conditions. The first EUROASPIRE survey was 
performed in 1995–96 in 9 European countries, the second in 1999–2000 in 15, 
and the third in 2006–07 in 22, including eight countries that participated in 
EUROASPIRE I and II (Czech Republic, Finland, France, Germany, Hungary, Italy, 
The Netherlands, Slovenia and Spain). Although these data are not necessarily 
representative of national prescribing patterns, since in some cases only one 
region within the country was covered, they give some indication of the scale of 
drug use across Europe.
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The trends in the proportion of drugs prescribed for secondary prevention in 
CHD patients, in all eight EUROASPIRE populations, between survey I and III, are 
described in Figure 8. Overall, the proportion of patients treated with antiplatelet 
increased slightly, but the proportion was already high in 1995–96; on the other 
hand the proportion of ACE-inhibitors/ARB and statins was three- and four-fold 
higher in 2006/7 comparing with 1995–96, respectively. There was also a large 
increase in the prescription of beta-blockers.
Considering the results from the 22 countries included in EUROASPIRE III sur-
vey, in 2006/07, the use of pharmacological treatment varied considerably 
across survey populations. Antiplatelet drugs were the most widely used drugs, 
between 88% and 99% of patients in the countries studied. Beta blockers were 
used by more than 60% of patients in all countries (from 60% in Cyprus to 94% 
in Finland). The use of ACE-inhibitors/ARB varied two-fold, from 46% of patients 
in Belgium to 90% of patients in Poland. Statins were the treatment with highest 
variation between countries, from 38% in Lithuania to 96% in Finland. Data from 
Portugal were not reported in any of the surveys.
1.6. Coronary heart disease policy models
Understanding the trends of a disease is a complex process which involves the 
quantification of a lot of different factors, most of them susceptible of being 
influenced by policy decisions. Variations in exposure to risk factors and in the 
use of medical interventions may have an important effect on disease incidence 
and case-fatality, and therefore mortality.
Models can be designed to accommodate complexity around the development 
of an illness in a population. A model is a simplification of reality 66, which starts 
with some specific data and, based on mathematical equations, can explain past 
disease trends and predict future events such as disease occurrence 67. Models 
have been increasingly used in policy making and resource allocation, because 
they allow the simulation of different scenarios in populations and hence guide 
future policy decisions 68. They can also help to explore the potential importance 
of factors on which evidence is sparse or lacking. Modeling complements other 
epidemiological studies, with advantages in allowing questions to be addressed 
that traditional research methods do not. The main problem with using models 
is that they require considerable data input and the data sources need to be 
Figure 8
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appropriate, accurate and reliable. The data can be obtained from a variety of 
sources including clinical trials, meta-analyses, surveys, clinical databases and 
registries, medical records, audits or routine statistics. The availability of com-
prehensive high quality data is the main challenge 69. 
A basic cardiovascular model may include levels of the main risk factors, uptake 
of treatments, demographic information and some outcome measure of CVD, 
most commonly mortality. In order to explain the CHD mortality trends in the 
last decades, several models were developed 70. Their main objective has been to 
understand if the observed trends mainly reflect increasing use of evidence-based 
treatments for individual patients, or cardiovascular risk factor improvements 
across entire populations. 
The results from the WHO MONICA study suggested that approximately one 
third of the CHD mortality fall in the mid-1980s/1990s was attributable to the 
decrease in case-fatality, mainly reflecting treatments, while some two thirds 
were attributable to fewer events, mainly reflecting prevention through reduc-
tions in major risk factors such as smoking, cholesterol and blood pressure 71. 
More recently, Lopez and colleagues developed the Global Burden of Disease 
model, which has been valuable for international comparisons, emphasising the 
powerful contributions from elevated cholesterol, smoking and hypertension 72. 
However, a more detailed understanding of CHD trends in specific populations 
combining both risk factors and treatment data and quantified the uncertainties 
around the model estimates was necessary.
In the last 30 years, several models were developed to explore trends in CHD 
73-75. Existing CHD policy models vary widely in their depth, quality, utility and 
versatility (Table 3). Some simply consider risk factors alone 72, 74, 75, while others 
include selected cardiovascular treatments 76-78. Few models have been cali-
brated against observed data, replicated in different settings or adequately 
validated.
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Table 3.
Main 
characteristics of 
the six principal 
CHD policy 
models (adapted 
from Unal B et al. 70)
Name of the 
model
Type of 
model
Risk factors 
included
Treatments 
included Outcomes
Other 
characteristics
CHD Policy 
Model 76
State 
transition 
Markov 
Model
Smoking, 
cholesterol, blood 
pressure and 
obesity 
Yes DPPs, 
LYG, CHD 
incidence, 
CHD 
prevalence, 
CHD 
mortality, 
cost per life 
year
First policy model 
rather basic, but 
steadily refined 
since then.
PREVENT 74 Cell based Smoking, 
cholesterol,blood 
pressure, obesity, 
physical inactivity 
and alcohol
No DPPs, LYG Mainly a primary 
prevention model. 
CHD Life 
Expectancy 
Model 75
Life table 
analysis 
or Markov 
model 
from 1998 
onwards
Smoking, 
cholesterol, blood 
pressure, glucose 
intolerance
Only 
treatments 
for primary 
prevention
LYG, cost 
per life 
year saved, 
years of life 
without CHD 
symptoms
This model uses 
hypothetical 
cohorts of 
participants. 
In most of the 
papers, time 
and the specific 
population are not 
clear.
Global 
Burden of 
Disease 72
Population 
attributable 
risk method
Malnutrition, poor 
water, unsafe sex, 
alcohol, tobacco 
occupation, 
hypertension, 
physical 
inactivity, illicit 
drugs, and air 
pollution
No DALYs A comprehensive 
and global 
model for WHO 
strategies. CHD 
is modelled as 
caused by the 
main risk factors.
CHD Policy 
Analysis 77
Micro 
simulation
Smoking, 
cholesterol, blood 
pressure
Yes DPPs, CHD & 
non-cardiac 
deaths, 
unstable 
angina 
admissions, 
PCI, CABG
Separate risk 
factor and 
treatment 
components. 
No sensitivity 
analyses. Model fit 
appears better for 
men than women.
IMPACT 78 Cell based Smoking, 
cholesterol, blood 
pressure, obesity, 
diabetesand 
physical inactivity
Yes DPPs, LYG Considers all 
major effective 
treatments 
available for CHD 
and all major risk 
factors. 
CABG – coronary artery bypass grafting; CHD – coronary heart disease; DPPs – deaths prevented or postponed; LYG – life 
years gained; PCI – percutaneous coronary intervention. 
One of the models that both comprehensively assesses the potential contribu-
tion of cardiovascular treatments and risk factors changes to CHD mortality and 
considers sensitivity analysis and validation is the IMPACT model 78. This model 
was originally developed in the 1990s by Capewell and colleagues, and since 
then has been progressively refined 78, 79. The main objective of the authors was 
to build a conceptually simple model, but methodologically sophisticated, where 
all assumptions are explicit, transparent, and subjected to rigorous sensitivity 
analyses. Using an Microsoft Excel® spreadsheet, the model has attempted a 
comprehensive consideration of all standard treatments and all major risk factors 
80. It combines data from many sources on patient numbers, treatment uptake, 
treatment effectiveness, risk factor trends and consequent mortality effects, 
expressed as deaths prevented or postponed 80. The model also estimates life 
years gained and cost-effectiveness for specific interventions 81, 82. For risk fac-
tors the model includes smoking, cholesterol, blood pressure, obesity, diabetes 
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and physical inactivity 78. The disease categories and treatments include: AMI 
(aspirin, ACE-inhibitors, beta-blockers, CABG surgery, PCI, rehabilitation, cardio-
pulmonary resuscitation and thrombolysis); unstable angina (aspirin, aspirin & 
heparin, platelet IIB/IIIA inhibitors, CABG surgery and PCI); secondary preven-
tion following AMI, and, separately, following CABG surgery or PCI (statins, aspi-
rin, warfarin, ACE-inhibitors, beta-blockers and rehabilitation); chronic angina 
(statins, aspirin, CABG surgery and PCI); heart failure (aspirin, statins, ACE-
inhibitors, beta-blockers and spironolactone); statins therapy for dyslipidemia; 
and all standard treatments for hypertension 78. The model can therefore be used 
to estimate the proportion of the mortality decline or increase over a certain 
time span that might be attributed to specific treatments or risk factors changes. 
This model was validated in several countries around the world, comparing the 
estimated fall in CHD deaths with the observed fall in deaths in specific age and 
sex categories. The results highlight the importance of a comprehensive strat-
egy that promotes both primary and secondary prevention programs and help 
to clarify which are the risk factors with adverse trends and treatments that are 
being underused. 
The application of the IMPACT model in Portugal will allow policy makers and 
clinicians to assess the impact changes in the levels of each risk factor or uptake 
medical intervention in the whole adult population, and to decide which sub-
groups should be prioritized, offering a broader view than other types of individ-
ual studies.
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2. Aims
With this research project we intended to contribute to a better understanding 
of the epidemiology of coronary heart disease (CHD) in Portugal, in the last two-
three decades. This disease is of great importance in public health, and plays a 
leading role as a competitive risk for other diseases, emphasizing the potential 
impact of its temporal trends. 
Time trends in CHD mortality have shown considerable heterogeneity across 
countries, even within the same geographic region and at similar broad income 
level. From a public health point of view, it is important to monitor and understand 
the underlying factors, taking into account the dynamic interactions between 
diverse driving forces dependent on varying actors.
In Portugal, the time trends in the frequency of the main risk factors and treat-
ments used for coronary heart disease were essentially unexplored in a system-
atic and oriented approach. The particular differences regarding the risk factor 
profile, such as the delay in the tobacco smoking epidemic and the high prev-
alence of hypertension, as well as the organization and delivery of health care 
services preclude the generalization of the evidence obtained in other countries 
to understand the impact in the Portuguese setting. In particular, of modifying 
the many factors acting together to determine coronary heart disease mortality. 
Therefore, the specific aims in this thesis were:
1. To describe time trends in mortality rates, absolute number of deaths and 
years of life lost from cardiovascular diseases and cancer (Paper I)
2. To critically summarize the evidence from studies providing data on the distri-
bution of risk factors in adults, in order to analyze time trends 
 a) Hypertension and blood pressure (Paper II)
 b) Diabetes mellitus and fasting blood glucose (Paper III)
3. To critically summarize the evidence from studies providing data on the use 
of pharmacological therapy for secondary prevention, during hospitalization and 
prescribed at hospital discharge, following an acute coronary syndrome, in order 
to analyze time trends (Paper IV)
4. To analyze the proportion of patients receiving pharmacological therapy as 
secondary prevention after an ACS admission in a large sample of patients con-
secutively discharged from ten Portuguese hospitals, and to explore potential 
age- and sex-differences (Paper V)
5. To model the decline in coronary heart disease mortality, quantifying the con-
tribution of changes in the use of evidence-based medical and surgical treat-
ments, and in major cardiovascular risk factors (Paper VI)
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RESEARCH ARTICLE Open Access
Changing patterns of cardiovascular diseases and
cancer mortality in Portugal, 1980–2010
Marta Pereira1*, Bárbara Peleteiro1, Simon Capewell2, Kathleen Bennett3, Ana Azevedo1 and Nuno Lunet1
Abstract
Background: Cardiovascular diseases and cancer are jointly responsible for more than half all deaths in Portugal.
They also share some important risk factors and act as mutual competing risks. We aimed firstly to describe time
trends in death rates and years of life lost due to cardiovascular diseases and cancer in the Portuguese population
from 1980 to 2010; and secondly to quantify the contribution of the variation in population and age structure, and
age-independent “risk” by cardiovascular or oncological causes to the change in the corresponding number of
deaths.
Methods: We estimated the annual percent change in age-standardized mortality rates from cardiovascular
diseases and cancer, in each sex. The specific contribution of demographic changes (due to changes in population
size and in population age structure) and the variation in the age-independent “risk” of dying from the disease to
the observed trends in the number of deaths was quantified using the tool RiskDiff. Years of life lost were
computed using the Global Burden of Disease method.
Results: Among men, the mortality rate from all cardiovascular diseases was more than two-fold higher than
cancer mortality in 1980. However, three decades later mortality from cancer surpassed cardiovascular diseases.
After 2005, the years of life lost from cancer were also higher than from cardiovascular diseases. Among women,
despite the decrease in death rates, cardiovascular diseases remained the leading cause of death in 2010 and their
absolute burden was higher than that of cancers across the whole period, mainly due to more events in older
women.
Conclusions: In Portugal, the 20th century witnessed a dramatic decrease in the cardiovascular disease mortality
and YLL, and the transition towards cancer. In more recent years, the highest burdens of disease came from
cancers in men and from cardiovascular diseases in women.
Keywords: Cancer, Cardiovascular diseases, Mortality, Trends, Portugal
Background
In 2004, cardiovascular diseases (CVD) were the leading
cause of death in the world, responsible for approxi-
mately 32% of all deaths in women and 27% in men.
After infectious and parasitic diseases, cancer ranked
third, causing some 12% of all deaths among women and
13% among men [1]. Taking the age at death into ac-
count, however, CVD were responsible for only 14% and
cancer for 8% of the total years of life lost (YLL) in
2004, surpassed by infectious and parasitic diseases,
perinatal conditions and unintentional injuries.
Age-standardized mortality rates from CVD have been
declining for several decades in Europe [2,3], while the
downward trend in mortality from some common can-
cers is more recent, and varies with the type of cancer.
The overall cancer mortality has been decreasing less
steeply, and in some Eastern European countries is still
increasing [4]. While the proportion of all deaths from
CVD was almost three-fold higher than from cancer in
Europe, the YLL were less than two-fold higher for CVD
than cancer, in 2004 [1,5].
In Portugal, CVD were the leading cause of death in
2006, followed by cancer, and these two groups of
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diseases were responsible for more than half of all deaths [6].
Portugal is characterized by a very higher contribution of cere-
brovascular disease to mortality relative to coronary heart dis-
ease [1] and long-standing higher systolic blood pressure, as
compared to most other European countries [7]. The types of
cancers that cause more deaths in Portugal are lung and stom-
ach among men and breast among women [4]. The relatively
early stage of Portugal in the smoking epidemic results in an
expected increase in the smoking-related burden of disease
and deaths, particularly among women [8,9].
We aimed to describe time trends in the absolute number
of deaths, death rates and YLL from CVD and cancer in the
Portuguese population, during the period 1980–2010, and
to quantify the contribution of the variation in the popula-
tion’s size and age structure, and age-independent “risk” of
death by cardiovascular or oncological causes to the change
in the corresponding number of deaths.
Methods
Sources of data
The number of deaths from all CVD [International Clas-
sification of Diseases 10th revision (ICD 10): I00-I99; 9th
revision (ICD 9): 390–459] and all malignant neoplasms,
hereafter just referred as cancer (ICD 10: C00-C99; ICD
9: 140–239), as well as the estimates of the population at
risk in each year, were obtained from official statistics
[10,11].
All data were obtained from 1980 to 2010 for each sex
in age groups (<1, 1–4, 5-year age groups up to 80–84
and ≥85 years).
Trends in mortality rates and years of life lost
Standardized mortality rates were computed by the dir-
ect method using the European standard population as
reference [12]. We performed a joinpoint regression ana-
lysis, using JoinpointW version 3.4 from the Surveillance
Research Program of the US National Cancer Institute
[13], to calculate the annual variation in mortality and to
identify points of significant change in the log-linear
slope of the trend (joinpoints) [14]. The analysis starts
with the minimum number of joinpoints (no joinpoints
corresponds to a straight line), and tests whether one or
more joinpoints significantly improve model fit. The
minimum number of observations from a joinpoint to
the earliest or the latest years and between two join-
points was set to 5. We present the results of best fitting
models for the trends in men and women. The estimated
annual percent change (APC) in mortality for each
period was calculated assuming a Poisson distribution
and taking the calendar year as the independent variable.
The analyses of the trends in the mortality rates and
numbers of deaths were performed for all ages and by
age groups (0–14, 15–34, 35–54, 55–74 and ≥75 years).
The YLL due to premature mortality for each cause
(CVD and cancer), gender and age group were com-
puted using the Global Burden of Disease method [15]
by multiplying the number of deaths at each age by the
life expectancy at the age at which death occurs. We
considered the recommended standard life expectancy at
birth of 80 years for men and 82.5 for women. The aver-
age age at death was set to the mid-point of each five-
year age group, apart from the infant deaths (where it is
assumed to be 0.1 years in low mortality countries), the
1–4 year age group (assumed to be 2.6 years) and the
oldest group (assumed to be 87.5 years) [15]. We applied
a 3% time discount rate to assign less weight to the YLL
corresponding to the periods more distant to the mo-
ment of death than to those referring to the first years
after death, an age-weighting parameter to weigh YLL in
very young and old ages less than other ages (Global
Burden of Disease standard value is 0.04) and an age-
weighting correction constant so that the introduction
of age-weights did not alter the total number of YLL
(Global Burden of Disease standard value is 0.1658) [15].
The total YLL for each cause and gender was obtained
by adding the YLL of all age groups.
Contribution of changes in demographics and
age-independent “risk”
We used the tool RiskDiff, a web-based application from
the Catalan Institute of Oncology to assess the specific
contribution of demographic changes (due to changes in
population size and in population age structure) and the
variation in the age-independent “risk” of dying from the
disease to the observed trends in the number of deaths
[16]. This analysis was performed for the periods with
constant log-linear trend identified in the joinpoint ana-
lysis. RiskDiff outputs the results over an entire time
period. To allow comparisons among intervals of differ-
ent length, we estimated annual effects assuming geo-
metric change over time [17].
Results
Trends in mortality rates and years of life lost
Among men, the age-adjusted mortality from CVD
decreased between 1980 and 2010 (Figure 1 and Table 1).
The decrease was more pronounced after 1993, with an
APC of −4% per year versus −1.5% per year between
1980 and 1993. The age-adjusted mortality rate from
cancers increased 0.9% per year between 1980 and 1997,
then declined slightly, 0.7% per year, until 2006 and
increased 1.5% per year thereafter, in men. Among
women, the pattern of the age-adjusted mortality from
CVD was similar to that of men, decreasing between
1980 and 2010, more pronouncedly after 1996, reaching
an APC of −4.6% per year. The mortality rate from can-
cer increased from 1980 to 1990, then decreased slightly
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until 2006 (more steeply between 2002 and 2006, by 2%
per year), and then increased 1.3% per year until 2010.
Among men, in 1980 the mortality rate from CVD
was more than two-fold higher than that from cancer,
but in 2008 the mortality rate from cancer surpassed the
mortality rate from CVD, due to opposite trends be-
tween the two groups of diseases since the mid-2000s
(Figure 1 and Table 1); the total number of deaths from
CVD was higher than from cancer between 1980 and
2010, but converged to around 15000 deaths each in
2010. Among women, despite the convergence in the
mortality rates from both diseases, CVD remained the
leading cause of death in 2010. Between 1980 and 2010,
the burden of CVD was much higher compared to can-
cer and, in 2010, CVD were responsible for 10,000
deaths more than cancers.
Among men, the YLL from cancer increased between
1980 and 2010, while the YLL from CVD decreased,
mainly after the mid-1990s (Figure 1); in 2005, the YLL
from cancer surpassed those from CVD and were clearly
higher thereafter. Among women, the trends in YLL
from CVD and cancer were very similar to those
observed for mortality rates.
When analyzing trends by age groups, the mortality
rate from CVD decreased between 1980 and 2010, for
all age groups among men, while a decrease in the mor-
tality rates from cancer was only observed for the
younger age groups (up to 35 years) (Figure 2). Cancer
was a cause of death more frequently than CVD among
those under 35 years of age between 1980 and 2010, in
the last two decades for those aged 35 to 54 years and in
the last decade for those aged 55 to 74 years. Cardiovas-
cular diseases were the main of these two causes of
death from 1980 to 2010 among men aged over 75 years.
Among women, the mortality rate from CVD decreased
between 1980 and 2010 in all age groups, while mortality
Figure 1 Time trends in cardiovascular diseases and cancer 1980–2010, by sex: age-standardized (European population) mortality
rates, number of deaths and years of life lost.
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rates decreased in younger women, with a recent attenu-
ation for ages 35–54 years, and remained approximately
constant in the two older age groups (Figure 2). Cancer
was the main cause of death until 55 years between 1980
and 2010 and in the last decade in the age group 55–74
years, while CVD were always the main cause of death
in women over 75 years.
Contribution of changes in demographics and
age-independent “risk”
Between 1980 and 2010, the increase in population size
and changes in the age structure towards a higher pro-
portion of older subjects contributed to an increase in
the number of deaths by CVD (around 0.2% per year
and 2% per year, respectively) (Table 1). Similarly, be-
tween 1980 and 2006, the increase of the population size
contributed to an increase in the number of cancer
deaths [between 0.2% per year in women (1980–1990)
and 0.6% per year in men (1997–2006)], as did the age-
ing of the Portuguese population (1.6% per year in men
from 1980 to 1997 and 1.3% per year in men from 1997
to 2006 and in women overall). In the period 2006–
2010, the Portuguese population decreased in number,
thereby contributing to a decrease in number of deaths
by cancer (less than 0.3% per year), while the population
ageing contributed to the change in the cancer mortality
rates by an annual variation of 0.7% in men and 1.1% in
women (Table 1).
The age-independent “risk” of death from CVD
decreased between 1980 and 2010, more significantly
since the mid-1990s, after which point it translated into
a decrease in the total number of deaths of around 2%
per year. After declining for several years, the risk of
death from cancers increased by more than 2% per year
from 2006 to 2010. Overall, the number of cancer deaths
increased in both sexes between 1980 and 2010, except
for a short period between 2002 and 2006, among
women (Table 1).
Discussion
We observed a dramatic decrease in Portuguese CVD
mortality rates from 1980 to 2010 in both sexes. How-
ever, this decrease was reflected in a fall in the total
number of deaths only since the mid-1990s, due to the
increases and ageing of the population. For cancer, we
observed a much smaller decrease in the mortality rates
from the 1990s until 2006 in both sexes, and an increase
thereafter. These trends, together with increased prema-
ture mortality from cancer, meant that in men, YLL
from cancer surpassed those from CVD after 2005.
In recent years, cancer has become the leading cause
of death among men, in many other European countries,
such as France, Spain, Netherlands and Italy [18,19].
Cardiovascular diseases and cancer interact as mutually
competing risks. The observed decreasing trends in CVD
mortality may have contributed to the recent increase in
Table 1 Annual change and contribution of demographic changes and age-independent “risk” to cardiovascular
diseases and cancer mortality 1980–2010, by sex
Disease
Period *
Annual change in Annual variation in number of deaths due to variation in
Age-standardized mortality
rate % (95% CI)
Number of
deaths %
Population
size %
Population age
structure %
Age-independent
“risk” %
Men All cardiovascular
diseases
1980-1993 −1.5 (−2.0 to −1.0) 1.00 0.15 2.08 −1.59
1993-2010 −4.3 (−4.7 to −3.9) −2.20 0.18 1.35 −5.26
All cancers
1980-1997 0.9 (0.7 to 1.1) 2.76 0.28 1.65 1.16
1997-2006 −0.7 (−1.2 to −0.2) 1.18 0.60 1.32 −0.78
2006-2010 1.5 (0.2 to 2.9) 2.85 −0.26 0.66 2.47
Women All cardiovascular
diseases
1980-1996 −2.0 (−2.3 to −1.6) 0.75 0.17 1.98 −1.94
1996-2010 −4.6 (−5.1 to −4.2) −1.79 0.23 2.00 −5.92
All cancers
1980-1990 0.4 (0.2 to 0.7) 2.09 0.18 1.36 0.65
1990-2002 −0.6 (−0.9 to −0.4) 1.19 0.37 1.32 −0.61
2002-2006 −1.9 (−3.4 to −0.5) −0.62 0.41 1.26 −2.39
2006-2010 1.3 (0.4 to 2.3) 3.17 −0.10 1.08 2.24
* We considered the periods with constant log-linear trend identified in the joinpoint analysis.
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Figure 2 Time trends in cardiovascular diseases and cancer 1980–2010, by sex: mortality rates and numbers of deaths, by age groups.
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mortality rates from cancer, with more individuals surviv-
ing at risk of cancer. We also observed a decrease in the
number of deaths caused by gastro-intestinal diseases, in-
juries and poisoning, and infectious and parasitic diseases
in the last three decades, in Portugal [10]. Since some of
these causes of death are more common in the young and
middle-aged population, these trends leave more at risk
for the diseases associated with older age, such as diabetes,
CVD or cancer [20].
The mortality trends from CVD in Portugal paralleled
steady mortality declines in Western Europe, North
America, Japan and other developed areas of the world
[2,3]. This reflects decreases in both cerebrovascular and
ischaemic heart diseases, the two major contributors to
this group and more frequent in the older population
[3,21]. In Portugal, cerebrovascular disease has been the
main cause of death during the last decades [6,22]. In
developed countries, the mortality rates from stroke
have been decreasing more steeply in countries with
higher departure rates, which is the case of Portugal
[23]. This could reflect general improvements in living
conditions, lower salt consumption thanks to improved
methods for food preservation and recently, perhaps,
lower case-fatality due to stroke units and better emer-
gency care [24]. Regarding ischaemic heart disease, mod-
eling studies in many developed countries consistently
suggest that 45% to 75% of the mortality declines can be
attributed to decreases in major risk factors, with the
remaining attributable to medical and surgical treat-
ments [25-28]. In Portugal, we likewise observed notable
decreases in the mean systolic blood pressure and blood
cholesterol, smoking consumption among men, and some
dietary modifications, accompanied by the increased use
of therapies for acute coronary syndromes [7,9,29,30].
Deaths from CVD in younger age groups probably
reflected improved diagnostic capacities and successful
early surgical interventions for congenital heart disease,
plus better medical care for hypertension, cardiac arrhyth-
mias and endocarditis [31]. The pattern in the trends of
YLL suggests that death by CVD is being increasingly
delayed, clearly affecting mostly the elderly population.
Interpreting trends in cancer mortality rates can be
challenging, because they reflect trends in several com-
mon cancers. In Portugal, the specific cancers that could
particularly contribute to the slight decrease in overall
cancer mortality rate between the 1990s and 2006
among adults include stomach cancer (in both sexes),
prostate and lung among men and breast and uterus
among women [4]. Despite the trends in mortality rates,
the total number of deaths and YLL have increased
steadily. Among the more frequent cancers stomach,
lung and breast cancer are associated with death at rela-
tively younger ages [20], contributing more to the in-
crease in YLL due to cancer. On the other hand, we
expected a lower contribution to YLL from prostate can-
cer, since this is a disease mainly of the elderly popula-
tion [20]. In younger ages, the decrease in leukaemia
may also contribute [4]. The few adult cancers increas-
ing in more recent years differ between women and
men. In women, the very recent increase in breast can-
cer mortality plus the long-term increase in the lung
cancer mortality could help explain the turning point
observed in the cancer mortality rate and YLL in 2006
[32]. In men, colorectal cancer is the only common can-
cer which is increasing [10]. However, further close ana-
lyses during the forthcoming years are clearly necessary
to confirm that the trends observed in the 4 years since
2006 persist longer term. The steady decline in cancer
mortality is likely to reflect improvements in risk factors
such as male smoking and diet, compounded by better
access to earlier and specialized diagnosis, staging and
treatment [33]. Worryingly, the mortality for some can-
cers has increased since 2006, which may reflect an in-
crease exposure to other risk factors, such as obesity
[34]. The transition to a more Westernized diet has oc-
curred faster in Portugal than in some other Mediterranean
countries [35]. The continued increases in smoking among
women across the Eastern, Western and Southern parts of
Europe [36] are very concerning. Unless halted, these will
inevitably increase cancer mortality among women in Por-
tugal. Furthermore, the late implementation and the low
participation rate in organised cancer screening pro-
grammes [37] may delay the potential benefits. In 2008, the
breast and cervical cancer screening did not cover the en-
tire country and the screening program for colorectal can-
cer was still in its infancy [37]. Apart from the variation in
the population structure, we identify an increase in the risk
of dying from cancer after 2006, which inverts the previous
decrease observed in the 1990s.
The interpretation of the reported trends depends on
the quality of the source data. Misattribution or miscoding
can occur mainly because of incorrect diagnoses, incorrect
or incomplete death certificates, misinterpretation of ICD
rules for coding underlying causes, and variations in the
use of categories for unknown and ill-defined causes [38].
Like most developed countries Portuguese mortality data
have high coverage, but have been considered to have low
quality regarding the high proportion (21%) of deaths
coded as ill-defined causes [38]. Additionally, and more
specifically, there is evidence of inaccuracies in attribution
of frequent causes of death. For instance, in a validation
study in the mid-2000s, stroke was not confirmed in a
large proportion of death certificates indicating it as the
underlying cause of death, and 5% of patients were identi-
fied only after the review of death certificates [39]. The ac-
curacy in attribution to causes of death varies over time
due to quality of diagnoses and also due to changes in the
coding rules. In Portugal, two revisions of the ICD were
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used in the calendar period considered in this study, with
ICD-10 replacing ICD-9 in 2002. However, since the ICD-
10 is more detailed than ICD-9 and we used two large
groups of diseases, without focusing on very specific
codes, errors might have been minimised.
Although we do not have information on CVD inci-
dence and case-fatality in this population, we predict that
death from CVD will be mainly associated with old age in
Portugal, as in highly developed Western European coun-
tries. However, the prevalence of CVD is likely to increase
and so is the related demand for healthcare. The observed
trends in cancer mortality highlight the importance of
primary and secondary prevention, demanding better
planning in health services, in order to obtain improve-
ments in earlier detection and/or increasing proportions
of patients receiving new or more aggressive treatment.
Conclusions
The 20th century witnessed a dramatic decrease in car-
diovascular disease mortality and YLL in Portugal and a
recent transition towards a higher burden of cancer. Fur-
thermore, the sustainability of gains against CVD is
threatened by recent trends in obesity among men and
women and increasing smoking among women. These
same risk factors play an important causal role in several
cancers, highlighting the importance of future preven-
tion strategies. This analysis of the mortality data taking
into account demographic effects, produced results that
are easily usable for policy makers. The data on the ab-
solute number of cases and demographic determinants
is potentially highly relevant for planning purposes and
also for predicting future needs.
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 Abstract 
 Aims. We aimed to describe the temporal trends of the mean blood pressure and prevalence of hypertension in studies that 
evaluated Portuguese adults.  Methods. Pubmed was searched and 42 eligible studies were identifi ed. Reference screening 
and data extraction were conducted independently by two researchers. We fi tted linear regression models to compute eco-
logical estimates of hypertension prevalence and mean blood pressure, adjusting for sex, age and signifi cant interaction 
terms.  Results. Between 1990 and 2005, the prevalence of hypertension defi ned as blood pressure    140/90 mmHg and/or 
drug treatment remained approximately constant in young adults and decreased in middle-aged and older adults, whereas 
the prevalence of self-reported hypertension increased 0.4% per year (95% confi dence interval 0.1 – 0.7) overall. Between 
1975 and 2005, mean systolic and diastolic blood pressures decreased in middle-aged and older adults, reaching a 32-mmHg 
decrease in systolic blood pressure among women at average age 70.  Conclusion. The trends in the last decades show a 
decrease in blood pressure levels, probably attributable to increasing awareness and a higher treatment proportion. Although 
this absolute trend in blood pressure parallels the observed in other high income European countries, Portugal maintains 
its position above the mean levels in other Western settings. 
 Key Words:  Blood pressure, hypertension;  Portugal , trends 
 Introduction 
 Worldwide, 7.1 million deaths are attributable to 
hypertension each year (1). This modifi able risk fac-
tor is strongly associated with the risk of coronary 
heart disease (2), heart failure (3) and stroke (4), 
making it a leading cause of cardiovascular morbidity 
and mortality. Mortality by coronary and cerebrovas-
cular diseases have been steadily declining in most 
developed countries (5) and the decrease in mean 
systolic blood pressure (SBP) is estimated to explain 
around 20% of the decline in coronary heart disease 
in the last quarter of the 20th century (6). 
 In Portugal, cardiovascular diseases were respon-
sible for approximately one-third of all deaths in 
2008 (7), but mortality rates have been decreasing 
since the mid 1970s (8). During the past 30 years, 
Portugal has been described as one of the countries 
with highest median blood pressure levels (9,10), 
and in 2003 three million adults (42.1%) had 
hypertension (11). 
 Data on trends of hypertension prevalence are 
important to predict the burden of cardiovascular 
outcomes as well as to understand the effect of deter-
minants of hypertension and to monitor the impact 
of public health measures. The accurate estimation 
of the burden of hypertension and distribution of 
blood pressure in Portugal requires the best use of 
all available resources to obtain detailed information 
from different age groups and populations across the 
widest possible time span. This requires a compre-
hensive review and a synthesis of the results that 
takes into account methodological aspects such as 
the sampling strategy, selection and recruitment of 
participants, and the methods for assessment of 
hypertension, which may compromise the samples ’ 
representativeness and the studies ’ validity. 
Blood Pressure, 2012; Early Online: 1–7
ISSN 0803-7051 print/ISSN 1651-1999 online © 2012 Scandinavian Foundation for Cardiovascular Research
DOI: 10.3109/08037051.2012.666380
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 We conducted a systematic review to critically 
summarize the evidence from studies that provide 
data on the distribution of blood pressure and hyper-
tension in Portuguese adults, in order to analyze time 
trends. 
 Methods 
 The present systematic review was conducted as part 
of a more comprehensive review that addressed the 
distribution of six major cardiovascular risk factors, 
including diabetes mellitus, dyslipidemia, hyperten-
sion, obesity, physical inactivity and tobacco consump-
tion, in Portuguese adults. The systematic review 
fl owchart and a detailed description of the method-
ological characteristics and results of the studies con-
sidered in the systematic review, as well as their 
references, are presented in a Supplementary Appen-
dix available online at http://www.informahealthcare.
com/doi/abs/10.3109/08037051.2012.666380. 
 A Pubmed search was conducted, in January 
2011, and 2887 publications were identifi ed 
(Supplementary Appendix, Figure A1 available 
online at http://www.informahealthcare.com/doi/abs/
10.3109/08037051.2012.666380). The reference lists 
of review articles addressing the distribution of car-
diovascular risk factors were screened to identify 
potentially eligible original reports, adding 71 poten-
tially relevant references to the original search. The 
current analysis only considers studies with data on 
hypertension. 
 Studies were excluded by  a priori defi ned criteria: 
not written in Portuguese, English, Spanish, French 
or Italian; not involving humans (e.g.  in vitro or ani-
mal research); case reports; editorials or comments; 
reports not providing data specifi cally for Portu-
guese subjects; studies not evaluating adult popula-
tions; studies evaluating samples of participants not 
expected to represent the general population regard-
ing the frequency of the cardiovascular risk factors 
under study (e.g. subjects with diabetes, athletes, 
sedentary elderly); not presenting data on hyperten-
sion, mean SBP and/or diastolic blood pressure 
(DBP); not presenting data in an eligible format for 
extraction (e.g. studies that had Portuguese data but 
only presented it as joint estimates for Southern 
Europe); insuffi cient characterization of the meth-
ods (e.g. lack of information about the criteria for 
hypertension defi nition, not specifying the region 
where the sample was assembled). In case of mul-
tiple publications using data from the same sample, 
we considered the results provided in the analysis 
with the largest sample size or, in case of equal sam-
ple size, the one presenting more strata-specifi c 
information (e.g. sex and age stratifi cation). The 
information on the study methods could be obtained 
from any of the publications referring to the same 
investigation. 
 For selection, studies were evaluated in three con-
secutive steps. In step 1, 1892 studies were excluded 
based on title and abstract assessment. When the 
abstract of a particular article was not available, the 
article was further assessed, except when the title 
unequivocally presented information for exclusion 
(e.g. case report). The full text of studies that were 
not excluded in the fi rst step was then evaluated in 
step 2, applying the same criteria and 822 studies 
were excluded. In the third step, relevant data were 
extracted, with 161 further studies in which data were 
not presented in an eligible format being excluded. 
Of the remaining 88 studies, 46 presented exclusively 
data on other risk factors and we included in this 
systematic review 42 studies with data concerning 
hypertension (Supplementary Appendix, Figure A1 
available online at http://www.informahealthcare.
com/doi/abs/10.3109/08037051.2012.666380). 
 The decisions for studies ’ selection were made by 
two reviewers independently at all steps and the 
disagreements were discussed and resolved by 
consensus, involving a third researcher when neces-
sary. The agreement between the reviewers increased 
with increasing available information, being 73.0%, 
81.7% and 82.0%, in steps 1, 2 and 3, respectively. 
 Data from each report were extracted indepen-
dently by two investigators and differences were 
resolved in consensus. To characterize the studies, we 
collected data on fi rst author, year of publication, 
period of data collection, geographical coverage, pop-
ulation characteristics (e.g. general, primary health 
care users, volunteers, mixed), type of sampling (prob-
ability or non probability) and sample size. In studies 
presenting data from two or more regions indepen-
dently, these were extracted separately. We also col-
lected data on participants ’ sex and age. We extracted 
sex- and age-specifi c estimates of prevalence of hyper-
tension and mean SBP and DBP, the source of this 
information (clinical records, physical measures, self-
reported), the device used for blood pressure mea-
surement, the number of measurements, the time of 
rest before the fi rst measurement and between the 
measurements, the time of day and the criteria for 
hypertension defi nition. In an article that presented 
information about mean SBP and DBP at the fi rst and 
third minutes after rest (12), we extracted the second 
evaluation. When data were presented only in graph-
ics, we contacted the authors in order to obtain more 
reliable information. If no reply was obtained, we 
extracted data read from projection to axes, if possible; 
otherwise, the article was excluded since data were not 
presented in an eligible format. Data on prevalence of 
hypertension based on unknown criteria for its defi ni-
tion were not considered. We obtained age- and sex-
specifi c estimates directly from the authors of fi ve of 
the largest studies representing subjects within a 
wide age range (11,13 – 16).In order to summarize the 
evidence, when a study did not present the mean age 
of the participants in each stratum, we assumed it as 
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the mid-point of the age intervals. When an age 
group included subjects both aged less and more 
than 18 years (e.g. age group 17 – 20 years old), we 
excluded the data if the mid-point age was lower than 
17.5 years old. 
 For analysis, because of the high heterogeneity of 
defi nitions of hypertension, we considered SBP/DBP 
   139/89mmHg and/or treated for hypertension, SBP/
DBP    140/90 mmHg and/or treated for hyperten-
sion, and SBP/DBP    140/90 mmHg and/or in use of 
blood pressure lowering medication to be equivalent. 
 We fi tted linear regression models to assess time 
trends in the prevalence of hypertension and mean 
blood pressure. Hypertension prevalence was ana-
lyzed using two dependent variables: objectively 
defi ned hypertension, defi ned as SBP/DBP    140/90 
mmHg and/or drug treatment, and self-reported 
medical diagnosis of hypertension. In fi tting models, 
we studied the role of age, sex and fi rst-level interac-
tion terms of survey year with sex and age. For mean 
DBP, we also included an interaction term of age as 
a continuous variable and age as dichotomous vari-
able (   60 vs    60 years) to account for the fact that 
DBP increased with age up to 60 years and then 
decreased. The steps in model fi tting are presented in 
Table I. For each outcome, we selected a fi nal model 
including the year of the survey and the participants ’ 
age and sex, as well as the statistically signifi cant inter-
action terms between the year of the survey and the 
participants ’ age or sex. When the outcome of interest 
was DBP, we also tested an interaction term between 
age and age group (using the age of 60 years as the 
cut-off) to account for the decrease in the mean DBP 
among the older subjects that is observed in Figure 
2. Studies that did not present data stratifi ed by sex 
were excluded from this analysis. As one or more esti-
mates of the outcomes were extracted from each 
study, corresponding to different age strata, we ana-
lyzed them as a cluster defi ned by the identifi cation 
of the study and computed robust standard error esti-
mates. Given that the trends were confi rmed to be 
linear and that the effect of time depends on age and 
sex, the most readable way of reporting trends was to 
provide an estimate from the adjusted models for two 
extreme calendar years in the range in which we found 
data for each outcome (1990 and 2005 for prevalence 
of hypertension and 1975 and 2005 for mean blood 
pressure) and at specifi c sex and age groups, covering 
young, middle-aged and older adults. 
 Results 
 We identifi ed 42 studies eligible for the systematic 
review, of which 40 presented data on prevalence of 
hypertension and 13 on mean SBP and DBP. 
 The studies were published between 1974 and 
2010, mostly covering only one region in the country 
(62%) and only seven using representative samples 
at national level, of which four were National Health 
Surveys. The samples were obtained from the general 
population in 14 studies, from primary health care 
centers users in 12 and from volunteers in seven. 
Data were obtained by physical measurement in 36 
studies and self-report in 15. Of those that presented 
objectively defi ned hypertension, blood pressure was 
measured most frequently using a standard mercury 
sphygmomanometer (14 studies) and there was no 
information about the device used in 16 studies. 
Only three studies mentioned the time of the day 
when blood pressure was measured (two studies in 
the  “ morning ” and one  “ all day ” ) and 12 did not 
describe the number of measurements considered. 
Twelve studies did not present the results stratifi ed 
by sex and 19 did not stratify the results by age 
groups (Supplementary Appendix, Table AI avail-
able online at http://www.informahealthcare.com/
doi/abs/10.3109/08037051.2012.666380). 
 Prevalence of hypertension 
 In the 40 eligible studies with data on hypertension 
prevalence, 13 different criteria to defi ne hyperten-
sion were reported (Supplementary Appendix, Table 
AII available online at http://www.informahealth-
care.com/doi/abs/10.3109/08037051.2012.666380). 
The prevalence of hypertension defi ned as blood 
pressure    140/90 mmHg and/or drug treatment (10 
studies) increased with age, both in men and women 
(Figure 1). The age- and year-adjusted prevalence 
was 6.8% (95% CI 0.7 – 12.2%) higher among men 
than women. Self-reported hypertension (seven stud-
ies) increased 0.7% (95% CI 0.6 – 0.9%) per year of 
age, independently of survey date and sex (Figure 1). 
The adjusted prevalence was 6.2% higher among 
women than men (95% CI 3.8 – 8.9%). 
 Between 1990 and 2005, the prevalence of objec-
tively defi ned hypertension remained approximately 
constant in the younger adults, and decreased in 
middle-aged and older adults, reaching a decrease of 
22% in 15 years, at average age 70 years. In the same 
period, the prevalence of self-reported hypertension 
increased 0.4% per year (95% CI 0.1 – 0.7%), adding 
up to a cumulative increase of 6.2% over the 15-year 
period (Table II). 
 Mean blood pressure 
 The variation of mean blood pressure with age is 
presented in Figure 2 (10 studies). While SBP 
increased linearly with age, DBP increased with age 
up to 60 years and then decreased. 
 Between 1975 and 2005, mean SBP decreased in 
men after middle-aged and in women at all ages 
(Table I), adding up to a cumulative decrease of 22 
and 32 mmHg in SBP at average age 70 years, in 
men and women, respectively. DBP remained 
B
lo
od
 P
re
ss
 D
ow
nl
oa
de
d 
fr
om
 in
fo
rm
ah
ea
lth
ca
re
.c
om
 b
y 
U
ni
ve
rs
id
ad
e 
D
o 
Po
rto
 o
n 
03
/2
7/
12
Fo
r p
er
so
na
l u
se
 o
nl
y.
48 | Explaining the decline in coronary heart disease mortality in Portugal, 1995-2008
4 M. Pereira et al.
  T
ab
le
 I
. 
R
eg
re
ss
io
n 
m
od
el
s 
fo
r 
th
e 
va
ri
at
io
n 
of
 p
re
va
le
nc
e 
of
 h
yp
er
te
ns
io
n 
(o
bj
ec
ti
ve
ly
 m
ea
su
re
d 
an
d 
se
lf
-r
ep
or
te
d)
 a
nd
 m
ea
n 
sy
st
ol
ic
 (
S
B
P
) 
an
d 
di
as
to
lic
 b
lo
od
 p
re
ss
ur
e 
(D
B
P
) 
w
it
h 
ye
ar
 o
f 
su
rv
ey
, 
ta
ki
ng
 i
nt
o 
ac
co
un
t 
pa
rt
ic
ip
an
ts
 ’  
se
x 
an
d 
av
er
ag
e 
ag
e.
  
C
on
st
an
t
Ye
ar
 o
f 
su
rv
ey
  β 
 P
 -v
al
ue
P
ar
ti
ci
pa
nt
s 
ag
e 
(y
ea
rs
) 
 β 
 P
 -v
al
ue
P
ar
ti
ci
pa
nt
s 
se
x a
   β 
 P
 -v
al
ue
A
ge
 �
 ye
ar
 
of
 s
ur
ve
y 
 β 
 P
 -v
al
ue
S
ex
 �
 ye
ar
 
of
 s
ur
ve
y 
 β 
 P
 -v
al
ue
A
ge
 �
 ag
e
60
 b   
 β 
 P
 -v
al
ue
 R
  s
qu
ar
ed
P
re
va
le
nc
e 
of
 o
bj
ec
ti
ve
ly
 d
efi
 n
ed
 
hy
pe
rt
en
si
on
 c   
(1
0 
st
ud
ie
s,
 7
7 
es
ti
m
at
es
 d  )
M
od
el
 1
  �
 20
28
.4
1.
03
0.
01
0.
08
M
od
el
 2
13
0.
2
 �
 0.
08
0.
48
9
1.
37
 �
    0
.0
01
0.
84
M
od
el
 3
79
.3
 �
 0.
05
0.
69
8
1.
37
 �
    0
.0
01
6.
44
0.
03
2
0.
85
 M
od
el
 4
 
   �
 30
44
.9
 
 1.
51
 
 0.
01
0 
 86
.4
7 
 0.
00
3 
 6.
8 
 0.
02
5 
  �
 0.
04
 
 0.
00
3  
 0.
87
 
M
od
el
 5
  �
 32
66
.3
1.
62
0.
00
1
88
.5
2
0.
00
1
25
3.
23
0.
61
9
 �
 0.
04
0.
00
1
 �
 0.
12
0.
62
9
0.
87
P
re
va
le
nc
e 
of
 s
el
f-
re
po
rt
ed
 
hy
pe
rt
en
si
on
 (
7 
st
ud
ie
s,
 7
7 
es
ti
m
at
es
 d  )
M
od
el
 1
 �
 12
68
.1
0.
65
0.
00
1
0.
05
M
od
el
 2
 �
 81
3.
9
0.
4
0.
01
1
0.
74
 �
    0
.0
01
0.
79
 M
od
el
 3
 
  �
 82
5.
9 
 0.
41
 
 0.
01
2 
 0.
74
 
  �
    0
.0
01
 
  �
 6.
16
 
 0.
00
2  
 0.
83
 
M
od
el
 4
 �
 23
4.
0
0.
11
0.
60
4
 �
 11
.1
8
0.
38
2
 �
 6.
16
0.
00
2
0.
01
0.
35
3
0.
83
M
od
el
 5
 �
 47
9.
0
0.
23
0.
40
6
 �
 11
.2
2
0.
38
4
48
0.
44
0.
23
3
0.
01
0.
35
4
 �
 0.
24
0.
22
8
0.
83
M
ea
n 
S
B
P
 (
10
 s
tu
di
es
, 
89
 e
st
im
at
es
 d  )
M
od
el
 1
44
4.
5
 �
 0.
16
0.
1
0.
02
M
od
el
 2
86
2.
5
 �
 0.
38
0.
00
1
0.
68
 �
    0
.0
01
0.
76
M
od
el
 3
86
3.
2
 �
 0.
38
0.
00
1
0.
68
 �
    0
.0
01
0.
2
0.
92
2
0.
76
M
od
el
 4
 �
 11
61
.4
0.
63
0.
01
1
44
.7
0.
00
2
0.
24
0.
90
4
 �
 0.
02
0.
00
2
0.
85
 M
od
el
 5
 
  �
 80
9.
9 
 0.
46
 
 0.
06
5 
 44
.1
2 
 0.
00
3 
  �
 65
6.
44
 
  �
    0
.0
01
 
  �
 0.
02
 
 0.
00
3 
 0.
33
 
   �
    0
.0
01
 
 0.
87
 
M
ea
n 
D
B
P
 (
10
 s
tu
di
es
, 
89
 e
st
im
at
es
 d  )
M
od
el
 1
31
3.
2
0.
12
0.
11
4
0.
06
M
od
el
 2
45
2.
4
 �
 0.
19
0.
00
9
0.
23
0.
00
8
0.
47
M
od
el
 3
45
5.
5
 �
 0.
19
0.
00
8
0.
23
0.
00
8
0.
84
0.
38
5
0.
47
M
od
el
 4
 �
 96
9.
5
0.
52
0.
02
3
31
.2
0.
00
2
0.
87
0.
25
5
0.
02
0.
00
3
0.
7
M
od
el
 5
 �
 90
4.
0
0.
49
0.
05
31
.1
0.
00
3
 �
 12
1.
47
0.
38
 �
 0.
02
0.
00
3
0.
06
0.
37
5
0.
7
 M
od
el
 6
 
  �
 78
3.
8 
 0.
42
 
 0.
02
5 
 26
.0
9 
 0.
00
1 
 0.
92
 
 0.
24
 
  �
 0.
01
 
 0.
00
1 
  �
 0.
07
 
  �
    0
.0
01
 
 0.
74
 
    a  S
ex
: 
w
om
en
 �
   0;
 m
en
 �
   1.
  b
 A
ge
60
: �
   60
 y
ea
rs
 o
f 
ag
e �
   0;
 �
   60
 y
ea
rs
 o
f 
ag
e �
   1.
  c
 D
efi
 n
ed
 a
s 
S
B
P
/D
B
P
 �
   14
0/
90
 m
m
H
g 
or
 u
nd
er
 d
ru
g 
tr
ea
tm
en
t.
  d
 A
ge
- 
an
d 
se
x-
sp
ec
ifi 
c 
es
ti
m
at
es
. 
F
or
 e
ac
h 
ou
tc
om
e,
 t
he
 
fi n
al
 m
od
el
 i
s 
pr
es
en
te
d 
in
 b
ol
d.
   
B
lo
od
 P
re
ss
 D
ow
nl
oa
de
d 
fr
om
 in
fo
rm
ah
ea
lth
ca
re
.c
om
 b
y 
U
ni
ve
rs
id
ad
e 
D
o 
Po
rto
 o
n 
03
/2
7/
12
Fo
r p
er
so
na
l u
se
 o
nl
y.
Paper 3.2 | 49 
     Hypertension and blood pressure trends in Portugal  5
approximately constant in young adults and decreased 
in middle-aged and older participants, up to 15 
mmHg over the 30-year period, in older adults of 
both sexes (Table II). 
 Discussion 
 In Portugal, over the last 15 years, the prevalence of 
hypertension, defi ned as blood pressure    140/90 
mmHg and/or drug treatment, remained stable in 
younger adults and decreased in middle-aged and 
older adults, whereas self-reported hypertension 
increased 6.2% in both sexes and all age groups. 
From 1975 to 2005, mean SBP decreased in men 
after middle-aged and women at all ages, reaching 
32 mmHg at the average age of 70 years. DBP 
remained constant in younger adults and decreased 
in middle-aged and older adults, more strongly with 
advancing age. 
 Our results are consistent with studies of blood 
pressure trends in most developed countries, that 
observed a decrease in average SBP (17,18). A recent 
pooled analysis reported that average SBP decreased 
since 1980 in the world population, but trends varied 
signifi cantly across regions and countries (9). Despite 
the heterogeneity of reported average annual trends 
in SBP among different populations, our estimate of 
the absolute change over time is within the range of 
most estimates from Western European countries 
(19). The increase in self-reported hypertension was 
already reported in other countries, both in men and 
women (19,20), and refl ects higher awareness. 
 This review is to the best of our knowledge the 
most comprehensive analysis of estimates on hyper-
tension prevalence and mean blood pressure in 
Portugal to date. The strengths of this study are the 
analysis of long-term trends of both prevalence 
(objectively measured and self-reported) and SBP 
and DBP, including as detailed description of the 
studies included as possible. 
 In general, the quality of the reporting options 
adopted in the primary sources of evidence was poor. 
The lack of important methodological information in 
many reports precluded an appropriate characteriza-
tion of all studies (Supplementary Appendix, Table 
AI available online at http://www.informahealthcare.
com/doi/abs/10.3109/08037051.2012.666380). 
Overall, we observed a considerable heterogeneity 
across the investigations, especially in methods for 
sample selection, target populations, methods for 
determining blood pressure and criteria for defi ning 
hypertension. For quantitative synthesis of data, we 
only included studies with estimates on hypertension 
defi ned as SBP/DBP    140/90 mmHg and/or drug 
treatment or self-reported, and that presented data 
stratifi ed by sex. In most studies, hypertension was 
defi ned on the basis of blood pressure measurements 
taken in one visit, and thus the prevalence may have 
been overestimated, whereas in some others protocol 
details were not documented. We hypothesized that 
 Figure 1. Prevalence of hypertension according to age, in men and women, by national or regional coverage. 
B
lo
od
 P
re
ss
 D
ow
nl
oa
de
d 
fr
om
 in
fo
rm
ah
ea
lth
ca
re
.c
om
 b
y 
U
ni
ve
rs
id
ad
e 
D
o 
Po
rto
 o
n 
03
/2
7/
12
Fo
r p
er
so
na
l u
se
 o
nl
y.
50 | Explaining the decline in coronary heart disease mortality in Portugal, 1995-2008
6 M. Pereira et al.
 Table II. Prevalence of hypertension and mean systolic (SBP) and diastolic blood pressure (DBP), estimated by linear regression models 
of individual stratum-specifi c estimates on sex, age and year of survey. 
Men Women
Year 30 years 50 years 70 years 30 years 50 years 70 years
Prevalence of 
objectively 
defi ned 
hypertension a , 
% (95% CI)
1990
2005
20.2 (15.2 – 25.2)
23.7 (19.6 – 27.8)
58.3 (55.0 – 61.6)
49.1 (46.5 – 51.6)
96.4 (87.0 – 105.9)
74.5 (72.3 – 76.6)
13.4 (7.2 – 19.6)
16.7 (11.7 – 22.0)
51.5 (45.9 – 57.1)
42.3 (37.9 – 46.7)
89.6 (78.8 – 100.5)
67.6 (63.1 – 72.2)
Prevalence of 
self-reported 
hypertension, 
% (95% CI)
1990
2005
0.8 (  3.2 – 4.9)
6.9 (5.5 – 8.3)
15.6 (10.9 – 20.2)
21.7 (19.4 – 24.0)
30.3 (24.0 – 36.7)
36.5 (31.8 – 41.2)
7.0 (5.0 – 8.9)
13.1 (10.5 – 15.7)
21.7 (18.4 – 25.1)
27.8 (24.4 – 31.3)
36.5 (30.9 – 42.1)
42.6 (37.0 – 48.2)
Mean SBP, 
mmHg 
(95% CI)
1975
2005
122 (118 – 125)
126 (121 – 130)
145 (140 – 150)
136 (132 – 140)
168 (157 – 179)
146 (141 – 152)
127 (124 – 130)
121 (118 – 125)
151 (146 – 155)
132 (130 – 134)
174 (163 – 185)
142 (138 – 146)
Mean DBP, 
mmHg 
(95% CI)
1975
2005
76 (72 – 80)
77 (75 – 79)
88 (86 – 89)
81 (79 – 83)
95 (91 – 98)
80 (79 – 82)
75 (70 – 80)
76 (74 – 78)
87 (85 – 89)
80 (78 – 82)
94 (91 – 97)
80 (77 – 82)
 a Defi ned as SBP/DBP    140/90 mmHg or under drug treatment.
95% CI, 95% confi dence interval. 
 Figure 2. Mean values of systolic and diastolic blood pressure according to age, in men and women, by national or regional coverage. 
studies on regional populations were more likely to 
have smaller samples and mostly from urban areas, 
and these factors would contribute to both random 
and systematic error. However, we found no differ-
ences between the estimates obtained from regional 
or national samples. We identifi ed only one cross-
sectional study reporting the prevalence of objectively 
defi ned hypertension in a representative sample of the 
Portuguese population, in 2003 (11). Given the high 
mortality from cerebrovascular disease in Portugal 
and being hypertension one of the main risk factors, 
good quality studies in representative samples of the 
country population should be performed over time. 
 The reliance on electronic literature search alone 
and utilization of one single search engine is an addi-
tional limitation of this study. However, publication 
bias should not be a major issue, because there was 
no analytical dimension in the hypothesis and suc-
cessful publication likely does not depend on actual 
prevalence. We assumed that studies including larger 
samples and more thorough methods were more 
likely to be published in more highly ranked journals 
that are indexed in Medline. Additionally, inclusion 
of relevant studies identifi ed in the bibliographic ref-
erences of the review articles was important to 
identify older and non-Pubmed indexed publications. 
 Hypertension is involved in a complex web of 
causation, in which some factors are both its cause 
and consequence. Moreover, many of these risk fac-
tors interact with hypertension in the infl uence on 
cardiovascular risk. The lifestyle measures that are 
widely agreed to lower blood pressure are weight 
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reduction in the overweight or obese, moderation in 
alcohol consumption, physical activity, reduction of 
salt intake and increase in fruit and vegetables con-
sumption (20). Despite the increasing awareness of 
the population to the problems caused by hyperten-
sion, this does not necessarily translate into healthier 
lifestyles. For instance, the mean body mass index 
increased approximately 0.5 kg/m 2 per decade in 
Western Europe, between 1980 and 2008, and spe-
cifi c data from Portugal followed the same trend 
(21). A report on food consumption in Porto, Portu-
gal, reported that the adult population intakes about 
9.2 g of salt per day (22), almost double the amount 
recommended by the World Health Organization 
(23). In 2009, a new public health law restricted the 
salt level in bread (24), but this law has not been 
implemented for long enough to be refl ected in the 
overall levels of mean blood pressure in Portugal. 
 The trends in the last 15 years suggest that 
increasing awareness translates into a higher treat-
ment proportion, resulting in a decrease in blood 
pressure level. Although Portugal is following the 
trends observed in other high-income European 
countries, further effort is needed because the paral-
lel absolute trend in mean blood pressure results in 
Portugal maintaining its position above the mean 
levels in other Western European countries. 
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Trends in prevalence of diabetes mellitus and mean fasting glucose in 
Portugal (1987-2009): a systematic review
[submitted]
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Abstract
Aims: To assess time trends of the prevalence of diabetes and mean blood glu-
cose in Portuguese adults, through a systematic review.
Methods: The search strategy included Pubmed search and screening of bib-
liographic references of reviews. Studies addressing only type 1 diabetes, relying 
on random blood glucose or not presenting sex-stratified data were excluded. 
Sex-specific linear regression models of diabetes prevalence and mean fasting 
glucose, with survey year and participants’ age as independent variables, were 
used to predict estimates of the outcomes. 
Results: Twenty-seven eligible studies were identified. Time trends of objec-
tively defined diabetes could not be quantified due to the heterogeneity of the 
diagnostic criteria. For self-reported diabetes there was a significant interaction 
between year and sex. Between 1987 and 2009, the prevalence of self-reported 
diabetes remained approximately constant in young adults, while it increased in 
middle-aged and older adults, more than two-fold among women and three-fold 
among men. In the same period, mean fasting glucose increased 7mg/dL among 
women and 8mg/dL among men.
Conclusions: The prevalence of self-reported diabetes and mean fasting glucose 
increased in the last two decades, demanding for effective strategies to reverse 
this tendency and to manage the increasing number of people with diabetes in 
the Portuguese population.
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Introduction
Diabetes is a chronic disease responsible for a heavy burden of mortality and 
morbidity. In 2004, it was estimated to cause 3.4 million deaths 1 and the World 
Health Organization projects that this number will be doubled by 2030 1, 2. 
Patients with diabetes have a lower life expectancy by approximately 12 years 
3. The absolute risk of major coronary events in these patients is similar to that 
of people with established coronary heart disease in the absence of diabetes 
4, leading it to be considered a coronary heart disease equivalent for purposes 
of risk assessment and management of secondary prevention 5. Other disabling 
consequences of diabetes include renal failure and blindness 6, 7.
Trends in prevalence of diabetes and blood glucose are important to understand 
the effects of lifestyles, assess the performance of interventions, and plan health 
services. In the last decades, glycaemia and diabetes increased globally, parallel-
ing the increasing trends in body mass index 8 and population ageing. In 2008, 
the worldwide age-standardized prevalence of diabetes mellitus in adults was 
9.2% among women and 9.8% among men 9. The number of people with diabe-
tes is expected to increase by 122% between 1995 and 2025 10. However, there 
is considerable variation in time trends across countries and regions, making 
generalizations based on subjective assessments of similarities of populations 
unadvisable 9.
In Portugal, cardiovascular diseases are leading causes of death 11 and more than 
half of the Portuguese population was overweight or obese in 2005 12. The most 
comprehensive data on the frequency of diabetes mellitus in Portugal comes 
from the self-reported data of the National Health Surveys 13-16, and only recently 
were three national surveys carried out using standardized criteria for diabetes 
identification 17-19. However, as long as the type of population sampled, represent-
ativeness at national and community levels, methods and conditions for glucose 
measurement, and criteria for definition of diabetes are taken into account, a sys-
tematic review of available data across a wider time span could provide an accu-
rate estimation of the trends of diabetes mellitus and fasting glucose in Portugal. 
We conducted a systematic review to critically summarize the evidence from 
studies that provided data on the distribution of diabetes mellitus and fasting 
blood glucose levels in Portuguese adults, in order to analyze time trends.
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Methods
The present systematic review was conducted as part of a more comprehensive 
review that addressed the distribution of six major cardiovascular risk factors, 
including hypertension 20, obesity 12, dyslipidaemia 21, diabetes mellitus, smoking 
and physical inactivity, in Portuguese adults. The current analysis only considers 
studies with data on prevalence of diabetes and/or mean blood glucose. This 
systematic review was prepared in strict compliance with PRISMA guidelines for 
systematic reviews.
Search strategy
We searched Pubmed from inception to November 2011, to identify original 
reports and review articles providing data on the distribution of the prevalence of 
diabetes and mean fasting glucose levels in Portuguese populations; the search 
expression is provided in the systematic review flowchart (Figure 1). The refer-
ence lists of the review articles addressing the distribution of cardiovascular risk 
factors in Portugal were screened to identify potentially eligible original reports. 
Eligibility criteria and screening of reference lists
Studies were excluded when fulfilling the following criteria, defined a priori: 
written in languages other than Portuguese, English, Spanish, French or Italian; 
research not involving humans (e.g. in vitro or animal research); editorials, reviews 
or comments; not providing data specifically for Portuguese subjects; not eval-
uating adult populations; evaluating samples of participants not expected to 
represent the general population regarding the frequency of the cardiovascular 
risk factors under study (e.g. athletes, sedentary elderly); not presenting data on 
diabetes prevalence or mean glucose levels; insufficient characterization of the 
methods (e.g. not specifying the region where the sample was assembled, not 
describing the data collection procedures).
The screening of the reference lists was accomplished in three consecutive steps. 
In step 1 the exclusion of irrelevant studies was decided by considering only the 
title and abstract; the article was selected for evaluation in step 2 except when 
the title or abstract (when available) unequivocally presented information for 
exclusion. The full texts of studies selected for step 2 were then evaluated to 
decide on their eligibility and availability of relevant data. The studies selected 
for step 3 were re-evaluated to determine their adequacy for data extraction.
When more than one report referred to the same study, we considered the one 
providing data for the largest sample or, when the sample was the same, we used 
the source presenting the results with more detail, although any of these reports 
could be used to collect information on the study characteristics.
The decisions taken independently by the two reviewers were compared in all 
steps and the disagreements were resolved by consensus or after discussion 
with a third researcher.
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Data extraction
Two investigators independently collected data from the studies selected for the 
systematic review on period of data collection, recruitment place, geographical 
coverage of the study (regional/national), type of population studied (e.g. gen-
eral population, primary health care users, occupational group, volunteers, uni-
versity students and pharmacy attendants), type of sampling (probability or non 
probability), sample size and participants’ mean age and sex. When the period 
of data collection was not reported, we assumed the publication year minus the 
median difference between the publication year and date of data collection in 
the articles for which that information was available (3 years). When a study did 
not present the mean age of the participants in each age group we assumed the 
mid-point of the age interval. When an age group also included subjects aged 
below 18 years old (e.g. age group 17-20 years), we computed the mid-point 
and excluded the data if the mid-point year was lower than 17.5 years old. For 
surveys that reported data by age groups but provided open age intervals at 
the extremes, we estimated the midpoint of the highest/lowest categories by 
adding or subtracting the width of the adjacent class to the lowest/highest value, 
respectively, of the extreme classes (e.g. for surveys reporting data in partici-
pants aged <30, 30–39, 40–49, and ≥50 years, we considered the overall range 
as 20–59 years).
The source of data on the presence of diabetes or fasting blood glucose (e.g. 
biochemical tests, self-report or clinical records), the device for glucose mea-
surement and the fasting status of participants upon blood withdrawal were also 
extracted. Age- and sex- specific estimates of prevalence of diabetes and blood 
glucose levels, and the respective criterion for the definition of the former, were 
extracted whenever available. When only graphs were presented we extracted 
the data by reading from projections to axes; the articles were excluded when 
no accurate reading was possible. From the six largest studies involving subjects 
within a wide age range we obtained age- and sex-specific estimates directly 
from the authors.
Differences in the data extracted by the two investigators were discussed until 
consensus, and involving a third investigator whenever necessary.
Data analysis
Studies that did not present data stratified by sex were excluded from all quan-
titative analyses, as well as one study addressing specifically type 1 diabetes. 
Studies relying on non-fasting blood glucose in the whole or part of the sam-
ple were included to provide estimates of objectively defined diabetes only if 
appropriate cut-offs, different from the criteria used for fasting glucose, were 
used to define diabetes, but excluded from analyses on mean blood glucose. We 
considered self-reported diabetes, previous diagnosis of diabetes and being on 
treatment as equivalent criteria for the definition of self-reported diabetes, under 
the assumption that the proportion of treated among aware is very high.
To assess time trends of the prevalence of diabetes and mean fasting glucose 
levels we fitted sex-specific linear regression models, including the year of survey 
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and participants’ mean age as independent variables. We studied the role of an 
interaction term between survey year and age, which had a significant effect 
only for self-reported diabetes. We provide estimates of the prevalence of diabe-
tes and mean fasting glucose obtained from the linear regression models for two 
extreme calendar years for which data was available (1987 and 2009), at specific 
ages (30, 50, 70 years) aiming to represent young, middle-aged and older adults. 
As one or more estimates of the outcomes were extracted from each study, 
corresponding to different age strata, we considered them to belong to a same 
cluster and computed robust standard error estimates.
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Results
We identified 27 studies eligible for the systematic review (Figure 1), published 
between 1989 and 201113-19, 22-41. The detailed description of the methodological 
characteristics and results presented in the primary data sources are presented 
in a supplementary file, available online. Ten studies presented data on the prev-
alence of objectively defined diabetes, 18 studies on the prevalence of self-re-
ported diabetes and 6 studies on mean blood glucose. Twelve studies assessed 
representative samples at mainland or national level, of which 4 were National 
Health Surveys. Most studies considered samples of the general population (16 
studies) or users of primary health care centers (8 studies). Among the 12 studies 
with data on blood glucose measurements, used either for estimation of mean 
blood glucose or prevalence of objectively defined diabetes, 6 did not identify 
the method used to measure glucose and in 4 not all participants were in fast-
ing conditions when blood glucose was measured. Seven studies did not pres-
ent the results stratified by sex and 9 did not stratify the results by age groups 
(Supplementary file, available online).
Prevalence of diabetes
Overall, 25 studies presented data on diabetes prevalence, using 10 different 
criteria to define diabetes (Supplementary appendix, available online).
Time trends of objectively defined diabetes could not be quantified due to the 
heterogeneity of the criteria for the diagnosis of diabetes and the scarcity of 
data pertaining to each criterion. The prevalence of objectively defined diabetes 
ranged from 0.0%, when defined as fasting glucose >110mg/dL, among male uni-
versity students, in 2005, to 40.0%, when defined as fasting glucose ≥126mg/dL 
and/or previous diagnosis and/or being on pharmacological treatment, among 
women aged 85-93 years, in 1999-2003. In general, the proportion of subjects 
with high fasting glucose increased with age and was higher among men, regard-
less of the criterion used to define the outcome.
The prevalence of self-reported diabetes increased with age, both in women and 
men (Figure 2), with no significant differences between sexes.
Table I depicts the estimated prevalence of self-reported diabetes in 1987 and 
2009, in women and men, at 30, 50 and 70 years of age. In this period, the 
prevalence of self-reported diabetes remained approximately constant among 
younger adults, while it increased in middle-aged and older adults, more than 
doubling among women and tripling among men. In 2009, the prevalence of 
self-reported diabetes estimated from the linear regression model was 8.6% and 
9.4%, assuming an average age of 50 years, among women and men, respec-
tively (Table I). 
Mean fasting glucose levels
Mean fasting glucose increased linearly with age, in women and men (Figure 2). 
Mean fasting glucose was 6 mg/dL [95% confidence interval (95%CI): 2 to 10] 
higher among men, independently of the year of survey and age.
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Between 1987 and 2009, mean fasting glucose increased 7 mg/dL (95%CI: 1 to 
12) among women and 8 mg/dL (95%CI: 0 to 19) among men. In 2009, assuming 
an average age of 50, the mean glucose levels were 96 mg/dL and 103 mg/dL, 
among women and men, respectively (Table I). 
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Discussion
We describe an important increase in the prevalence of self-reported diabetes in 
middle-aged and older adults, and in mean fasting glucose in all adult ages, both 
in women and men, in the last two decades, in Portugal.
This review represents the most comprehensive analysis of estimates of diabetes 
prevalence and mean blood glucose in Portugal to date. Our results are based 
on an extensive literature search that allowed the analysis of long-term trends 
of both prevalence of diabetes and mean glucose, taking into account the meth-
odological variation among studies. Nevertheless, some limitations need to be 
acknowledged. The utilization of a single search engine could decrease the com-
pleteness of the review. However, we may assume that studies including larger 
samples and more thorough methods were more likely to be published in journals 
with wider circulation that are indexed in Medline. Furthermore, our search strat-
egy included the screening of the bibliographic references of the review articles 
addressing the cardiovascular risk factors, fulfilling a potential gap of information 
due to smaller studies published in non-indexed journals. Since successful publi-
cation is not likely to be determined by the prevalence of a condition, we do not 
expect publication bias to be a major issue in this review.
Although the lack of some methodological information in some reports impaired 
an appropriate detailed characterization of all studies (Supplementary appendix, 
available online), those that failed to report on methodological characteristics 
deemed essential to interpret the evidence were excluded from our review.
In the included studies, we observed a considerable heterogeneity across the 
investigations, regarding target populations, methods for determining blood glu-
cose and criteria for defining diabetes. Since some studies referred to selected 
population samples, such as primary health care users, we reproduced our anal-
ysis using only the results from the studies involving samples of the general pop-
ulation but the conclusions remained the same (data not shown). Additionally, 
we included the geographical coverage of the studies as an independent variable 
in the models, but the results also did not change meaningfully. In statistical 
analyses on mean blood glucose, we excluded studies based on random blood 
glucose, but no other quality indicators, such as duration of fasting or laboratory 
methods, were considered in model fitting, since they were not systematically 
reported in the primary studies. Assessment of trends using population-based 
studies must take these factors into account, either by restricting to compa-
rable criteria or by converting scales when possible. The heterogeneity of the 
criteria used in primary studies for diagnosis of diabetes precluded a quantita-
tive analysis of trends in objectively defined diabetes in our study. However, this 
partially results from the continuous debate on and refinement of such criteria, 
with diabetes definitions varying among expert committees and over time 42, 43. 
Changes in criteria for diagnosis over time are also expected to directly influence 
the prevalence of self-reported diabetes. However, the awareness of a diagnosis 
of diabetes is intimately related with the need for pharmacologic treatment and 
the threshold for initiation of treatment is expected to depend on the overall 
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risk and not only on blood glucose levels. Therefore, despite the impossibility of 
knowing the specific contribution of the proportion of people with diabetes, the 
proportion of diabetics diagnosed and the awareness of patients diagnosed to 
the change in the prevalence of self-reported diabetes over time, this reflects a 
complex construct whose relevance goes beyond having blood glucose above 
a specified cut-off. Self-reported diabetes may be interpreted as the proportion 
of people aware of a blood glucose level that confers a high risk to that person 
at that time. The interpretation of the trends in self-reported diabetes should 
be made in light of this perspective. Additionally, we were not able to ensure 
that the self-reported diabetes only included type 2 diabetes. However, since the 
analysis regarded adult populations and there is no reason to believe that the 
prevalence of type 1 diabetes changed visibly during this period, we assumed 
that trends in self-reported diabetes reflect mainly changes in type 2 diabetes.
We were not able to quantify trends in objectively defined diabetes, but the 
trends in mean glucose levels argue in favour of an increase in the prevalence of 
diabetes in this time period. Current guidelines for the diagnosis of diabetes rec-
ommend a cut-off of fasting plasma glucose of 126 mg/dL. The absolute level of 
mean fasting glucose reported in this study was 93.4 mg/dL overall and in older 
ages approximated a lot to the diagnostic cut-off. Our results are in accordance 
with the trends in Western European populations, reported by a recent pooled 
analysis that assessed the variation in mean fasting glucose since 1980 worldwide 
9. This is further supported by the increase in the prevalence of self-reported dia-
betes, which is likely to reflect an increase in the awareness of diabetes, but also 
the trend towards higher blood glucose.
Despite men’s higher mean glucose levels at all ages, we did not find differences 
in self-reported prevalence of diabetes by sex. We hypothesize that this pat-
tern results from a lower use of health care services particularly primary care 44, 
resulting in a lower proportion of diagnosis and consequently lower awareness 
among men 18
The time trends in prevalence of diabetes and mean glucose levels observed in 
our review are likely to be driven by the variation in exposure to important deter-
minants of type 2 diabetes, such as physical inactivity, unhealthy diet and obesity 
45-47. In Portugal, there are no robust data on the trends in physical activity levels. 
However, data from the National Health Survey of 1998-1999 showed that 71% 
of the Portuguese adult population was sedentary 15. The dietary pattern in the 
country markedly changed in the last decades, towards a more westernized diet 
48. The prevalence of overweight increased 3% and 4%, and the prevalence of 
obesity increased 7% and 1% among women and men, respectively, between 1995 
and 2005, resulting in more than 40% of the Portuguese adults being overweight 
and around 20% obese in 2005. Specifically overweight and obesity markedly 
increased among young subjects between 1986 and 2000 12. The apparent con-
trast with the constant prevalence of self-reported diabetes among young adults 
in the current study is likely related with a lower attendance to health care ser-
vices and a considerable proportion of undiagnosed subjects at such young ages 
cannot be ruled out, since diabetes can remain asymptomatic for many years 
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42. The variation in the mean glucose levels results from the balance between 
changes in lifestyles and in the uptake of anti-diabetic medications. The increase 
in prevalence of self-reported diabetes is expected to be accompanied by an 
increase in the uptake of pharmacological treatment, contributing to lower fast-
ing glucose in treated diabetic patients. The estimates of mean glucose levels 
come from the whole samples, which also include treated diabetics, and thus 
reflect the true trend in population’s risk, including primary and secondary pre-
vention perspectives.
Numerous studies have found an inverse relation between the incidence of type 
2 diabetes and education, occupation, and income 49, putting people in lower 
socio-economic position at a particularly high risk. This effect is particularly wor-
risome in the current scenario of economic and financial crisis which Portugal is 
going through, translated into increased unemployment, lower purchase power 
to access healthy foods and use of private physical activity facilities, and a gen-
eral decrease in the quality of life of the population 50.
The reported increase in prevalence of self-reported diabetes and mean fast-
ing glucose requires the implementation of effective strategies to promote 
whole-population changes in body weight, regular physical activity and healthy 
diet as measures to prevent or delay the onset of type 2 diabetes.
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Table 1. Prevalence of self-reported diabetes and mean fasting glucose, predicted from linear regression models of each 
outcome on participants’ age and year of survey, for specific ages, in women and men.
Women Men
Year 30 years 50 years 70 years 30 years 50 years 70 years
Prevalence of self-
reported diabetes a
% (95% CI)
[11 studies, 65 age- and 
sex-specific estimates]
1987
2.0 
(0.0 to 4.4)
4.3
(1.2 to 7.3)
6.6
(2.5 to 10.6)
1.6 
(0.0 to 3.5)
3.0
(0.6 to 5.4)
4.4
(0.7 to 8.1)
2009
1.4
(0.0 to 3.9)
8.6
(6.8 to 10.4)
15.8
(12.7 to 19.0)
1.8
(0.0 to 4.1)
9.4
(8.2 to 10.7)
17.0
(14.7 to 19.4)
Mean fasting glucose
mg/dL (95% CI)
[4 studies, 28 age- and 
sex-specific estimates]
1987
82
(81 to 83) 
89 
(86 to 92) 
96
(89 to 103) 
86
(83 to 88) 
95 
(88 to 102) 
104
(92 to 115) 
2009
89
(82 to 95) 
96
(93 to 98) 
103
(101 to 104) 
94
(86 to 103) 
103
(95 to 112) 
112
(102 to 123) 
95% CI- 95% confidence interval
a This model includes an interaction term between the year of survey and participants’ age.
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a
If a study provided data on different outcomes, it is represented in more than one of the speciﬁc categories
 
87 studies with data only on other risk factors
114 studies
 
876 studies excluded based on full text 
assessment:
53 non humans
1 8 case reports
21 7 reviews or editorials
53 non Portuguese subjects
29 non adult population
286 sample selection dependent on cardiovascular risk 
factors
1 82 no data about risk factors or lack of information
38 data described on other reports on the same
sample
1 70 studies excluded during data extraction:
33 reviews or editorials
32 not presenting data in an eligible format
56 data described in other reports on the same
sample
49 insufﬁcient information to characterize population
284publications
 
2063 studies excluded based on title and 
abstract assessment:
1 1 non eligible language
1 80 non humans
269 case reports
416 reviews or editorials
69 non Portuguese subjects
19 8 non adult population
920 sample selection dependent on cardiovascular risk 
factors
1 160 publications
 
3223 publications
(3133 identified through Pubmed search and 90 from bibliographic references of reviews)
Search expression:
[humans[MeSH Terms] AND (Portugal[ad] OR portugal OR acta med port OR rev port cardiol OR rev port cir cardiotorac vasc 
OR rev port pneumol OR acta reumatol port OR lisboa[ad] OR lisbon[ad] OR (porto[ad] NOT (brasil[ad] OR brazil[ad])) OR 
coimbra[ad] OR braga[ad] OR covilha[ad]) AND ((hypertension OR "high blood pressure" OR "blood pressure" OR systolic OR 
diastolic) OR (obes* OR "body mass index" OR bmi OR overweight) OR (cholesterol OR triglycerides OR HDL OR LDL OR 
dyslipidemia) OR (smoking OR smoke OR tobacco OR cigarette) OR (diabetes OR glycemia OR hyperglycemia OR "impaired 
fasting glucose" OR IFG OR "impaired glucose tolerance") OR ("physical activity" OR "leisure activities" OR motor activity[mh] 
OR sedentariness OR exercise))]  
27 studies with data on mean blood glucose levels and/or prevalence of diabetes 
a
10 studies with data on the 
prevalence of objectively deﬁned
diabetes 
17 studies with data on the
prevalence of self -reported 
diabetes
 
6 studies with data on mean 
fasting glucose
 
Figure 1 Systematic review flowchart
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Figure 2 Prevalence of self-reported diabetes and mean fasting glucose according to age, in women and men.
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Abstract
Aims: To assess time trends in the use of main drug classes for secondary pre-
vention, during hospitalization and at hospital discharge, following an ACS, in 
Portugal, using a systematic review.
Methods: We searched PubMed, from inception until 2012, to identify stud-
ies reporting the proportion of ACS patients treated with aspirin, clopidogrel, 
beta-blockers, angiotensin-converting enzyme (ACE) inhibitors and statins. We 
used linear regression to quantify the annual variation in use of drugs, adjusting 
for the proportion of men in the sample and patients’ mean age, and including a 
quadratic term of data collection year when relevant.
Results: In 25 eligible studies, including patients treated from 1993 to 2009, we 
observed an increase in the prescription of pharmacological treatments at hospi-
tal discharge. Extrapolating from these data,  and assuming a mean patient age 
of 65 years and 70% of men, we estimate that, in 2008, 95% of patients would 
have been discharged with aspirin, 92% with clopidogrel, 82% with beta-block-
ers, 80% with ACE inhibitors and 91% with statins. Treatment during hospitaliza-
tion followed a similar pattern, except for a steeper increase in ACE inhibitors 
use, which was initially lower, but reached similar levels to those at discharge in 
recent years.
Conclusions: In Portugal, there was an increase in the use of recommended phar-
macological therapy for secondary prevention after an ACS over the last 15 years, 
during hospitalization and at hospital discharge.
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Introduction
Patients who survive an acute coronary syndrome (ACS) are at high risk for 
recurrent events and premature death 1. Aggressive comprehensive risk factor 
management improves survival, reduces recurrence and the need of interven-
tional procedures, and improves the quality of life of these patients 1. Current 
guidelines recommend lifestyle changes and advocate combination therapy with 
four drug classes for secondary prevention: antiplatelet agents, beta-blockers, 
angiotensin-converting enzyme (ACE) inhibitors and statins 2, 3. Additionally, 
starting secondary prevention early, during the hospitalization for the acute 
event, further improves outcomes 3, 4.
In most developed countries, including Portugal, the ischemic heart disease 
mortality rate has been declining since the 1980s 5, 6. The increasing use of evi-
dence-based therapies is expected to play an important role in these trends. In 
European countries, around 45% of the fall in coronary heart disease deaths was 
attributed to treatments, whereas the contribution of secondary prevention was 
around 10% of all prevented or postponed deaths 7-9. However, patients with ACS 
are still not always optimally managed. According to the EUROASPIRE III survey 
10, the use of cardioprotective medication at hospital discharge following an ACS 
ranged from 71% for ACE inhibitors to 91% for antiplatelets, suggesting that there 
is potential to raise the optimal use of prophylactic drug therapies throughout 
Europe.
Monitoring the patterns of care is essential for policy makers, health system 
managers, health professionals and consumers for the assessment of the effec-
tiveness of care and guidance towards its improvement. Data on the temporal 
changes in management patterns of pharmacological therapy across the broad 
spectrum of ACS in Portugal are scarce. Therefore, we conducted a systematic 
review to summarize the published data and to assess time trends in the use of 
pharmacological therapy for secondary prevention, during hospitalization and 
prescribed at hospital discharge, following an ACS in Portugal.
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Methods
Search strategy
We searched PubMed from inception until July 2012 to identify original reports 
providing data on the proportion of patients with ACS, stable angina or heart 
failure treated with pharmacological and non-pharmacological therapies in 
Portugal, according to the search expression provided in the systematic review 
flowchart (Figure 1). This study focuses only on pharmacological therapies in 
ACS. The reference lists of review articles about treatment of ACS patients were 
screened to identify other potentially relevant original studies.
Screening of references lists
Two reviewers independently evaluated the studies in two steps, following the 
same predefined criteria, to determine the eligibility of each report. In the first 
step the exclusion of irrelevant studies was decided by considering only the 
title and abstract; when the abstract of a particular article was not available, the 
article was selected for further evaluation, except when the title unequivocally 
presented information for exclusion (e.g. case report). The full texts of studies 
selected for the second step were then evaluated to decide on their eligibility and 
availability of relevant data. The decisions made independently by two reviewers 
were compared in the two phases and the disagreements were resolved by con-
sensus or after discussion with a third researcher if necessary.
The criteria for exclusion of studies were: not involving humans (e.g. in vitro stud-
ies; animal research); case reports; reviews, editorials or comments; not involving 
Portuguese hospitals; involving ACS patients whose selection was dependent on 
having undergone some diagnosis or treatment procedure under study and with 
no information about any other procedure (e.g. samples including only patients 
that were treated with aspirin); not providing data on treatments in ACS patients; 
data described on other reports of the same studies; insufficient information to 
characterize the population (e.g. not providing information on patients’ age or 
sex, or sample size).
When more than one study referred to the same sample, we applied the follow-
ing criteria, consecutively, to select only one: participants selected according 
to a broader criteria to define the eligible diagnoses [e.g. ACS patients instead 
of ST segment elevation myocardial infarction (STEMI) patients]; longer time 
period considered; largest sample size; information available for more eligible 
treatments. When two publications studied the same sample, but reported com-
plementary results about eligible treatments, both articles were used to extract 
data, but the information about each eligible treatment was considered only 
once in the data analysis. 
Data extraction
Papers were scrutinized using a standardized data extraction sheet. The cate-
gories of data extracted included identification of the first author, year of pub-
lication, year or period of data collection, region, sample characteristics (study 
population, proportion with STEMI, proportion of men, age and sample size) 
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and proportion of patients who received aspirin, clopidogrel, beta-blockers, 
ACE inhibitors or statins during hospitalization or at hospital discharge. When 
an article presented data stratified by a variable with no interest to our analysis 
(e.g. diabetic versus non-diabetic patients), we calculated the weighted average 
of the proportions over strata. We considered two types of study population 
regarding their representativeness: when patients’ selection was dependent on 
having undergone a treatment or a diagnostic procedure, the population was 
considered selected; otherwise, it was considered unselected. We extracted 
sex-, age- and year-specific estimates whenever available. 
Statistical methods
To assess time trends in the proportion of patients treated with each drug class 
we fitted linear regression models, including the year of survey, proportion of 
men in the sample or stratum and patients’ mean age as independent variables. 
Additionally, we included a quadratic term of the year of data collection as an 
independent variable if the model fit improved, according to the Akaike (AIC) 
and Bayesian information criteria (BIC). As one or more estimates of the out-
comes were extracted from each study, corresponding to different age and sex 
strata, we considered them to belong to the same cluster and computed robust 
standard error estimates.
The statistical analysis was performed using Stata version 9 ® (Stata Corporation, 
College Station, Texas, USA).
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Results
We identified 25 studies 12-36 eligible for the systematic review, published between 
1996 and 2011 (Figure 1). Eighteen studies reported data on medication during 
hospitalization 12, 13, 15-17, 19, 22-27, 29-33, 36 and 15 studies at hospital discharge 12, 14, 16, 18, 20, 
21, 24, 26-28, 30, 31, 33-35.
The detailed description of the methodological characteristics and results pre-
sented in the primary data sources are presented in a supplementary file, avail-
able online. The vast majority of the studies contained data from one institution 
only, mainly from Lisboa, and three studies 16, 23, 26 used data from national regis-
tries. All studies included consecutively admitted patients fulfilling the selection 
criteria and 20 relied on unselected samples. No studies presented sex-specific 
estimates, two studies 19, 35 presented age-specific estimates and one study 26 
stratified the data by calendar year.
Figures 2 and 3 display the age-specific estimates of the use of secondary pre-
vention during hospitalization and at hospital discharge reported in the original 
studies, respectively, according to year of data collection. Figure 4 represents 
estimates from our models for specific years, assuming 70% of male patients and 
a mean age of 65 years.
During hospitalization, the use of aspirin remained consistently very high, increas-
ing 0.7% per year [95% confidence interval (95% CI): 0.4 to 1.0], between 1995 and 
2008 (Figures 2 and 4), independently of patients’ mean age and the proportion 
of men in the sample. The use of clopidogrel increased quadratically from null to 
almost universal during the mid-2000s (Figure 2), with an estimated proportion 
of patients treated increasing from 12% to 96%, between 2002 and 2008 (Figure 
4). The use of beta-blockers during hospitalization increased approximately 
two-fold between 1995 and 2000 and remained constant since 2000 (Figure 2), 
reaching 74% of patients in 2008 (Figure 4). The age- and sex-adjusted uptake 
of ACE inhibitors increased 3.5% per year (95% CI: 2.1 to 4.9) between 1995 and 
2008, and 9 out of 10 patients took a drug from this class during hospitaliza-
tion, in 2008. The use of statins during hospitalization increased quadratically, 
mainly between 2000 and 2005, reaching around 90% of the patients after that 
(Figures 2 and 4).
At hospital discharge, between 1995 and 2008, the prescription of aspirin 
remained approximately constant [variation of 0.5% per year (95% CI: -0.1 to 
1.2)] covering above 95% of patients, in 2008 (Figures 3 and 4). The prescription 
of clopidogrel increased 12.0% per year (95% CI: 6.6 to 17.4 from a small minority 
to the vast majority of patients, between 2002 and 2008. The age- and sex-ad-
justed use of beta-blockers and ACE inhibitors increased 3.6% per year (95% CI: 
2.2 to 5.0) and 1.4% per year (95% CI: -0.5 to 3.3), respectively, up to 85% and 
80% of ACS patients in 2008 (Figures 3 and 4). Statins prescription at hospi-
tal discharge increased quadratically, mainly between 2000 and 2005, reaching 
about 90% of the patients in the late 2000s (Figures 3 and 4).
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Discussion
In the last 10-15 years, we observe an increase in the prescription of pharma-
cological treatments at hospital discharge after an ACS in Portugal, and it is 
estimated that, in 2008, almost all patients were discharged with aspirin, 9 out 
of 10 with clopidogrel and a statin, and 8 out of 10 with a beta-blocker and/or 
an ACE inhibitor. A similar pattern was observed for the trends in the uptake of 
these drug treatments during hospitalization, except for ACE inhibitors, whose 
use was lower in the hospital than at discharge in the mid-1990s, but increased 
more steeply in this setting, reaching similar levels to those at discharge in recent 
years.
The present study had the objective of identifying not only the larger observa-
tional studies, such as those based on national registries, but also smaller studies, 
which generally have lower visibility. We based our results on an extensive liter-
ature search that allowed the analysis of long-term trends taking into account 
the methodological variation among studies. The inclusion of all published data 
is important, because the consecutive recruitment is not ensured in the national 
registries, possibly limiting their representativeness. Administrative databases, 
such as the national register of hospital discharges, do not include data on phar-
macological treatments. 
Study limitations
Although a systematic review was the best approach to answer our objective 
regarding the assessment of trends, some limitations need to be acknowledged. 
The utilization of a single search engine may have limited our results. However, 
inclusion of revelant studies identified in the bibliographic references of the 
review articles was important to identify non-PubMed indexed publications. 
The generalizability of our results is debatable, since it is likely that our esti-
mates reflect mostly the usual care in higher quality specialized centers of the 
public system. The national health system provides universal access to health 
care and, until very recently, severe acute events like an ACS were exclusively 
treated in public hospitals. However, most of the studies reported data from 
urban hospitals, and centers with lower adherence to recommendations are not 
expected to publish their performance, yielding an overestimation of the propor-
tion of patients treated in the country. It would be useful to have sex-, age- and 
year-specific estimates to assess trends in the use of pharmacological treatments 
in ACS patients more precisely. Since some studies referred to selected patients 
(Supplementary file, available online), we reproduced our analysis using only the 
results from the studies involving samples of the unselected patients but the 
conclusions remained the same (data not shown). 
Our results are in accordance with the proportion of use of pharmacological 
treatment as secondary prevention after an ACS reported in other European 
countries. Recent estimates from Euro Heart Survey 10, an European program that 
did not include specific data from Portugal, suggested that, at hospital discharge, 
the majority of patients were prescribed antiplatelet drugs (91%), beta-blockers 
(80%), ACE-inhibitors (71%) and statins (78%), in 2006-2007. This study focused 
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on consecutive patients, with a clinical diagnosis of CHD, in 76 hospitals from 22 
European countries. The comparison of these estimates with previous data from 
an older Euro Heart Survey study 37 shows a general improvement in the man-
agement of ACS in Europe. However, considerable variation among European 
countries was found in the trends of use of some prophylactic drug therapies 
10, and this warrants monitoring these indicators in each specific population and 
health system. 
Evidence for the efficacy of different pharmacological treatments for the sec-
ondary prevention after an ACS has become available gradually over the last 
two decades. Of the drugs included in our analysis, aspirin was the first with 
proven effectiveness in coronary heart disease patients, in the 1980s 38, and we 
observed that it was already highly used by our medical community in the mid-
1990s. Persuasive data showing that beta-blockers were effective in the treat-
ment of myocardial infarction resulted firstly from the Norwegian Timolol Trial 39 
and the Beta Blocker Heart Attack Trial (BHAT) 40, also in the 1980s. The effect of 
early intervention with ACE inhibitors in slowing the progression of cardiovascu-
lar disease and improving survival rates was first described in the early 1990s 41, 
42. In the mid-1990s, several large randomized clinical trials have established the 
effectiveness of statins43 in preventing mortality and non-fatal coronary events, 
in the context of secondary prevention. Finally, it was only in the late 1990s that 
a role for clopidogrel in the management of coronary heart disease was estab-
lished 44. Therefore, it was expected that we would only have primary data about 
the use of these two treatments after the early 2000s.
Initiation of secondary prevention measures prior to hospital discharge clearly 
confers improved longer-term treatment use and patient compliance 45. Moreover, 
starting multiple new medications in a closely monitored setting may also help 
alleviate patient’s concerns about medication tolerability and side effects 46. The 
importance of initiation of pharmacological therapy during hospitalization is 
also highlighted by the fact that hospital physicians are more likely than general 
practitioners to prescribe drugs for secondary prevention and the likelihood of 
ever receiving prophylactic drugs if the treatment is not initiated at the time 
of discharge is small 47.In our study, we estimated that a large proportion of 
patients initiated the drug treatment during hospitalization, and specifically 
aspirin, clopidogrel and statins were used in almost every hospitalized patient, 
in 2008. However, while the prescription of drugs during hospitalization means 
100% uptake by the patients, the prescription of drugs at hospital discharge 
clearly overestimated the real use of the drugs by patients 48, because some of 
them discontinue active follow-up by a doctor, some have difficulties in access to 
medical care after the acute event, and others might simply decide to stop taking 
the drugs due to financial reasons or misperception of risk.
Despite the high proportion of ACS patients under effective drug therapies in 
Portugal, there remains a small proportion of patients who did not benefit from 
them. The lower use of beta-blockers and ACE-inhibitors, compared with the 
other treatments, in 2008, may be due to the contraindications and the adverse 
drug reactions attributed to these drugs, such as hypotension, sexual dysfunction 
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or nausea 1. Additionally, until recently 4, the treatment with ACE-inhibitors was 
only a class IIa recommendation for ACS patients without left ventricular dys-
function, meaning that the weight of evidence was in favour of its usefulness 
but there was not a general agreement about its utilization. In the absence of 
known contraindications, advanced age, female sex, history of heart failure, and 
renal dysfunction are usually independently associated with lower use of ther-
apy, despite their higher risk of cardiovascular complications or death and, thus, 
higher expected benefit in these groups. In contrast, patients with more exten-
sive coronary artery disease, as reflected by prior myocardial infarction or coro-
nary revascularization, are more likely to be given aggressive medical treatment 
49. In a multicenter Canadian registry, including 1956 non ST segment elevation 
ACS patients, in 2002/2003, the most commonly reported reason for not pre-
scribing evidence-based medical therapies to patients without specific contrain-
dications or proven drug intolerance was the physician´s subjective assessment 
that the patient’s risk was not enough to justify the treatment or that there was 
not enough evidence to support the prescription. 50. Unfortunately, in the present 
review we could not analyze individual determinants of access to the treatments 
in the Portuguese population.
There was an improvement in the use of the recommended pharmacological 
therapy for secondary prevention after an ACS in Portugal, with the vast majority 
of patients currently receiving antiplatelet therapy, statins, beta-blockers and 
ACE inhibitors, and a trend towards earlier start of therapy before discharge. 
The therapeutic goals set by the Joint European Societies recommendations on 
prevention after an ACS in clinical practice seem to be followed in high extension 
in Portugal, at least in cardiology centers. Beyond the continuous monitoring of 
practices with consistent prospective data, with the growing population of ACS 
survivors, future investigation should focus on the identification of the determi-
nants for the long-term adherence to evidence-based optimal treatment. 
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Figure 1. Systematic review flowchart.
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
a 
If a study provided data on treatment both during hospitalization and at hospital discharge, it 
contributed to both groups.    
b For each drug class, we considered age - and year -speciﬁc estimates when available, resulting 
in possibly more than one estimate from the same study.  
15  studies with data on 
medication prescribed at hospital 
discharge 
1 8 studies with data on 
medication during 
hospitalization 
humans[mesh] AND (portugal[ad] OR portugal OR "acta med port"[journal] OR "rev port cardiol"[journal] OR "rev port cir 
cardiotorac vasc"[journal] OR lisboa[ad] OR lisbon[ad] OR (porto[ad] NOT (brasil[ad] OR brazil[ad])) OR faro[ad] OR gaia[ad]) AND 
("ischemic heart disease" OR "coronary artery disease"[mesh] OR "coronary heart disease" OR "acute coronary syndrome"[mesh] OR 
"myocardial infarction"[mesh] OR "acute myocardial infarction" OR "angina pectoris"[mesh] OR "angina, unstable"[mesh] OR "stable 
angina" OR "chronic angina" OR angor OR "heart failure"[mesh]) AND (hospitalization[mesh] OR (therapeutics[mesh] OR treatments 
OR drug OR medication) OR "myocardial revascularization"[mesh] OR ("coronary artery bypass graft" OR cabg) OR (angioplasty, 
balloon[mesh] OR ptca OR "Percutaneous transluminal coronary angioplasty" OR "primary angioplasty") OR "hospital resuscitation" 
OR (thrombolysis OR "ﬁbrinolytic agents"[pharmacological action] OR actilyse OR streptase OR rapilysin OR metalyse) OR 
aspirin[mesh] OR ("adrenergic beta-antagonists"[pharmacological action] OR "beta blockers") OR ("ace inhibitors" or "angioten-
sin-converting enzyme inhibitors"[pharmacological action]) OR "platelet iib/iiia inhibitors" OR clopidogrel[substance name] OR 
heparin[mesh] OR "platelet aggregation inhibitors"[pharmacological action] OR statins OR warfarin[mesh] OR spironolactone[mesh] 
OR rehabilitation OR "angiotensin ii type 1 receptor blockers"[pharmacological action] OR ("resynchronization therapy" OR "cardiac 
resynchronization therapy" OR crt OR "biventricular pacemaker") OR ("implantable cardiodeﬁbrillator" OR "implantable cardio 
deﬁbrillator" OR "implantable cardiac deﬁbrillator" OR "implantable cardioverter deﬁbrillator" OR icd) OR (heart transplant* OR heart 
transplantation[mesh terms] OR "allogeneic graft") OR Cardiac Surgical Procedures[mesh]) AND (english[lang] OR spanish[lang] OR 
portuguese[lang])
682 publications
(626 identiﬁed through Pubmed search and 56 from bibliographic references of reviews)
600 publications excluded:
6 –  not involving humans
58 –  case reports
244 – reviews, editorials or comments
46 – not involving Portuguese hospitals
75 –  patients’ selection dependent on having            
undergone some diagnosis or treatment under 
study
110 –  not providing data on treatments 
10 –  insufﬁcient information to characterize the 
population 
51 –  data described on other reports on the same
studies
57 – publications with data exclusively on other 
diagnoses and treatments
25 publications with data on pharmacological treatments a
Number of estimates b
23 Aspirin
14 Clopidogrel
26 Beta-blockers
25 ACE inhibitors
21 Statins
Number of estimates b
16 Aspirin
12 Clopidogrel
19 Beta-blockers
18 ACE inhibitors
17 Statins
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ACE inhibitors –angiotensin-converting-enzyme inhibitors;
Dotted lines represent the prediction for the proportion of use of each therapy based on linear (for aspirin and ACE inhibitors) 
or quadratic (for clopidogrel, beta-blockers and statins) models, as a function of calendar year.
ACE inhibitors –angiotensin-converting-enzyme inhibitors;
Dotted lines represent the prediction for the proportion of use of each therapy based on linear (for aspirin, clopidogrel, beta-
blockers and ACE inhibitors) or quadratic (for statins) models, as a function of calendar year.
Figure 3
Use of pharmacological 
therapy for secondary 
prevention prescribed 
at hospital discharge, 
according to year of 
data collection.
Figure 2.
Use of pharmacological 
therapy for secondary 
prevention during 
hospitalization, 
according to year of 
data collection.
aspirin
clopidogrel
aspirin
clopidogrel
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ACE inhibitors - angiotensin-converting-enzime inhibitors; Horizontal lines are 95% confidence intervals of estimated 
proportions.
Figure 4
Estimated proportion 
of patients treated with 
aspirin, beta-blockers 
and ACE inhibitors 
in 1995 and 2008, 
clopidogrel in 2002 
and 2008, and statins 
in 2000 and 2008, 
assuming 70% of male 
patients and a mean 
age of 65 years, during 
hospitalization and 
prescribed at hospital 
discharge. 
Hospitalization Hospital discharge
Proportion of patients treated (%) Proportion of patients treated (%)
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Abstract
Aims: To assess the proportion of patients receiving pharmacological therapy for 
secondary prevention after an acute coronary syndrome (ACS) in Portugal, and 
to identify age and sex inequalities.
Methods:  We studied 747 episodes of ST segment elevation myocardial infarc-
tion (STEMI) and 1364 of non-ST segment elevation ACS (NSTE-ACS), within a 
sample of ACS cases consecutively discharged from ten large Portuguese hospi-
tals, in 2008-2009. We estimate adjusted odds ratios (OR) for the association of 
age and sex and the use of each pharmacological treatment.
Results: In STEMI and NSTE-ACS patients, the proportion of patients discharged 
with aspirin was 96% and 88%, clopidogrel 91% and 78%, aspirin+clopidogrel 88% 
and 71%, beta-blockers 80% and 76%, ACE-inhibitors/ARB 82% and 80%, statins 
93% and 90%, 3-drug (aspirin/clopidogrel+beta-blocker+statin) 76% and 69% and 
5-drug treatment (aspirin+clopidogrel+beta-blocker+ACE-inhibitor/ARB+statin) 
61% and 48%, respectively. Among STEMI patients, those aged ≥80 years were 
substantially less often discharged with clopidogrel [OR=0.22, 95% confidence 
interval (95%CI):0.08-0.56], aspirin+clopidogrel (OR=0.34, 95%CI:0.15-0.76), 
beta-blockers (OR=0.39, 95%CI:0.18-0.82), 3-drug (OR=0.41, 95%CI:0.21-0.83) 
and 5-drug treatments (OR=0.44, 95%CI:0.23-0.83) than those <60 years; women 
were less likely to be discharged with aspirin+clopidogrel (OR=0.52, 95%CI:0.29-
0.91). Among NSTE-ACS patients, those aged ≥80 years were much less likely to 
be discharged with beta-blockers (OR=0.58, 95%CI:0.36-0.93), statins (OR=0.35, 
95%CI:0.19-0.64) and 3-drug treatment (OR=0.47, 95%CI:0.30-0.75); sex had no 
significant effect on treatment prescription.
Conclusions: The vast majority of younger patients were discharged on evi-
dence-based secondary preventive medications, but only half received the 
5-drug combination. Worse still, recommended therapies were substantially 
underprescribed in older patients. 
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Introduction
Ischemic heart disease remains a leading cause of death worldwide and in 
Portugal 1, 2. Acute coronary syndrome (ACS) is the most prevalent manifestation 
of unstable ischemic heart disease and can lead to life-threatening complications 
after discharge. A combination of evidence based secondary preventive med-
ications and lifestyle interventions can substantially reduce that risk. However, 
these management strategies need to be considered and implemented at hospi-
tal discharge for all ACS survivors, regardless of age or sex 3, 4.
 
Age is associated with a higher risk of atherosclerotic diseases, due to the 
degenerative process associated with aging per se, together with the cumulative 
impact of the worsening risk-factor profile. In Portugal, the proportion of people 
aged 65 years and over almost doubled from 1980 to 2010 5. Patients with a first 
non-fatal ACS have an almost 10% risk of death within 6 months and advanced 
age is one of the most powerful independent predictors of death 6. The proportion 
of individuals aged over 75 years admitted to public Portuguese hospitals with an 
acute myocardial infarction increased from 27% in 2000 to 35% in 2008 7. Case 
fatality in these older patients is over twice that in those aged under 75 years 6. 
Women have traditionally been seen as a low-risk population for cardiovascular 
diseases. However, the incidence of cardiovascular diseases in women increases 
rapidly after menopause to levels similar to those observed in older men 8. Thus 
in Portugal, in 2010, over 18,000 women and 15,000 men died from cardiovas-
cular diseases 9. Women now account for over one third of acute myocardial 
infarction cases 7.  Furthermore, the age-adjusted prognosis after an ACS admis-
sion is worse in women than in men, possibly reflecting delays in diagnosis, more 
frequent atypical presentation and, crucially less aggressive treatment 10.
According to the European Society of Cardiology, all patients recovering from 
an ACS should initiate treatment with low-dose aspirin indefinitely, an oral aden-
osine diphosphate receptor antagonist for up to one year post event, a beta-
blocker, statin and angiotensin-converting-enzyme (ACE) inhibitor, for second-
ary prevention, unless contra-indicated 3, 4. However, many international studies 
have reported an underutilization of evidence-based treatment in ACS patients 
discharged from hospitals, particularly in women and older patients 11, 12.
Data on the use of pharmacological therapy after an ACS in Portugal are scarce 
13. Therefore, we analysed the proportion of patients receiving pharmacological 
therapy as secondary prevention after an ACS admission in ten Portuguese hos-
pitals, and explored potential age- and sex-differences.
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Methods
The EURHOBOP project is a multicenter and multinational retrospective study 
of patients hospitalized with a final diagnosis of ACS, consecutively discharged 
from 70 hospitals in 7 European countries (Finland, France, Germany, Greece, 
Italy, Portugal and Spain). The current analysis only considers data from patients 
admitted to the 10 representative Portuguese hospitals. 
Portuguese hospitals
The 10 hospitals were a convenience sample of public hospitals, selected to cover 
the mainland country from North to South and East to West, while serving both 
urban and rural populations. Participating hospitals are listed in the acknowl-
edgments section. Since we aimed to have hospitals with different levels of spe-
cialization represented in our sample, we invited hospitals with diverse charac-
teristics, regarding facilities, infrastructure and human resources’ specialization. 
Overall, five hospitals had a catheterization laboratory, three had a cardiac sur-
gery department, while one only had a general internal medicine department 
with no cardiology department or cardiologists; four were university hospitals; 
the number of beds ranged from 280 to 1124.
Study participants 
From each hospital we obtained a series of 300 consecutive patients, inde-
pendently of the departments where the patient had been hospitalized. The 
inclusion criteria were a discharge diagnosis of myocardial infarction, with or 
without ST-segment elevation, or unstable angina (International Classification of 
Diseases 10th revision: I21.0 – I21.9 and I20.0). We aimed to study patients from 
2009 but in hospitals whose annual number of cases was not enough to obtain 
the 300-patient sample we extended the recruitment period backwards to 2008. 
The overall sample included a total of 3009 ACS patients. For this analysis, we 
excluded patients who died during hospitalization (8%), who were transferred to 
another hospital (11%) and patients with no data on discharge medication (9%) 
(Figure 1), leaving 2231 for analysis. In comparison with patients included in analy-
sis, those without data on discharge medication were slightly older (median age: 
71 versus 68, p value<0.001), more frequently had a non-ST segment elevation 
ACS (NSTE-ACS) (74.8% versus 64.6%, p value=0.003). However, the proportion 
of men was identical (68.7% versus 68.7%, p value=0. 552).
Data collection
Data was collected by trained medical record extractors using a standardized 
data collection form. The main source of information was the discharge letter, 
and information on emergency room records and laboratory information sys-
tems was accessed, whenever available. We extracted information on type of 
diagnosis, demographic characteristics, previous medical history, admission 
data, procedures used during hospitalization, severity indicators and complica-
tions during hospitalization and discharge medication.
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All drugs prescribed at discharge were recorded and classified according to the 
Anatomical Therapeutic Chemical Classification System (ATC). The discharge 
therapy considered for this analysis was aspirin (ATC code: B01AC06), clopido-
grel (ATC code: B01AC04), beta-blockers (ATC codes: C07), ACE inhibitors or 
angiotensin receptor blockers (ARB) (ATC codes: C09A, C09B, C09C and C09D) 
and statins (ATC codes: C10AA and C10BA). Other oral adenosine diphosphate 
receptor antagonists were not considered as there was no use of these agents in 
2008 and 2009. Additionally, we computed composite variables for drug com-
binations: double antiplatelet therapy with aspirin and clopidogrel, 3-drug treat-
ment [(aspirin or clopidogrel) and beta-blocker and statin] and 5-drug treatment 
[aspirin and clopidogrel and beta-blocker and (ACEi or ARB) and statin]. 
Statistical analyses
Proportions were compared using Pearson Chi-square tests (Figure 1). We used 
mixed-effects logistic regression to estimate odds ratios (OR) for the association 
of age and sex with the use of each pharmacological treatment. The models 
included variables that are likely to influence the prescription due to their role 
as compelling indication or relative contraindication for each drug (please see 
the footnotes presented in Table 1)as fixed effects and random intercept at the 
hospital level to account for differences between hospitals. The potentially rele-
vant confounders were identified based on previous knowledge, independently 
of their significant effect in this sample 3, 4. The main analysis presented in this 
paper was stratified by type of ACS: ST segment elevation myocardial infarc-
tion (STEMI) or non-ST segment elevation ACS (NSTE-ACS). Those who had 
non classifiable type of ACS and missing data on that variable were excluded 
from this analysis. However, in the Table 4 of the supplementary appendix we 
report the effect of age and sex in all ACS patients, adjusting for the type of ACS, 
beyond other confounders.
The statistical analysis was performed using Stata®, version 11.2 (Stata Corporation, 
College Station, Texas, USA).
Ethics
The ethics committee of the University of Porto Medical School and the National 
Commission for Data Protection approved the study. These two entities agreed 
that it would not be necessary to ask for patients’ informed consent, since the 
study was based on the collection of retrospective clinical data from the medical 
records during hospitalization, and the confidentiality of patients’ identification 
was assured. 
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Results
Patient characteristics 
The median age of the 2231 patients was 68 years (range 21–99 years), and 20% 
were aged over 80 years. Approximately two-thirds of the participants were men 
(67%), with a lower median age than women (65 versus 75 years). Most patients 
were admitted with a NSTE-ACS (61%), while a third (33%) had a STEMI and 
nearly 5% had a non-classifiable type of ACS due to either subacute presentation 
or left bundle branch block of unknown duration. We could not obtain informa-
tion on the type of ACS in 0.5%. Compared with the NSTE-ACS patients, those 
admitted with STEMI were younger, more frequently males and smokers, but 
less frequently hypertensive, diabetic and had a lower prevalence of previous 
myocardial infarction (Figure 1). 
Proportion of patients receiving pharmacological therapy
Overall, at discharge, 91.0% of the patients had a prescription of aspirin, 81.5% 
of clopidogrel, 76.5% of both aspirin and clopidogrel, 77.6% of a beta-blocker, 
80.0% of an ACE-inhibitor or ARB, 91.3% of a statin, 71.4% of the 3-drug treat-
ment and 51.8% of the 5-drug treatment. 
Among those with a diagnosis of STEMI, the proportion of patients discharged 
with aspirin was 96.2%, clopidogrel 91.0%, aspirin and clopidogrel 88.5%, beta-
blocker 80.5%, ACE-inhibitor/ARB 81.9%, statin 93.3%, 3-drug treatment 75.6% 
and 5-drug treatment 61.2%. The corresponding proportions for NSTE-ACS 
patients were consistently lower: 88.1% for aspirin, 77.7% for clopidogrel, 71.4% for 
aspirin and clopidogrel, 76.2% for beta-blockers, 79.0% for ACE-inhibitors/ARB, 
90.3% for statins, 69.5% for 3-drug treatment and 47.9% for 5-drug treatment. 
Considering only patients with a first ACS the proportions reported were very 
similar, except for a marginally significant difference in clopidogrel use in STEMI 
patients (85.0% versus 91.8%, in patients with and without previous myocardial 
infarction, respectively, p value=0.05). 
Age and sex differences in treatment
Overall the proportion of patients discharged with pharmacological treat-
ments was higher in younger patients for almost all medications (Figure 2). We 
observed a difference of more than 20% between the youngest and the oldest 
patients (<60 versus ≥80 years) in the proportion of STEMI patients treated with 
aspirin and clopidogrel (94.2% versus 72.9%), 3-drug treatment (84.5% versus 
61.5%) and 5-drug treatment (84.5% versus 61.5%).  Similar differences were 
noted among NSTE-ACS patients for clopidogrel (85.7% versus 62.6%), aspirin 
and clopidogrel (81.2% versus 55.5%), 3-drug treatment (76.1% versus 55.9%) and 
5-drug treatment (53.9% versus 31.5%). The sex differences were smaller than 
those observed with age (Figure 3).  Women were significantly less likely to 
receive clopidogrel, aspirin and clopidogrel, and 5-drug treatment, among STEMI 
patients; and clopidogrel and statins, among NSTE-ACS patients. 
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Table 1 presents the independent associations between age and sex and the use 
of each pharmacological treatment. The detailed tables presenting the OR for 
all variables included in the final models are presented in the supplementary 
appendix, available online. Among STEMI patients, women were much less likely 
to be discharged with aspirin and clopidogrel (OR=0.52). Compared to patients 
aged under 60 years, those aged over 80 years were far less often discharged 
with clopidogrel (OR=0.22), aspirin and clopidogrel (OR=0.34), beta-blockers 
(OR=0.39), statins (OR=0.74), 3-drug treatment (OR=0.41) and 5-drug treat-
ment (OR=0.44). Among NSTE-ACS patients, patients ≥80 years were less likely 
to be discharged with beta-blockers (OR=0.58), statins (OR=0.35) and 3-drug 
treatment (OR=0.47), comparing with patients aged <60 years.  There were 
no significant sex differences in pharmacological treatment prescribing among 
NSTE-ACS patients. 
When considering only patients with a first ACS, the independent associations 
between age and sex and the use of each pharmacological treatment were very 
similar, in both STEMI and NSTE-ACS patients. 
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Discussion
We report a large sample of consecutive ACS patients discharged from ten 
Portuguese representative hospitals across 2008 and 2009. A large majority of 
these patients were discharged with the main evidence-based pharmacologi-
cal treatments. However, only half received the recommended 5-drug treatment 
(aspirin and clopidogrel and beta-blocker and ACEi or ARB and statin). Worse 
still, increasing age had an independent and powerful adverse effect on the pro-
portion of patients discharged on effective therapies. 
Approximately 10% of post-ACS patients have a recurrent event within a year 
after discharge and mortality after discharge remains relatively high 14. However, 
pharmacological secondary prevention is potentially very effective in improving 
these outcomes, but only if prescribed 3, 4. Decisions on how to manage individual 
patients should be based on existing recommendations, taking into account the 
possible contraindications and cautions warranted for each treatment, as well 
as possible drug interactions.  There is a powerful international consensus that, 
after having considered contraindications, all ACS patients should be discharged 
on low-dose aspirin, an oral adenosine diphosphate receptor antagonist, a beta-
blocker, and a lipid-lowering drug 3, 4.  Furthermore, although the use of ACE 
inhibitors in all ACS patients is not unanimously accepted 15, the current European 
guidelines clearly recommend their prescription at discharge for all patients 3, 4. 
Despite the universal acceptance of clinical guidelines and management tools 
for ACS, there are geographic variations in the management of ACS 16. Several 
studies have reported the proportion of ACS patients discharged with phar-
macological treatment in European countries, and in general these propor-
tions were high 16. Estimates from the Euro Heart Survey, an European program 
that included data from 22 countries and in which Portugal did not participate, 
reported that 91% of the ACS patients were discharged with antiplatelet drugs, 
80% with beta-blockers, 71% with ACE inhibitors and 78% with statins, at hospital 
discharge, in 2006-2007 16. However, the proportions obtained in most of the 
existing registries may be overestimates, since they may represent higher risk 
patients, admitted in cardiology departments, in urban or teaching hospitals with 
cardiac intensive care units. For instance in Portugal, the National Registry of 
Acute Coronary Syndromes suggested that between 2002 and 2008, approxi-
mately 94% of ACS patients were discharged with aspirin, 52% with aspirin and 
clopidogrel, 71% with beta-blockers, 71% with ACE inhibitors, 87% with statins, 
and 63% with the combination of aspirin, clopidogrel, beta-blockers, ACE inhib-
itors and statins 13. Our data cannot be directly compared with those estimates, 
since that registry only covers cardiology departments, it does not assure the 
consecutiveness of patients within participating centers and generates estimates 
not necessarily representative for age or sex. In contrast, the diverse settings 
covered in our study potentially offer greater better representativeness of the 
general ACS population. Furthermore, the large consecutive sample of cases 
within a narrow time span regardless of the department where they had been 
hospitalized provides potentially important new data. Also, the sample provided 
unique data on the potentially important confounders of age and sex. While 
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treatment with invasive procedures may be dependent on hospital facilities such 
as a catheterization laboratory, the prescription of pharmacological treatment at 
discharge only depends on the medical decision. Thus, any variation in treatment 
that persisted after adjusting for the wide range of confounders was likely to 
reflect true inequalities. 
Despite the prescription of pharmacological treatment to the vast majority of 
patients at discharge, there is still scope for considerable improvement. In order 
to achieve optimal treatment it is particularly important to identify which groups 
of patients are being undertreated and the underlying reasons.
The proportion of STEMI patients treated according to the guidelines was higher 
than among NSTE-ACS patients. This may reflect differences in the patients’ 
characteristics. However, NSTE-ACS patients had a lower probability  of being 
treated with aspirin, aspirin and clopidogrel or with the 5-drug treatment even 
after adjustment for possible confounders (Table 4, supplementary appendix, 
available online). 
The major differences according to age suggest that physicians remain reluctant 
to prescribe these post-ACS medications to older patients 17, 18, despite the strong 
evidence that the old and very old would obtain a particularly large absolute 
benefit 19, 20. The general belief that the elderly are at higher risk of side effects 
from pharmacological treatment, such as bleeding with antiplatelet agents and 
anticoagulants, hypotension, bradycardia, and renal failure, may partly explain 
the under-prescription of these drugs in this population. We assessed the effect 
of age independently of the main contraindications or variables with a possible 
role as compelling indication, and older patients were undertreated even after 
adjustment. Despite previous reports highlighting the need to address age-de-
pendent inequalities in the quality of care for ACS 21-23, elderly patients hospital-
ized with an ACS continue to be disadvantaged when compared with younger 
aged patients. These persistent inequalities argue for future studies of motives 
and perceived barriers in using these evidence-based treatments, including a 
comparison between real and perceived clinical contraindications.
Although most therapeutic guidelines explicitly state that both sexes should be 
evaluated and treated in the same way, women with ACS have been less likely 
than men to receive evidence-based treatment in some populations 24, 25. Women 
with an ACS diagnosis are more likely to be older than men and to have diabe-
tes, hypertension, heart failure, or other co-morbidities 26, 27. This might perhaps 
justify part of the observed differences. Fortunately, our study suggests some 
improvements. We observe very few sex-differences in discharge medications 
after adjusting for the potential confounding effect of age, co-morbidities, and 
contraindications. 
Study characteristics and limitations
This was the first study to examine treatments after ACS including consecutive 
patients recruited in a large sample of Portuguese hospitals, from whom only 11% 
were transferred to other hospitals. To compute the independent effect of age 
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and sex, we considered the main confounding variables at the individual level 
and the effect of the hospital, using a hierarchical approach. However, some lim-
itations need to be acknowledged. Given the retrospective nature of this study, 
the validity of the conclusions relies on the accuracy and completeness of the 
original documentation. Although we had information for the most important 
variables to address our objectives, we must recognize that it would be best to 
have a better characterization of patient’s socio-economic position and other 
clinical information (for instance, peptic ulcer, and previous experience with 
these drugs in the same patient). It is important to note that this study did not 
examine the appropriateness of dosage or adherence rates and, therefore, no 
inference can be made on these issues. Patient’s adherence to medications was 
not assessed, but our primary focus was on physicians’ prescription patterns, 
and their compliance to guidelines. In addition to pharmacological treatment, 
lifestyle changes are important in secondary prevention 3, 4. Since this informa-
tion was not described systematically in the original documentation, we were 
not able to assess the extent to which this recommendation was given to the 
patients. Finally, we had missing data on discharge medication in 9% of the study 
population, and those excluded were significantly older and more frequently had 
a NSTE-ACS diagnosis, when compared with the patients with information on 
discharge medication. This suggests that the proportions reported are slightly 
overestimated when comparing with the initial sample selected for this study.
In conclusion, the vast majority of patients received evidence-based pharmaco-
logical treatment, but only half were discharged with the combination of the rec-
ommended 5 drugs. Further improvements are necessary, especially in elderly 
patients, in order to reduce future events and to improve their quality of life. 
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Figure 1 Flowchart illustrating the sample selection for the present analysis and the main characteristics of the patients, by 
type of acute coronary syndrome.
3009 ACS patients 
(2008-2009)  
311 transferred to another hospital 
234 deceased 
233 missing data on discharge medication 
2231 ACS patients 
747 STEMI patients  
10 missing data on type of ACS  
1364 NSTE-ACS patients 
-Age [median (interquartile range)]: 63 (53-75) years  
-Proportion of men: 75%  
-Previous history:  
 myocardial infarction: 11%  
 hypertension: 59%  
 diabetes: 21%  
 smoking: 35%   
-PCI or thrombolysis during hospitalization: 81%  
-Age [median (interquartile range)]: 70 (59-78) years  
-Proportion of men: 63%  
-Previous history:  
myocardial infarction: 26%  
hypertension: 72%  
diabetes: 36% 
smoking: 20% 
-PCI during hospitalization: 41%  
110 non classiﬁable ACS 
ACS – acute coronary syndrome; NSTE-ACS – non-ST segment elevation acute coronary syndrome; PCI – percutaneous coronary 
intervention; STEMI - ST segment elevation myocardial infarction.  
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Figure 2 Patients discharged after acute coronary syndrome with or without ST segment elevation.  Proportion discharged on 
aspirin, clopidogrel, aspirin & clopidogrel, beta-blocker, angiotensin-converting enzyme inhibitor (ACEi or ARB), statin, 3-drug 
treatment [(aspirin/clopidogrel) & beta-blocker & statin] and 5-drug treatment [aspirin & clopidogrel & beta-blocker & (ACEi /
ARB) & statin] according to age.
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ACEi – angiotensin-converting-enzyme inhibitor; ARB – angiotensin receptor blocker; NSTE-ACS – non-ST segment elevation acute coronary syndrome;  STEMI - ST segment 
elevation myocardial infarction.
  p value <0.05;
  3-drug treatment: (aspirin / clopidogrel) & beta-blocker & statin;
  5-drug treatment:  aspirin & clopidogrel & beta-blocker & (ACEi  / ARB) & statin.
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Figure 3 Patients discharged after acute coronary syndrome with or without ST segment elevation.  Proportion discharged on 
aspirin, clopidogrel, aspirin & clopidogrel, beta-blocker, angiotensin-converting enzyme inhibitor (ACEi or ARB), statin, 3-drug 
treatment [(aspirin/clopidogrel) & beta-blocker & statin] and 5-drug treatment [aspirin & clopidogrel & beta-blocker & (ACEi /
ARB) & statin] according to sex.
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ACEi – angiotensin-converting-enzyme inhibitor; ARB – angiotensin receptor blocker; NSTE-ACS – non-ST segment elevation acute coronary syndrome; 
STEMI - ST segment elevation myocardial infarction.
  p value <0.05;
  3-drug treatment: (aspirin / clopidogrel) & beta-blocker & statin;
  5-drug treatment:  aspirin & clopidogrel & beta-blocker & (ACEi  / ARB) & statin.
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ACEi – angiotensin-converting-enzyme inhibitor; ARB – angiotensin receptor blocker; NSTE-ACS – non-ST segment elevation acute 
coronary syndrome; PCI – percutaneous coronary intervention; STEMI - ST segment elevation myocardial infarction.
a Smoking was defined as current smoker or ex-smoker for less than 1 year;
b  Bradycardia was defined as heart rate <60 beat/min;
c Hypotension was defined as systolic blood pressure <90 mmHg;
d Heart failure was considered when there was a record of heart failure or Killip score ≥2 in the clinical record;
e Patients were considered as having left ventricular systolic dysfunction if the left ventricular ejection fraction was <40%;
f Renal failure was classified as acute if the patient presented new-onset renal dysfunction or a significant deterioration superimposed on 
chronic renal failure; it was considered only chronic when self-reported at admission or if the creatinine clearance at admission was <60 ml/
min with no further decompensation during hospitalization;
g Atrial fibrillation includes both chronic and new-onset cases.
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Supplementary table 3 Adjusted odds ratios (OR) for factors associated with the prescription of 3-drug treatment [(aspirin/
clopidogrel) & beta-blocker & statin] and 5-drug treatment [aspirin & clopidogrel & beta-blocker & (ACEi /ARB) & statin] at 
discharge, among patients with acute coronary syndrome with or without ST segment elevation.
STEMI
N=747
NSTE-ACS
N=1364
3-drug treatment a 5-drug treatment b 3-drug treatment a 5-drug treatment b
OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
Demographic
Age
(years)
< 60
60-79
1 1 1 1
0.45 (0.28-0.73) 0.65 (0.42-0.99) 0.86 (0.61-1.21) 1.20 (0.87-1.64)
≥ 80 0.41 (0.21-0.83) 0.44 (0.23-0.83) 0.47 (0.30-0.75) 0.77 (0.50-1.20)
Sex
Men 1 1 1 1
Women 1.25 (0.79-2.00) 0.74 (0.49-1.12) 1.13 (0.85-1.51) 0.96 (0.73-1.27)
Previous history
Smoking c
No 1 1 1 1
Yes 0.55 (0.33-0.90) 0.50 (0.32-0.77) 0.93 (0.65-1.35) 1.06 (0.75-1.49)
Diabetes
No 1 1 1 1
Yes 0.87 (0.54-1.38) 0.92 (0.60-1.40) 1.10 (0.83-1.47) 1.08 (0.82-1.42)
Hypertension
No - 1 - 1
Yes - 1.48 (1.03-2.13) - 1.46 (1.09-1.94)
Clinical data at admission
Bradycardia d
No 1 1 1 1
Yes 0.56 (0.34-0.94) 0.71 (0.44-1.15 ) 0.54 (0.36-0.83) 0.62 (0.40-0.95 )
Hypotension e
No 1 1 1 1
Yes 0.48 (0.18-1.29) 0.84 (0.30-2.32) 0.29 (0.11-0.74) 0.53 (0.18-1.51)
Anaemia f
No 1 1 1 1
Mild 1.02 (0.59-1.76) 1.12 (0.68-1.84) 1.20 (0.84-1.69) 1.18 (0.85-1.62)
Severe 0.68 (0.26-1.80) 0.97 (0.38-2.51) 0.75 (0.47-1.20) 0.50 (0.31-0.81)
Procedures used during hospitalization
Thrombolysis
No 1 1 - -
Yes 1.91 (1.06-3.46) 1.41 (0.85-2.32) - -
PCI
No 1 1 1 1
Yes 3.36 (2.19-5.17) 3.71 (2.47-5.58) 1.78 (1.33-2.37) 3.37 (2.58-4.41)
Severity indicators and complications during hospitalization
Heart failure g 
No 1 1 1 1
Yes 0.67 (0.39-1.17) 1.01 (0.61-1.69) 0.67 (0.47-0.96) 0.83 (0.59-1.19)
Left ventricular 
dysfunction h
No 1 1 1 1
Yes 2.29 (1.30-4.04) 1.41 (0.89-2.26) 1.90 (1.23-2.94) 1.02 (0.70-1.49)
Not stated 1.05 (0.53-2.07) 0.85 (0.45-1.63) 0.83 (0.58-1.18) 0.75 (0.53-1.07)
Renal failure i 
No 1 1 1 1
Chronic 0.54 (0.32-0.90) 0.46 (0.28-0.76) 1.04 (0.75-1.45) 0.95 (0.69-1.31)
Acute 0.97 (0.41-2.30) 0.39 (0.18-0.83) 1.38 (0.82-2.34) 0.59 (0.36-0.97)
Atrial fibrillation j 
No 1 1 1 1
Yes 0.74 (0.42-1.28) 0.54 (0.32-0.92) 0.72 (0.50-1.04) 0.61 (0.42-0.89)
NSTE-ACS – non-ST segment elevation acute coronary syndrome; PCI – percutaneous coronary intervention; STEMI - ST segment elevation myocardial 
infarction
a 3-drug treatment was defined as aspirin/clopidogrel + beta-blocker + statin;
b 5-drug treatment was defined as aspirin + clopidogrel + beta-blocker + ACE-inhibitor/ARB + statin;
c Smoking was defined as current smoker or ex-smoker for less than 1 year;
d  Bradycardia was defined as heart rate <60 beat/min;
e Hypotension was defined as systolic blood pressure <90 mmHg;
f Anaemia was defined as mild if haemoglobin was between 10-12 g/dl in women and 11-13 g/dl in men and as severe if haemoglobin <10 g/dl in women and 
<11 g/dl in men;
g Heart failure was considered when there was a record of heart failure or Killip score ≥2 in the clinical record;
h Patients were considered as having left ventricular systolic dysfunction if the left ventricular ejection fraction was <40%;
i Renal failure was classified as acute if the patient presented new-onset renal dysfunction or a significant deterioration superimposed on chronic renal failure; 
it was considered only chronic when self-reported at admission or if the creatinine clearance at admission was <60 ml/min with no further decompensation 
during hospitalization;
j Atrial fibrillation includes both chronic and new-onset cases.
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Abstract
Aims: To quantify the contribution of medical and surgical treatments, and risk 
factors to the decline in the coronary heart disease (CHD) mortality in Portugal, 
between 1995 and 2008.
Methods: The IMPACT mortality model was used to integrate data on trends in 
uptake of treatments and exposure to risk factors to explain the variation in CHD 
mortality.
Results: Between 1995 and 2008, CHD mortality rates in Portugal decreased by 
29% in men and 21% in women aged 25-84 years, corresponding to 3760 fewer 
deaths in 2008 than expected if 1995 mortality rates had persisted. Approximately 
92% of the estimated decrease in number of deaths could be explained by the 
model; the remaining 8% were attributed to changes in unmeasured factors. 
Approximately 50% of the decrease explained by the model was attributable 
to increased uptake of treatments, mainly anti-hypertensive medication (12%) 
and initial treatments after an acute myocardial infarction (10%), and 42% to 
population risk factor reductions, mainly blood pressure (27% in men and 60% in 
women), total cholesterol (14% in men and 5% in women) and smoking in men 
(11%). However, these reductions were partially offset by adverse trends in dia-
betes (18% in men and 2% in women) and obesity (6% in men and 5% in women), 
and smoking in women (2%).
Conclusions: In this population at low CHD risk, modern treatments explained 
approximately half of the overall decline in CHD deaths. The biggest contribu-
tions to the CHD mortality decline came from secular decreases in blood pres-
sure and increases in hypertension treatment.
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Introduction
The trends in coronary heart disease (CHD) mortality rates differ widely across 
countries (1); in Europe there is a northeast to southwest gradient in age-stan-
dardized mortality from CHD (2) and Portugal has been a low risk country for 
decades (3). Although the CHD mortality rates have been declining since the 
1980s, more steeply after the mid-1990s, particularly among women (1, 3), CHD 
remains the second most common cause of death in Portugal (4).
A very high prevalence of hypertension and high stroke mortality are distin-
guishing features of the cardiovascular disease epidemiology in Portugal (5, 6). 
However, the risk factor distributions have changed in the last decades of the 
20th century, with steep decreases in blood pressure levels since the 1970s (5), a 
decrease in the prevalence of smoking among men but increase among women 
(7), and an increase in the frequency of obesity in the younger age groups (8). 
Additionally, there were several improvements in the management of CHD, 
namely in the availability of drug treatments, in the access to reperfusion and 
revascularization interventions, with the development of a hospital referral net-
work for interventional cardiology, and the implementation of a coronary fast 
track system (9). 
It is important to assess the relative contribution of these underlying factors to 
the observed decline in CHD mortality in different settings, in order to plan future 
health policy and prioritize strategies for primary and secondary prevention. 
In the present investigation, we aimed to model the decline in CHD mortality 
between 1995 and 2008 in Portugal, quantifying the contribution of changes in 
the use of evidence-based medical and surgical treatments, and in the levels of 
major cardiovascular risk factors.
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Methods
The IMPACT CHD mortality model 
We used an updated version of the IMPACT CHD mortality model to investigate 
how changes in risk factors and medical treatments have affected the substan-
tially decreasing mortality rates in CHD among men and women aged 25 to 84 
years in Portugal. This model has been previously validated in diverse popu-
lations, namely in the United States (10), New Zealand (11), China (12), and in 
Europe (13), including other Southern European populations, namely Italy (14) 
and Spain (15). 
The IMPACT model incorporates data on trends in the distribution of the main 
cardiovascular risk factors: high blood pressure, smoking, high total cholesterol, 
high body mass index (BMI), diabetes and physical inactivity. It also includes 
about 50 evidence-based medical and surgical treatments for all CHD patient 
groups: acute myocardial infarction (AMI), cardiac arrest, unstable and chronic 
angina and mild and acute heart failure (Supplementary Appendix). The model 
compares data from a baseline year (1995) against data observed in a more 
recent year (2008). The main outcome of the model is the relative contributions 
of cardiovascular risk factors and treatment groups to CHD mortality decline, 
measured as deaths prevented or postponed (DPPs).
Number of DPPs in 2008
Data on the total population and the number of CHD deaths for Portugal, 
according to the International Classification of Diseases (ICD), in 1995 and 2008, 
were obtained from the Portuguese official statistics, by 10-year age bands (4). 
Myocardial infarction deaths were defined by the codes 410.0 to 410.9 from ICD 
9 or I21.0 to I21.4 and I21.9 from ICD 10, unstable angina by the codes 411.1 from 
ICD 9 or I20.0 from ICD 10, and heart failure by the codes 428.0 to 428.4 and 
428.9 from ICD 9 or I50.0, I50.1, I50.9 from ICD 10.
We calculated the number of CHD deaths expected in 2008 if the CHD mortality 
rates in 1995 had persisted, by multiplying the age-specific mortality rates for 
1995 by the population for each 10-year age stratum in the year 2008. Subtracting 
the number of observed deaths in 2008 from the number of expected deaths 
generates the reduction in the number of CHD deaths in 2008, which the model 
aims to explain. We will refer to them as deaths prevented or postponed (DPPs).
Identification and assessment of relevant data
To build the Portuguese IMPACT model we used specific data from the Portuguese 
population, whenever possible. When more than one data source was available, 
we chose the most representative and least biased source. A detailed description 
of all the sources of data used is found in the Supplementary Appendix.
Data on number of patients admitted to a hospital with myocardial infarction, 
unstable angina, and heart failure were obtained from the National Hospital 
Discharge Registry, centrally held in the Central Administration of the Health 
System for Portugal (16). The proportion of patients treated for myocardial 
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infarction, unstable angina or heart failure during hospitalization were obtained 
from clinical epidemiologic studies on samples of patients consecutively admit-
ted to Portuguese hospitals (17, 18). The number of patients in the community 
eligible for treatments for chronic angina and heart failure, and for statin therapy 
to reduce cholesterol and anti-hypertensive medications to control blood pres-
sure were obtained from epidemiological studies on representative samples of 
the general Portuguese population; the proportion of patients treated for those 
conditions were taken from the same studies (19, 20).
Data on the effectiveness of therapeutic interventions, on the association 
between cardiovascular risk factors and CHD mortality and case-fatality rates 
were obtained from published meta-analyses, randomised controlled trials, and 
international cohort studies (see Supplementary Appendix).
In 1995, data on mean total cholesterol, mean systolic blood pressure, mean body 
mass index and prevalence of diabetes were obtained from a systematic review 
that summarizes the evidence from studies providing data on the distribution of 
risk factors in Portuguese adults (21-23); data on the prevalence of smoking and 
physical inactivity were obtained from the National Health Survey conducted 
1995-1996 (24). Risk factors data in 2008 was obtained from two cross-sectional 
studies in random samples of the general population (20, 25). 
Mortality reductions attributable to treatments 
The analysis of the contribution of treatments is reported for men and women 
together, after confirming that in this population there was no important sex 
heterogeneity in these results.
The DPPs associated with a specific CHD treatment within a disease subgroup at 
a specific time point (either in 2008 or 1995 for treatments available at that time) 
was estimated by taking the product of the number of people in the subgroup 
by the proportion of those patients who received the particular treatment at that 
time, 1-year case-fatality rates, and the relative risk reduction attributed to that 
specific treatment based on the published literature (Table 1). 
We assumed that the compliance (proportion of treated patients actually tak-
ing therapeutically effective levels of medication) was 100% among hospital 
patients, 70% among symptomatic community patients, and 50% among asymp-
tomatic community patients (26, 27)
. 
To avoid double counting of patients 
treated, we identified potential overlaps between different groups of patients 
and made appropriate adjustments (Supplementary Appendix). To address the 
potential effect of multiple treatments in the same patient on the relative reduc-
tion in case-fatality rate, we used the Mant and Hicks cumulative relative benefit 
approach (28) (Supplementary Appendix)
.
The effect of the increase in use of treatments from 1995 to 2008 was assessed 
by subtracting the DPPs attributable to each treatment in 1995 from those in 
2008.
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Mortality reductions attributable to changes in risk factors
The time trends in risk factors followed different patterns in men and women, 
resulting in heterogeneous contribution to the CHD mortality decline. The results 
of the analysis of the contribution of risk factors are therefore presented by sex.
Two approaches were used to calculate the DPPs as a result of changes in risk fac-
tors. We used a regression approach for continuous variables, namely, for systolic 
blood pressure, cholesterol and BMI. The number of DPPs as a result of the change 
in the mean of value for each risk factor (Table 2) was estimated as the product of 
three variables: the number of CHD deaths observed in 1995 (the baseline year), the 
absolute reduction in that risk factor and the regression coefficient quantifying the 
independent association between population change in a specific cardiovascular 
risk factor and the consequent change in mortality from CHD. For dichotomous 
variables, a population-attributable risk fraction approach was used to determine 
the impact of changing prevalence of smoking, diabetes and physical inactivity. The 
population-attributable risk fraction was calculated conventionally as (P * (RR-1)) / 
(1+P * (RR-1)), where P is the prevalence of the risk factor and RR is the relative risk 
for CHD mortality associated with that risk factor (Supplementary Appendix). The 
number of DPPs was then estimated as the number of deaths from CHD expected 
in 2008 if 1995 rates had persisted multiplied by the difference between the pop-
ulation-attributable risk fraction in 2008 and that in 1995 (Table 2).
Because independent regression coefficients and relative risks for each risk fac-
tor were taken from multivariate analyses, we assumed that there was no further 
confounding between the treatment and risk factor sections of the model or 
among the major risk factors. 
The numbers of DPPs as a result of risk factor changes were systematically quan-
tified for each specific age and sex group to account for potential differences 
in effect. Lag times between the change in the risk factor rate and event rate 
change were not modelled; we assumed that lag times were relatively unimport-
ant over a period of 13 years; also, lag times are not expected to have changed 
significantly over the period of analysis (29).
Comparison of estimated with observed mortality changes
The estimates from the model for the total number of DPPs explained by each 
treatment and each risk factor change were rounded to the nearest multiple of 
5 deaths. Any shortfall in the overall model estimate was then presumed to be 
attributable either to inaccuracies in our model estimates or to other unmea-
sured risk factors.
 
Estimates were then summed and compared with the observed 
changes in mortality for men and women in each age group (Figure 1). 
Sensitivity analyses
Given the uncertainty surrounding many of the values input in the model, multi-
way sensitivity analyses were performed using the analysis of extremes method 
(30). For each variable in the model, we assigned a lower value and an upper 
value, using 95% confidence intervals when available and otherwise using +/- 
20% (for the number of patients, use of treatment and compliance). 
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Detailed information on all methods is shown in the Supplementary Appendix, 
available online.
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Results
From 1995 to 2008, the age-adjusted mortality rate of CHD fell from 157.7 to 112.3 
cases per 100 000 population among men aged 25 to 84 years, and from 113.3 to 
89.1 among women of the same age range. This resulted in 3760 fewer deaths in 
2008, 2136 in men and 1624 in women, compared with the expected number if 
the rates in 1995 had persisted. 
Approximately 3465 (92%) of the estimated decrease in number of deaths 
between 1995 and 2008 could be explained using the Portugal IMPACT model. 
The remaining 8% were attributed to changes in other unmeasured factors. 
Under the assumptions of the sensitivity analysis, the extreme minimum and 
the maximum number of deaths from CHD that were explained was 2015 (54%) 
and 6725 (180%). The agreement between the estimated and observed mortal-
ity decreases for men and women in each age group was generally very good, 
except for men aged 65-74, where the model explained less than the observed 
DPPs, and women aged 75-84 years, where the model predicted more DPPs than 
observed (Figure 1). 
Medical and surgical treatments
Medical and surgical treatments together prevented or postponed approxi-
mately 1890 deaths (minimum estimate, 660; maximum estimate, 4845) related 
to CHD (Table 1). These treatment effects together explained about 50% of the 
mortality reduction. The largest reductions came from the use of antihyperten-
sive medication (12%) and initial treatments for AMI or unstable angina (11%). 
Within initial AMI treatments, the largest contributions came from percutaneous 
coronary intervention (PCI) and aspirin.
The mortality decreases attributable to secondary prevention following AMI and 
heart failure treatments were 7% and 8%, respectively. Smaller proportions were 
explained by primary prevention using statins (6%) and treatment of chronic 
angina (5%) Secondary prevention after coronary artery bypass surgery and PCI 
accounted for less than 2% of deaths DPPs (Table 1).
Major cardiovascular risk factors
Changes in the major cardiovascular risk factors together accounted for approx-
imately 1575 fewer deaths (42%) (minimum estimate: 1225; maximum: 2310) 
(Table 2), 630 (29%) among men and 945 (58%) among women, after subtract-
ing the effect of statins and anti-hypertensive treatment for primary prevention. 
Decreases in mean population systolic blood pressure, by 6.5 mmHg in men 
and 12.4 mmHg in women, were estimated to have prevented or postponed 845 
(40%) deaths in men and 1165 (72%) in women. This difference was mainly attrib-
utable to lifestyle changes, since the effect of antihypertensive treatment was 
smaller and similar in men and women (13% and 12%, respectively). Mean popula-
tion total cholesterol levels decreased by 0.10 mmol/L in men and 0.05 mmol/L 
in women, contributing to 390 (18%) estimated DPPs in men and 200 (12%) in 
women, approximately half attributable to lifestyle changes and half to the use 
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of statins. Physical inactivity prevalence decreased by 23.2% in men and 20.5% 
in women, contributing to an estimate of 75 (4%) DPPs in men and 30 (2%) in 
women (Table 2). Adverse trends were observed in diabetes and BMI, with the 
prevalence of diabetes increasing from 5.3 to 10.2% in men and 6.2 to 6.3% in 
women, and mean BMI increasing from 26.2 to 27.8 Kg/m2 in men and 26.6 to 
28.2 Kg/m2 in women, between 1995 to 2008. These two risk factors together 
generated approximately 530 (25%) additional CHD deaths in men and 115 (7%) 
in women. In men the prevalence of smoking decreased, contributing to 235 
(11%) DPPs, while it increased in women resulting in 35 (2%) extra deaths.
Sensitivity analyses
The proportional contributions of specific treatments and risk factor changes 
to the overall decrease in CHD mortality in Portugal between 1995 and 2008 
remained relatively consistent in the sensitivity analysis (Figure 2).
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Discussion
We quantified the contribution of risk factors and treatments to the decline in 
CHD mortality in Portugal, a country in Southern Europe where the CHD mor-
tality rates are much lower than in Northern Europe or in the United States (1, 
10). Coronary heart disease mortality rates in Portugal fell by over 25% between 
1995 and 2008. The reductions attributable to evidence-based medical therapies 
accounted for approximately half of the DPPs. Approximately 42% of the fall was 
due to the trends in major risk factors, mainly systolic blood pressure, although 
the rise in the prevalence of diabetes and mean BMI in both sexes, and in smok-
ing prevalence among women generated additional deaths.
The observed decrease in the mortality in the period considered was noteworthy 
(1), despite the lower rates in the baseline year, even when compared to other 
Southern European countries with low baseline CHD mortality rates where this 
model was applied, namely Spain (1988-2005) (15) and Italy (1980-2000) (14). 
The proportional contribution of treatments and risk factors for CHD mortality 
trends in Portugal is to some extent different from the aforementioned coun-
tries, mainly due to a higher contribution of treatments. Previous studies have 
consistently shown a either similar or slightly higher contribution of reduction in 
population risk factor levels compared to treatments (10, 14, 15). However, com-
parisons with previous models must be interpreted with caution due to different 
time periods being assessed and the pace of evolution in treatments in the last 
15 years (31). 
Advances in CHD diagnosis and treatment allowed the earlier identification of 
cases, the diagnoses of milder cases of disease and consequently the decrease 
in the proportion of fatal acute events. The increasing number of centers with 
catheterization laboratory and the implementation of the coronary fast track 
system in the early 2000s in Portugal allowed a more effective utilization of PCI 
and other invasive treatments (9). Also, the period of analysis covers a time of 
steep changes in the availability and uptake of drugs for the initial treatments 
after an acute coronary syndrome and for secondary prevention after an AMI. 
The prescription of double antiplatelet therapy during hospitalization increased 
significantly over time, from 33% in 2002 to 95% in 2008. The same trend was 
observed in the prescription of beta-blockers, ACE-inhibitors and statins (9). 
Also, recommended combined therapy for secondary prevention of events at 
hospital discharge (including the combination of double antiplatelets, ACE inhib-
itors, beta-blockers and statins) increased from 14% in 2002 to 63% in 2008 (9). 
These important recent changes may explain the larger contribution of treat-
ments, compared to risk factors, in our population.
Portugal has been described as one of the countries with highest median blood 
pressure levels (32, 33), and in 2003 three million adults (42%) had hypertension 
(34). However, from 1975 to 2005, mean SBP decreased remarkably in men after 
middle-age and in women at all ages, adding up to a cumulative decrease of 22 
and 32 mmHg in SBP at average age 70 years, in men and women, respectively 
(5). The proportion of hypertensives treated in Portugal increased in the last few 
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decades, and in the beginning of the 2000s almost half of hypertensives were 
treated (19, 34). The high prevalence of hypertension results in a large impact of 
any improvement in treatment rates, due to the high number of people experi-
encing such benefit. Although the European guidelines in 1995 already recom-
mended the prescription of pharmacological treatment aiming for the same tar-
get for blood pressure used today (35), pharmacological treatment for primary 
prevention was concentrated on high risk individuals in daily practice and conse-
quently only a small proportion of the population were treated. 
Total cholesterol has decreased slightly over the last years in Portugal (20, 22), 
like in most other European countries (36). The overall decline in cholesterol 
level does not yet reflect the recent trends in the food intake in Portugal, where 
the consumption of fish and soup is decreasing and the consumption of fat-con-
taining foods such as meat and snacks is increasing steeply (37). However, other 
developed countries have shown even higher decreases in cholesterol levels, 
despite the adverse trends in food intake (14, 15). When compared to other 
Mediterranean countries, we report a lower contribution of changes in the cho-
lesterol, after excluding the effect of pharmacological treatment (10% in Portugal 
versus 31% in Spain and 23% in Italy). The higher contribution of statins (6% in 
Portugal versus 1% in Spain and 3% in Italy) and the relatively faster trends in the 
diet transition towards a more unhealthy diet (38) suggest that in Portugal the 
reduction in total cholesterol was achieved mainly through the use of pharmaco-
logical treatment. In 1995 the use of statins was residual in Portugal (4.43 defined 
daily doses per 1000 inhabitants per day) but due to an average annual growth 
of 35%, in 2004 the number increased significantly (60.73 defined daily doses 
per 1000 inhabitants per day) (39). 
Recent reports on the trends in smoking prevalence are in line with the results of 
this study and place Portuguese women in the stage II of the smoking epidemic, 
while men are at the later stages, between stages III and IV (7). As expected, we 
found differences in the trends in smoking prevalence trends according to sex. 
Although smoking prevalence in men decreased, it increased among women, 
resulting in 35 additional coronary deaths.
Apart from smoking among women, two other major risk factors led to increases 
in CHD deaths. The contribution of BMI to the increase in the total number of 
CHD deaths was very important, as well as the dramatic increase in diabetes 
prevalence. These trends are consistent with recent studies in other industri-
alized countries (14, 15). Efforts to address obesity and diabetes should there-
fore receive particular attention in future policies to improve the public’s health, 
especially since the prevalence of overweight/obesity in younger age groups of 
the Portuguese population is increasing (8, 21).
Modelling studies have a number of potential strengths, including the ability to 
transparently integrate and simultaneously consider huge amounts of data from 
many sources and testing the uncertainty inherent to such complexity by sen-
sitivity analyses. However, models are highly dependent on the quality of data 
available. We made all the efforts to include in this model the most representative 
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and unbiased data available in Portugal. With this propose, we performed a sys-
tematic review that aimed to critically summarize the evidence from studies 
that quantified the distribution and the frequency of all risk factors included in 
this model (5, 7, 21, 22). The majority of the treatment data for 2008 was from 
EURHOBOP, a study that  reported data from 3009 ACS patients consecutively 
recruited in 10 Portuguese hospitals (17). Even so, in some cases the data used 
was obtained from studies possibly constrained by geographic or selection bias. 
Additionally, since we used data from different studies for the first and the last 
year, the variations in the study designs and study populations can potentially 
influence the results of the model. The majority of treatment uptake and case 
fatality rates were based on data from United Kingdom and United States of 
America because little or no specific Portuguese data were available. Although 
major efforts were made to address overlaps, residual double counting of some 
individual patients remains possible. We also assumed that, after adjustments for 
imperfect compliance (40), the efficacy of treatments in randomized controlled 
trials could be generalized to population effectiveness in usual clinical practice. 
All the assumptions that we made are presented in the Supplementary Appendix 
(Tables 1 and 2). 
In conclusion, CHD mortality in Portugal decreased 25% between 1995 and 2008. 
Overall, treatments explained half of the overall decline in CHD deaths and risk 
factor changes were more important among women than men. The decrease in 
mean blood pressure and increase in hypertension treatment contributed most 
to the CHD mortality decline. These results encourage the utilization of compre-
hensive efforts to actively promote primary prevention, particularly a healthy 
diet and tobacco control as well as maximizing the population coverage of effec-
tive treatments.
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eAppendix: The Portuguese IMPACT model
We evaluated the Portuguese population aged from 25 to 84 years using an 
updated version of the IMPACT model. This is a cell-based model, constructed 
using Microsoft Excel, which integrates available country-specific epidemiolog-
ical data to explain an observed change in coronary heart disease (CHD) mor-
tality. The main outcome of the model is the relative contributions of treatments 
and cardiovascular risk factors to the CHD mortality change. The tables included 
in this supplementary material provide details about these methods. This model 
has been validated in several European countries (1-11), Syria (12), West Bank (13), 
New Zealand (14), China (15), Canada (16) and the United States (17).
 
Changes in mortality rates from CHD in Portugal from 1995 to 2008
Mortality rates from CHD were calculated using the underlying cause of death 
according to the International Classification of Diseases (ICD) codes. Myocardial 
infarction was defined by the codes 410.0 to 410.9 from ICD 9 or I21.0 to I21.4 and 
I21.9 from ICD 10, unstable angina by the codes 411.1 from ICD 9 or I20.0 from ICD 
10, and heart failure by the codes 428.0 to 428.4 and 428.9 from ICD 9 or I50.0, 
I50.1, I50.9 from ICD 10. The data sources used are shown in eTable 1.
CHD deaths prevented or postponed in 2008
The primary output of the IMPACT model is the number of deaths prevented or 
postponed (DPPs) in 2008 due to the reduction in CHD mortality rates since 1995. 
This was calculated as the difference between the observed 2008 CHD deaths 
and the expected CHD deaths in 2008 if 1995 mortality rates had remained con-
stant. The expected number of CHD deaths was calculated by multiplying age- 
and sex- specific mortality rates in 1995 by the population size for each 10-year 
age- and sex- stratum in 2008.
Patient groups
• The treatment arm of the model includes the following target groups of patients:
• hospitalized patients with an acute myocardial infarction (AMI) within the last 
year;
• hospitalized patients with unstable angina within the last year;
• community-dwelling patients who have survived an AMI in the past 10 years; 
• community-dwelling patients with chronic angina who have undergone a 
revascularisation procedure (coronary artery bypass grafting (CABG) or a per-
cutaneous coronary intervention (PCI)), within the last year, for chronic angina;
• community-dwelling patients with chronic angina (no revascularisation and/or 
previous AMI);
• hospitalized patients with heart failure within the last year;
• community-dwelling patients with heart failure;
• hypertensive patients eligible for pharmacological therapy and who have not 
suffered any of the above events;
• hypercholesterolemic patients eligible for cholesterol lowering therapy (statin) 
and who have not suffered any of the above events.
166 | Explaining the decline in coronary heart disease mortality in Portugal, 1995-2008
Data sources for patient groups (eTable 1) 
Hospital patient groups: numbers of hospitalized patients in all public hospi-
tals, obtained from the National Hospital Discharge Register (eTable8, for study 
details), separately for AMI, unstable angina and acute heart failure. 
Patients with chronic angina: follow-up assessment of the EPIPorto cohort study 
(eTable 8, for study details). Estimates included in the model were reduced by 
50% to account for patients with chronic angina who also contributed as hospital 
CHD cases, CABG, AMI survivals and community heart failure.
Patients with heart failure in the community: follow-up assessment of the 
EPIPorto study (eTable 8, for study details). Estimates included in the model 
were reduced by 50%, assuming that only half of heart failure cases had CHD as 
etiology of heart failure. 
Patients eligible for treatment with a statin for primary prevention: PORMETS 
study (eTable 8, for study details), which provided estimates of the number 
of hypercholesterolemia patients (defined as total cholesterol ≥250 mg/dl or 
receiving lipid lowering drugs). 
Patients eligible for antihypertensive medication: PORMETS study (eTable 8, for 
study details), which provided estimates of the number of hypertensive patients 
(defined as systolic blood pressure ≥140 mmHg and/or diastolic blood pressure 
≥90 mmHg and/or receiving drugs for hypertension). 
Patients eligible for secondary prevention post AMI: calculated based on the 
number of hospitalised AMI in 2008. We assumed 10% fewer in each preceding 
year and 10% case fatality rate every year.
Patients eligible for secondary prevention following CABG/PCI: calculated 
based on the number of patients submitted to CABG, defined using the ICD 9 
code for procedures 36.1, and PCI, defined using the ICD 9 codes 36.01 to 36.07, 
in all public hospitals, obtained from the National Hospital Discharge Registry 
(eTable 8, for study details). We adjusted these numbers assuming that 50% the 
patients were AMI survivals and 33% later developed heart failure.
 
Potential overlaps between patient groups
There are potential overlaps between patient groups (meaning that one person 
may belong to more than one patient group). Each individual was considered 
only one time in hospital data and community data. The assumptions made to 
adjust for overlaps between groups were based on the literature and expert 
opinion. 
Treatments uptake
Treatment uptake during hospitalization for AMI, unstable angina and CABG 
or PCI patients was obtained from the EURHOBOP study (eTable 8, for study 
details). Treatment uptake during hospitalization for acute heart failure patients 
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was obtained from the EDIFICA study (eTable 8, for study details). According to 
local expert opinion, all treatment data for acute heart failure were adjusted by 
a factor of 0.9, since the quality of treatment in this hospital is expected to be 
higher than in a representative sample of the country.    
Treatment uptake for patient groups in the community was collected using two 
different sources of data: the PORMETS study (eTable8, for study details) was 
used to estimate the proportion of patients treated with statins and anti-hy-
pertensive medication (plain ACE-inhibitors and/or beta-blocking agents and/
or calcium channel blockers and/or diuretics); the EPIPorto study (eTable8, for 
study details) was used to estimate the proportion of treatment in patients with 
a diagnosis of chronic angina and heart failure.
For each of the groups, we estimated the number of DPPs that were attributable 
to various treatments. All treatments of interest are listed in eTable 2.
The DPPs associated with a specific CHD treatment at a specific time point 
within a disease subgroup, in comparison with no such treatment, was estimated 
by taking the product of the number of people in the subgroup (eTable 1) and 
the proportion of those patients who received a particular treatment (eTable 2) 
at that time, 1-year case-fatality rates (eTable 3), and the relative risk reduction 
attributed to that specific treatment based on the published literature (eTable 4). 
We assumed that compliance, defined as the proportion of patients actually on 
therapeutic doses of medication among those who received prescriptions, was 
100% among hospital patients, 70% among symptomatic community patients 
and 50% in asymptomatic individuals taking statins or anti-hypertensives for pri-
mary prevention (18-20).
The effect of the increase in use of treatments from 1995 to 2008 was assessed 
by subtracting the DPPs attributable to each treatment in 1995 from those in 
2008.
EXAMPLE 1: estimation of DPPs from a specific treatment
In Portugal in 2008, 1759 men aged 55-64 were hospitalized with AMI, utilization 
of aspirin in this age group in men was 84% (21), 1-year case-fatality rate was 
0.054. The relative risk reduction in CHD mortality associated with the use of 
aspirin is 15% (22).
The number of DPPs in 2008 due to aspirin use for AMI was calculated as:
Patient number * treatment uptake * one-year case fatality * relative mortality 
reduction
= 1759 * 0.84 * 0.054 * 0.15 = 12 DPPs in 2008
In 1995, 1106 men aged 55-64 were hospitalized with AMI, utilization of aspirin 
in this age group in men was 70% (expert opinion), 1-year case-fatality rate was 
0.054 (Medicare). The relative risk reduction in CHD mortality associated with 
the use of aspirin is 15% (22).
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The number of DPPs in 1995 due to aspirin use for AMI was calculated as:
= 1106 * 0.70 * 0.054 * 0.15 = 6 DPPs in 1995
The effect of the increase in use of treatments from 1995 to 2008 was calculated 
as:
DPPs in 2008 - DPPs in 1995 = 12 - 6 = 6 DPPs
Risk factors
The IMPACT model calculates the DPPs associated with changes in CHD risk fac-
tors, including smoking, total cholesterol, systolic blood pressure, body mass index, 
diabetes mellitus, and physical inactivity. Data sources are shown in eTable 5.
In 1995, data for mean total cholesterol, mean systolic blood pressure, mean 
body mass index and prevalence of diabetes were obtained from systematic 
reviews that summarize the evidence from studies providing data on the distri-
bution of risk factors in Portuguese adults (eTable 8, for study details); while data 
on prevalence of smoking and physical inactivity were obtained using data from 
the National Health Survey (eTable 8, for study details). In 2008, data on mean 
total cholesterol, mean systolic blood pressure, prevalence of smoking and prev-
alence of physical inactivity were obtained from the PORMETS study (eTable 8, 
for study details); while data on mean body mass index and prevalence of diabe-
tes were obtained from PREVADIAB study (eTable 8, for study details).
 
Two approaches were used to calculate DPPs, the regression approach and the 
population-attributable risk factor (PARF) approach. The regression approach 
was used for continuous variables (systolic blood pressure, total cholesterol, and 
body mass index). The number of expected deaths from CHD occurring in 2008 
was multiplied by the absolute change in risk factor prevalence, and by a regres-
sion coefficient quantifying the change in CHD mortality that would result from 
the change in risk factor level (eTable 6). Natural logarithms of the mean risk 
factor values were used, assuming a log-linear relationship between changes in 
risk factor levels and mortality.
Data sources for the number of CHD deaths and risk factors are shown in eTable 
5, and sources for the coefficients in eTable 6.
EXAMPLE 2: estimation of DPPs from risk factor change using the regression 
method:
Mortality fall due to reduction in systolic blood pressure in women aged 55-64
In 2008, there were 342 CHD expected deaths (had 1995 mortality rates remained 
constant) among 657 309 women aged 55-64 years. Mean systolic blood pres-
sure decreased by 11.2 mmHg (from 145.3 in 1995 to 134.1 mmHg in 2008). For 
every 20 mmHg reduction in systolic blood pressure, we estimated an age- and 
sex-specific reduction in mortality of 50%, which corresponds to a logarithmic 
coefficient of –0.035 (23).
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The number of DPPs:
= (1-(EXP(coefficient*change))*expected deaths in 2008)
= (1-(EXP(-0.035*11.2))* 342)
= 111 DPPs
The PARF approach was used for categorical variables (smoking, diabetes, and 
physical inactivity). PARF was calculated as:
(P * (RR-1)) / (P * (RR-1)) +1
where P is the prevalence of the risk factor and RR is the relative risk for CHD 
mortality associated with that risk factor. DPPs were then estimated as the 
expected CHD deaths in 2008 multiplied by the difference in the PARF between 
2008 and 1995.
Data sources for the prevalence of risk factors and for the number of CHD 
deaths are shown in eTable 1. The relative risks used in these PARF analyses were 
obtained from the INTERHEART study (eTable 6), which provides independent 
OR values, adjusted for other major risk factors.
EXAMPLE 3: estimation of DPPs from risk factor change using the PARF method
In 2008, there were 1702 CHD expected deaths (had 1995 mortality rates 
remained constant) among 449 870 men aged 65-74 years. The prevalence of 
diabetes was 20.6% in 1995 and 28.5% in 2008. Assuming a relative risk of 1.93 
(24), the PARF was 0.16 in 1995 and 0.21 in 2008. The number of deaths attrib-
utable to the increase in diabetes prevalence from 1995 to 2008 was therefore:
(1702) * (0.21-0.16) = 83 DPPs
Other methodological considerations
Systolic blood pressure and hyperlipidemia
In order to separate the DPPs from pharmacological versus non-pharmacolog-
ical primary prevention of hypertension and hyperlipidemia, we subtracted the 
age- and sex-specific DPPs calculated in the treatment section (i.e. for primary 
hyperlipidemia and hypertension patient groups), from the DPPs calculated in 
the risk factor section.
Polypharmacy issues
There is a paucity of data on the efficacy of treatment combinations. Simply 
assuming that the efficacy of multiple treatments was additive would lead to 
overestimate the treatment effect; we therefore we used the Mant and Hicks 
method to estimate case-fatality reduction by polypharmacy for all treatments 
evaluated (25). This approach was subsequently endorsed by Yusuf (26) and Law 
and Wald (27).This approach estimates a cumulative relative benefit as follows:
Relative Benefit = 1 - ((1-relative reduction in case-fatality rate for treatment A) * 
(1- relative reduction in case-fatality rate for treatment B) * ...* (1- relative reduc-
tion in case-fatality rate for treatment N)
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EXAMPLE 4: estimation of reduced benefit in patients taking multiple 
medications
For AMI survivors, applying relative risk reductions (RRR) for aspirin, beta-block-
ers, ACE-inhibitors, statins and rehabilitation gives:
Relative Benefit = 1 - [(1 –aspirin RRR) * (1 - beta-blockers RRR) * (1 – ACE-
inhibitors RRR) * (1- statins RRR) * (1- rehabilitation RRR)]
= 1 - [(1- 0.15) * (1-0.23) * (1-0.20) * (1- 0.22) * (1- 0.26)]
= 1 - [(0.85) * (0.77) * (0.80) * (0.78) * (0.74)]
= 0.70 i.e. a 70% lower case fatality
Sensitivity analyses
Because of the uncertainty surrounding many of the values, multi-way sensitivity 
analyses were performed (28). For each model variable, a maximum and mini-
mum plausible value were assigned using the 95% confidence intervals from the 
source documentation or 99% confidence intervals in the case of the odds ratios 
for the effect of risk factors; if this was unavailable, we defined these limits as 
20% above and below the best estimate. The maximum and minimum plausible 
values were fed in to the model generating maximum and minimum estimates 
for DPPs.
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eTable 1 Main data sources and criteria for population and patients in the Portuguese IMPACT model.
Information 1995 2008
Population Statistics Portuguese official statistics 29 Portuguese official statistics 29
Deaths by age and sex
AMI 
Unstable angina
Heart failure
Portuguese official statistics based on 
ICD-9 codes 30
410.0 to 410.9
411.1 
428.0 to 428.4 and 428.9
Portuguese official statistics based on 
ICD-10 codes 30
I21.0 to I21.4 and I21.9
I20.0
I50.0, I50.1, I50.9
Number of patients admitted yearly
AMI National Hospital Discharge Registry 31 National Hospital Discharge Registry 31
Unstable Angina National Hospital Discharge Registry 31 National Hospital Discharge Registry 31
Heart failure National Hospital Discharge Registry 31 National Hospital Discharge Registry 31
Number of patients eligible for treatment treated yearly
Post-AMI Expert opinion [50% of final year (2008)] National Hospital Discharge Registry 21
CABG Expert opinion (Assume zero) National Hospital Discharge Registry 21
PCI Expert opinion (Assume zero) National Hospital Discharge Registry 21
Community CPR Expert opinion (Assume zero) Expert opinion (15% of the AMI patients)
In-hospital CPR Expert opinion [50% of final year (2008)] EURHOBOP 21
Community chronic angina Expert opinion [50% of final year (2008)] EPIPorto (follow-up) * 32 
Community heart failure Expert opinion [75% of final year (2008)] EPIPorto (follow-up) 32
Acute heart failure Expert opinion [85% of final year (2008)] National Hospital Discharge Registry 31
Hypertension treatment Systematic review 33 PORMETS 34
Statins for primary 
prevention of raised 
cholesterol
Expert opinion [50% of final year (2008)] PORMETS 34 
AMI - Acute myocardial infarction; CABG - Coronary-artery bypass grafting; ICD - International Classification of Diseases; PCI - Percutaneous coronary 
intervention. 
* Since these data were self-reported, we adjusted by a factor of 1.3 in men, to take into account the lack of awareness; in women, we did not apply any 
correction assuming that any potential lack of awareness counterbalances with the proportion of women with false positives.
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eTable 2 Estimates of the treatment uptake and data sources
1995 Data source 2008 Data source
Initial treatments AMI
Community CPR 0% Expert opinion [50% of final year 
(2008)]
1% Expert opinion
Hospital CPR 3% Expert opinion [50% of final year 
(2008)]
5% EURHOBOP 21
Thrombolysis 4% Expert opinion [50% of final year 
(2008)]
7% EURHOBOP 21
Aspirin 70% Expert opinion 78% EURHOBOP 21
Beta-blockers 35% Expert opinion [50% of final year 
(2008)]
63% EURHOBOP 21
ACE-inhibitors 32% Expert opinion [50% of final year 
(2008)]
59% EURHOBOP 21
PCI (STEMI) 0% Expert opinion 60% EURHOBOP 21
PCI (NSTEMI) 0% Expert opinion 35% EURHOBOP 21
CABG 0% Expert opinion 2% EURHOBOP 21
Cardiac rehabilitation 0% Expert opinion 2% EURHOBOP 21
Initial treatments unstable angina
Aspirin and heparin 0% Expert opinion 56% EURHOBOP 21
Aspirin alone 70% Expert opinion 79% EURHOBOP 21
Platelet glycoprotein IIB/IIIA 
inhibitors
0% Expert opinion 17% EURHOBOP 21
CABG surgery 0% Expert opinion 1% EURHOBOP 21
PCI 0% Expert opinion 33% EURHOBOP 21
Secondary prevention post AMI 2003-2008
Aspirin 23% Expert opinion [50% of final year 
(2008)]
46% 50% reduction of treatment 
uptake upon discharge obtained in 
EURHOBOP 21 in 2008.
Beta-blockers 20% Expert opinion [50% of final year 
(2008)]
40% 50% reduction of treatment 
uptake upon discharge obtained in 
EURHOBOP 21 in 2008.
ACE-inhibitors 18% Expert opinion [50% of final year 
(2008)]
36% 50% reduction of treatment 
uptake upon discharge obtained in 
EURHOBOP 21 in 2008.
Statins 23% Expert opinion [50% of final year 
(2008)]
46% 50% reduction of treatment 
uptake upon discharge obtained in 
EURHOBOP 21 in 2008.
Warfarin 1% Expert opinion [50% of final year 
(2008)]
2% 50% reduction of treatment 
uptake upon discharge obtained in 
EURHOBOP 21 in 2008.
Cardiac rehabilitation 1% Expert opinion [50% of final year 
(2008)]
1% 50% reduction of treatment 
uptake upon discharge obtained in 
EURHOBOP 21 in 2008.
Secondary prevention post AMI 1998-2003
Aspirin 12% Expert opinion [50% of final year 
(2008)]
23% 25% reduction of treatment 
uptake upon discharge obtained in 
EURHOBOP 21 in 2008.
Beta-blockers 10% Expert opinion [50% of final year 
(2008)]
20% 25% reduction of treatment 
uptake upon discharge obtained in 
EURHOBOP 21 in 2008.
ACE-inhibitors 9% Expert opinion [50% of final year 
(2008)]
18% 25% reduction of treatment 
uptake upon discharge obtained in 
EURHOBOP 21 in 2008.
Statins 12% Expert opinion [50% of final year 
(2008)]
23% 25% reduction of treatment 
uptake upon discharge obtained in 
EURHOBOP 21 in 2008.
Warfarin 0% Expert opinion [50% of final year 
(2008)]
1% 25% reduction of treatment 
uptake upon discharge obtained in 
EURHOBOP 21 in 2008.
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1995 Data source 2008 Data source
Cardiac rehabilitation 0% Expert opinion [50% of final year 
(2008)]
1% 25% reduction of treatment 
uptake upon discharge obtained in 
EURHOBOP 21 in 2008
Secondary prevention following CABG/PCI 
Aspirin 42% Expert opinion [50% of final year 
(2008)]
85% EURHOBOP 21
Beta-blockers 36% Expert opinion [50% of final year 
(2008)]
71% EURHOBOP 21
ACE-inhibitors 33% Expert opinion [50% of final year 
(2008)]
66% EURHOBOP 21
Statins 0% Expert opinion 78% EURHOBOP 21
Warfarin 1% Expert opinion [50% of final year 
(2008)]
3% EURHOBOP 21
Cardiac rehabilitation 2% Expert opinion [50% of final year 
(2008)]
4% EURHOBOP 21
Chronic angina 
Aspirin 35% Expert opinion [85% of final year 
(2008)]
41% EPIPorto follow-up 32
Statins 0% Expert opinion 48% EPIPorto follow-up 32
Hospital heart failure 
ACE-inhibitors 26% Expert opinion [50% of final year 
(2008)]
53% EDIFICA 35 * 0.9 * 
Beta-blockers 0% Expert opinion 60% EDIFICA 35 * 0.9 * 
Spironolactone 0% Expert opinion 23% EDIFICA 35 * 0.9 * 
Aspirin 23% Expert opinion [50% of final year 
(2008)]
46% EDIFICA 35 * 0.9 * 
Heart failure in the community  
ACE-inhibitors 10% Expert opinion 48% EPIPorto follow-up 32
Beta-blockers 0% Expert opinion 32% EPIPorto follow-up 32
Spironolactone 0% Expert opinion 4% EPIPorto follow-up 32
Aspirin 0% Expert opinion 30% EPIPorto follow-up 32
Statins for primary prevention of raised cholesterol
Treated with statins (% of 
eligible population)
0% Expert opinion 27% PORMETS 34
Hypertension treatment
Treated (% of eligible 
population)
36% EPIPorto baseline 36 *0.8 † 63% PORMETS 34
AMI - Acute myocardial infarction; ACE - Angiotensin-converting enzyme; CABG - Coronary-artery bypass grafting; CPR- Cardiopulmonary resuscitation; 
NSTEMI - Non-ST Segment Elevation Myocardial Infarction PCI - Percutaneous coronary intervention; STEMI - ST segment elevation myocardial infarction
* According to expert opinion we adjusted by a factor of 0.9, since the quality of treatment in this hospital is expected to be higher than in the average of 
hospitals of the country;
† According to expert opinion we adjusted by a factor of 0.8, since the study collection was in 1999-2003 and not in 1995.
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eTable 3 Age-specific case-fatality rates for each patient group.
AMI
30 day
Unstable 
angina
One year
Post AMI
One year
CABG
One year
PCI
One year
Heart 
failure in 
hospital
One year
Heart 
failure in 
community 
One year
Hypertension 
One year
Statins for primary 
prevention 
One year
M 25-34 0.0110 0.0160 0.0080 0.0030 0.0030 0.0340 0.0110 0.0000 0.0000
M 35-44 0.0120 0.0240 0.0090 0.0050 0.0050 0.0680 0.0220 0.0010 0.0010
M 45-54 0.0230 0.0340 0.0170 0.0070 0.0070 0.0960 0.0320 0.0020 0.0020
M 55-64 0.0540 0.0560 0.0340 0.0120 0.0120 0.1400 0.0450 0.0060 0.0060
M 65-74 0.1010 0.0700 0.0730 0.0230 0.0250 0.2830 0.0930 0.0140 0.0140
M 75+ 0.1640 0.0910 0.1220 0.0420 0.0420 0.3370 0.1110 0.0350 0.0350
F 25-34 0.0110 0.0160 0.0040 0.0030 0.0030 0.0340 0.0110 0.0000 0.0000
F 35-44 0.0130 0.0240 0.0060 0.0050 0.0050 0.0680 0.0220 0.0010 0.0010
F 45-54 0.0260 0.0340 0.0100 0.0070 0.0070 0.0960 0.0320 0.0010 0.0010
F 55-64 0.0610 0.0560 0.0190 0.0120 0.0120 0.1400 0.0450 0.0020 0.0020
F 65-74 0.1140 0.0700 0.0840 0.0230 0.0270 0.2220 0.0810 0.0070 0.0070
F 75+ 0.1670 0.0910 0.1160 0.0420 0.0390 0.2890 0.0940 0.0210 0.0210
Source Medicare
Van 
Domberg, 
199937
Medicare Medicare Medicare Medicare Medicare
US Census / 
Vital Statistics
US Census / Vital 
Statistics
AMI - Acute myocardial infarction; CABG - Coronary-artery bypass grafting; F – female; M – male; PCI - Percutaneous coronary intervention; STEMI - ST 
segment elevation myocardial infarction
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eTable 4 Clinical efficacy of interventions: relative risk reductions obtained from meta-analyses and randomized controlled trials.
 TREATMENTS Relative risk reduction, 
% (95% CI)
Initial treatments AMI
Community CPR 38, 39 5 (4; 15)
Hospital CPR 40 31 (10; 36)
Thrombolysis 41, 42 23 (14; 40)
Aspirin 43 15 (11; 19)
Beta-blockers 44 4 (-8; 15)
ACE-inhibitors 45 7 ( 2, 11)
PCI (STEMI) 46 32 (5; 51)
PCI (NSTEMI) 46 32 (5; 51)
CABG 47 20 (16; 24)
Cardiac rehabilitation 48 26 (10; 39)
Initial treatments unstable angina
Aspirin & Heparin 49 33 (-2; 56)
Aspirin alone 43 15 (11; 19)
Platelet glycoprotein IIB/IIIA inhibitors 50 9 (2; 16)
CABG 47 43 (19; 60)
PCI 46 32 (5; 51)
Secondary prevention post AMI
Aspirin 43 15 (11; 19)
Beta-blockers 44 23 (15; 31)
ACE-inhibitors 51 20 (13; 26)
Statins 52, 53 22 (10; 26)
Warfarin54, 55 22 (13; 31)
Cardiac rehabilitation 48 26 (10; 39)
Secondary prevention post CABG/PCI
Aspirin 43 15 (11; 19)
Beta-blockers 44 23 (15; 31)
ACE-inhibitors 51 20 (13; 26)
Statins 52, 53 22 (10; 26)
Warfarin54, 55 22 (13; 31)
Cardiac rehabilitation 48 26 (10; 39)
Chronic angina
Aspirin 43 15 (11; 19)
Statins 56 22 (10; 26)
Heart failure in patients requiring hospitalisation
ACE-inhibitors 51 20 (13; 26)
Beta-blockers 57 35 (26; 43)
Spironolactone 58 30 (18; 41)
Aspirin 43 15 (11; 19)
Heart failure in the community
ACE-inhibitors 51 20 (13; 26)
Beta-blockers 57 35 (26; 43)
Spironolactone 58 31 (18; 42)
Aspirin 43 15 (11; 19)
Statins for primary prevention of raised cholesterol 59 22 (11, 52)
Hypertension treatment 60 13 (6; 19)
95% CI – 95% Confidence interval; AMI - Acute myocardial infarction; ACE - Angiotensin-converting enzyme; CABG - Coronary-artery bypass grafting; 
CPR- cardiopulmonary resuscitation; PCI - Percutaneous coronary intervention; STEMI - ST segment elevation myocardial infarction.
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eTable 5 Estimates of the risk factor values and data sources.
Risk factor 1995 Data source 2008 Data source
Men Women Men Women
Systolic blood 
pressure (mmHg)
137.5 139.0 Systematic review 33 131.0 126.3 PORMETS study 34
Smoking (%) 32.3 6.9 National Health Survey 61 25.6 10.3 PORMETS study 34
Total cholesterol 
(mmol/L)
5.40 5.30 Systematic review 62 5.26 5.22 PORMETS study 34 
Body mass index 
(kg/m2)
26.2 26.6 Systematic review 63 27.8 28.2 PREVADIAB study 64
Diabetes (%) 5.3 6.2 Systematic review 65 10.2 6.3 PREVADIAB study 64
Physical inactivity (%) 90.1 92.9 National Health Survey 61 67.0 72.4 PORMETS study 34
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eTable 7 Odds ratios for the effect of risk factors (dichotomous: smoking, exercise, diabetes).
Both sexes Men Women
 Young *
OR (99% CI)
 Old †
OR (99% CI)
≤55 years
OR (99% CI)
>55 years
OR (99% CI)
≤ 65 years
OR (99% CI)
> 65 years
OR (99% CI)
SMOKING 24 3.33 (2.86-3.87) 2.44 (2.10-2.84) 3.33 (2.80-3.95) 2.52 (2.15-2.96) 4.49 (3.11-6.47) 2.14 (1.35-3.39)
EXERCISE 24 0.95 (0.79-1.14) 0.79 (0.66-0.94) 1.02 (0.83-1.25) 0.79 (0.66-0.96) 0.74 (0.49-1.10) 0.75 (0.46-1.22)
DIABETES 24 2.96 (2.40-3.64) 2.05 (1.71-2.45) 2.66 (2.04-3.46) 1.93 (1.58-2.37) 3.53 (2.49-5.01) 2.59 (1.78-3.78)
99% CI – 99% Confidence interval; OR – odds ratio.
* Men ≤55 years and women ≤65 years; † Men >55 years and women >65 years.
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eTable 8 Description of the studies that provided data for the Portuguese IMPACT model.
Study Description of the study
EDIFICA 35 Acute heart failure prospective registry, in which all patients admitted due to acute heart 
failure (n=491) to the Internal Medicine Department of a tertiary care, university hospital 
(Hospital de São João, Porto) were included, during a 22-month period (2009 and 2010). 
The European Society of Cardiology guidelines 69 were used for the diagnosis of heart 
failure. Treatment during hospitalization and prescriptions to ambulatory upon hospital 
discharge were left at the discretion of the attending physicians and recorded in the 
registry.
EPIPORTO 32, 36 Population-based cohort of 2485 randomly selected dwellers from Porto, Portugal, aged 
≥18 years, assembled in 1999–2003 (baseline). A follow-up evaluation was conducted 
from 2005 to 2008 and the proportion of participation was 70%. Most of the data 
collected was objectively measured, but chronic angina and heart failure were self-
reported. Medication was recorded after review of all the medicines taken chronically in 
the previous year by the participants.
EURHOBOP 21 The EURHOBOP is a multicenter retrospective study of patients hospitalized with a 
final diagnosis of acute coronary syndrome consecutively discharged from 70 hospitals 
in 7 European countries. The 10 Portuguese hospitals were a convenience sample of 
public hospitals, covering the mainland country from north to south and east to 
west, serving urban and rural populations. The hospitals have diverse characteristics, 
regarding facilities, infrastructure and human resources’ specialization. The main source 
of information was the discharge letter, and information on emergency room records 
and laboratory information systems was accessed, whenever available. The final sample 
had 3009 patients. 
NATIONAL HEALTH SURVEY 61 Community-based cross-sectional study that evaluated a sample of the Portuguese 
population, representative at the national and regional levels, obtained through complex 
stratified and cluster sampling. Several surveys were conducted over time, and we 
included data from the national health survey performed in 1995-1996 (n=38504). The 
data collected was self-reported. 
NATIONAL HOSPITAL 
DISCHARGE REGISTRY 31
Data from all individuals admitted in all public hospitals, centrally held in the Central 
Administration of the Health System for Portugal. The national health service provides 
universal access to health care and, until very recently, severe acute events like an acute 
cardiovascular event were almost exclusively treated in public hospitals.
PORMETS 34 This study included two primary health care centres from each of the 18 Portuguese 
mainland districts, one from the district’s capital and another representative of the 
nonurban area. In each centre 120 participants were selected at random for inclusion. 
A total of 4105 participants were included between February 2007 and July 2009. The 
data collected was objectively measured. Medication was recorded after review of all the 
medicines taken by the participant.
PREVADIAB 64 Random sample of people aged between 20 and 79 years, selected from 122 locations 
(units) representative of the distribution of the Portuguese population. Of 8140 
participants invited to participate in the study, 83.8% took part. The data collection was 
concluded in January 2009. The data collected was objectively measured.
SYSTEMATIC REVIEW for risk 
factor estimates 33, 62, 63, 70
Comprehensive review that addressed the distribution of six major cardiovascular 
risk factors, including hypertension, obesity, dyslipidaemia, diabetes mellitus, smoking 
and physical inactivity, in Portuguese adults. The search was performed in Pubmed 
from inception to November 2011. The reference lists of review articles addressing the 
distribution of cardiovascular risk factors were screened to identify potentially eligible 
original reports.
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4. Discussion
Coronary heart disease monitoring and evaluation, in the approach proposed for 
this thesis, requires comprehensive and accurate population-based information 
on time trends in mortality, morbidity, risk factors and treatment uptake. We 
aimed to consider all valid and reliable data to describe the disease burden and 
the provision of health care. A useful by-product of this work is a systematic 
assessment of the availability and quality of descriptive data on CHD in Portugal. 
In contrast with Northern European countries, where very good CHD monitor-
ing systems were developed and implemented, available information on CHD in 
Portugal was frequently biased or simply not available. Linkage of multiple data 
sources, such as vital statistics, data on hospitalization episodes and censuses 
is not possible, and there is no access to data from primary care collected sys-
tematically at a national scale. There is also the disadvantage of not having con-
sistently participated in international surveys and registries, namely in the Euro 
Heart Survey, promoted by the European Society of Cardiology. 
We started by describing and quantifying the time trends in mortality from car-
diovascular diseases in the Portuguese population (Paper I). To interpret these 
trends in context, we analyzed the same information for cancer, due to the high 
and increasing burden of this other large group of chronic diseases. Also, cardio-
vascular diseases and cancer share some important determinants and play an 
important role as mutual competing risks. Data from the official statistics were 
easily accessible both electronically and in published form.
A series of surveys on nationally representative samples, combining interviews, 
physical examinations and laboratory data, would be ideal to assess the dis-
tribution of major cardiovascular risk determinants in the country over time. 
Unfortunately, the Portuguese National Health Surveys, conducted 4 times since 
1987 83-86, did not include physical examinations or laboratory tests, precluding 
the evaluation of the frequency of risk factors based on objectively measured 
information. 
A systematic review may allow the identification of studies and describe them 
in a standardized format, accounting for the methodological aspects from each 
study that may compromise their internal and external validity. Therefore, we 
decided to use this approach to address the mean population levels of body 
mass index, blood pressure, fasting blood glucose and serum lipids, as well as 
the prevalence of diabetes mellitus, dyslipidemia, hypertension, obesity, phys-
ical inactivity and tobacco consumption, in Portuguese adults. In addition to a 
Pubmed search, the reference lists of review articles addressing the distribution 
of cardiovascular risk factors were screened to identify potentially eligible orig-
inal reports. Important large studies that covered the outcomes of interest of 
which existence we were aware were confirmed to be captured by the electronic 
search. We relied on stratification to take into account important methodological 
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options adopted in each study, such as the method of data collection, sex, age 
and setting, as appropriate. 
In fact, this large review is a sum of several reviews, for the individual risk factors 
considered 87-92. In this thesis, we present the reviews on blood pressure and dia-
betes mellitus (Papers II and III), which contributed with estimates of those risk 
determinants to the CHD policy model. The reviews regarding the secular trends 
of the other risk factors contributed not only for the interpretation of the results 
of the IMPACT model, but also to the better understanding of the cardiovascu-
lar risk factor as a whole in Portugal. We conclude that this was an appropriate 
approach to deal with the absence of national studies reporting data objectively 
measured in the 1900s, though it resulted in little added value for some risk fac-
tors such as physical inactivity and dyslipidemia. 
The risk factors data inputted in the model was obtained from different sources. 
For the last year, 2008, we used data from two large national cross-sectional 
studies, which based their estimates on data collected using standardized meth-
ods through interviews and physical examinations. For the baseline year, we used 
data obtained in the National Health Survey, 1995-96, for risk factors that were 
not influenced by the awareness of the participants; and the estimates obtained 
in the systematic review when the data needed to be objectively measured.
A comprehensive and updated disease registry would be the ideal source of data 
about treatments on coronary heart disease.
Regarding acute events, The National Registry of Acute Coronary Syndromes is 
an excellent opportunity for reviewing data on acute coronary syndrome treat-
ment and to characterize the patients. This prospective and continuous registry 
started in 2002 and involved 45 Portuguese hospitals 92. However, it was assumed 
by its coordinators to be voluntary in nature and not to cover a representative 
sample of all events in the population, since only cardiology departments partic-
ipate (not internal medicine or other wards), not all hospitals participated, those 
who do may not have contributed consistently over time and in each institu-
tion consecutiveness of data extraction is not ensured. This registry sums up a 
cumulative number of registers surpassing tenths of thousands over practically a 
decade and has filled in an important gap in information in the country. However, 
for the population-based data required for an approach such as the aim of policy 
models, it has important limitations. Age- and sex-specific data from this registry 
was kindly provided by the Portuguese Society of Cardiology, and was essential 
to support the results obtained in the Papers V and VI of this thesis. The national 
hospital discharge register covers all episodes in all National Health Service insti-
tutions. However, it contrasts with the former cardiology registry regarding a 
very low refinement of clinical information, reflecting the fact that this database 
has an administrative purpose, namely supporting the funding of hospitals by the 
Ministry of Health. 
Regarding stable angina there was a huge lack of data. Even the prevalence of 
stable CHD in Portugal is unknown. The PULSAR registry aimed to quantify and 
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prospectively characterize patients with stable CHD in 2009 94. Although it is the 
largest registry of patients with stable coronary artery disease in Portugal, the 
sample included is highly selected by virtue of patients being followed mainly 
by cardiologists in private practice. We also contacted institutions or societies 
that could be expected to have data regarding this disease, namely the National 
Data Center in Cardiology from the Portuguese Society of Cardiology, and the 
National Institute of Health, considering their network of general practitioners 
(Rede Médicos-Sentinela), but both kindly replied that they had no national or 
regional data on chronic angina. Estimates for chronic angina, both of its preva-
lence and patters of management, have in general been difficult to obtain also in 
other countries 10.
Following the same approach used to obtained estimates for risk factors, we 
conducted a systematic review of the literature using Pubmed as the search 
engine to identify the studies that provide data on the proportion of use of prog-
nostic-modifying therapies, including pharmacological and non-pharmacological 
therapies, for the treatment of acute coronary syndrome, stable angina and heart 
failure in Portuguese patients. The studies identified were extremely heteroge-
neous in their methodology and for some kinds of interventions did not cover a 
long period. We gathered, analyzed and summarized the data in two different 
papers: one with data on the use of reperfusion and revascularization procedures 
following an acute coronary syndrome (article submitted and undergoing peer 
review, not included in this thesis), and another reviewing data on secondary 
pharmacological therapy following an ACS (Paper IV). At the end, we conclude 
this was a time-consuming task with relatively low yielding to deal with the lack 
of data on this issue. A deep analysis of the particular studies included revealed 
that the generalizability of the results is debatable, since it is likely that the esti-
mates obtained reflect mostly the usual care in higher quality specialized centers 
of the public system, yielding an overestimation of the proportion of patients 
treated in the country. 
In this context, data from a consecutive sample of the patients recruited in a 
large hospital sample seems to be the best option to obtain unbiased estimates. 
The EURHOBOP study, an European project that aims to define a set of indica-
tors of in-hospital mortality determined by the quality of treatment of patients 
with myocardial infarction or unstable angina, provide data on treatment in 
Portuguese patients 95. Three hundred patients were obtained consecutively in 
each of the 10 hospitals included. These were a convenience sample of public 
hospitals, selected to cover the mainland country from North to South and East 
to West, while serving both urban and rural populations. The data was retro-
spectively collected using the medical records. The data obtained in this study 
provided the estimates used in Paper V and allowed us to have good estimates 
of treatment uptake for the final year of the model (Paper VI). 
Data on the long-term effect of risk factors and treatment uptake levels in rep-
resentative samples of the general population are not easily available for most 
countries, because such studies are not easy to perform, as they traditionally 
require following large cohorts over years or decades. Furthermore, these 
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studies often have issues related to generalisability. Modeling studies potentially 
offer the opportunity to gather data from two specific years and generate valid 
conclusions relevant for policy makers.
We decided to model the decline in CHD mortality in Portugal, since no study 
analyzed this fall previously and authors diverge about the main cause for this 
decline in other countries. We selected the IMPACT model because it compre-
hensively includes all standard treatments and all major risk factors and was 
already applied and validated in other populations 78-80, 96-108. 
One of the assumptions of the IMPACT model is that the decline between the 
baseline and the final year is linear. To accomplish this assumption, we made an 
analysis, using the same methodology applied in Paper I for CHD mortality rates, 
to indentify the period that fulfills this criterion. Since we did not identify any 
inflection point in CHD mortality rate between 1995 and 2008 (data not shown), 
and in 1995 there was a National Health Survey that would provide relevant data 
on some risk factors, we decided to use this as the baseline year. The final year 
was the latest with available data.
Figure 9 describes the main results in the settings where the IMPACT model was 
applied. The effect of reductions in risk factors was higher than the effect of 
treatments in all countries, except in the USA and Portugal. The results obtained 
in Iceland, Northern Ireland and Syria indicated that major risk factors explained 
more than 60% of the fall in coronary mortality. In Beijing, China, the coronary 
heart disease mortality is rising and can be explained especially by rises in total 
cholesterol 109.
In Portugal, treatments explained half of the overall decline in CHD deaths and 
42% was explained by risk factor changes. The decrease in mean blood pressure 
and increase in hypertension treatment contributed most to the CHD mortality 
decline, although the rise in the prevalence of diabetes and mean body mass 
index in both sexes, and in smoking prevalence among women generated addi-
tional deaths. Portugal has been described as one of the countries with highest 
median blood pressure levels 110 but had remarkable decreases in systolic blood 
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pressure in the last decades 89. Data on trends in food intake in Portugal indicate 
that diet changed dramatically between 1987 and 1990, mainly among adults 
under 65 years, shifting from a traditional, Southern European diet, to a more 
Westernized, protein-rich diet 111. This could be reflected in the increasing obesity 
and diabetes observed in our population. The results of the application of the 
IMPACT model in Portugal encourage the utilization of comprehensive efforts 
to actively promote primary prevention, particularly a healthy diet and tobacco 
control as well as maximizing the population coverage of effective treatments. 
The proportion of deaths unexplained by the model is justified since there were 
some CHD risk factors that were not included in the model, such as alcohol or 
fruit and vegetables consumption. Numerous minor risk factors may make an 
additional but small contribution, since they are highly correlated with other risk 
factors already included in the model. 
When analyzing the results presented in Figure 9 one cannot ignore the fact 
that in Portugal the magnitude of the decrease in CHD mortality over the period 
considered was smaller than the observed in other countries. The low deaths 
rates observed in the baseline year and/or the period considered could explain 
the 25% decrease in CHD mortality rates in Portugal, while even in the Southern 
European low-risk countries the decline was around 40% 97, 105. We could also 
speculate that this attenuation in the decline observed in Portugal, could rep-
resent the observed flattening in CHD risk factors distribution and mortality in 
young adults already seen in many countries, proving that favourable trends can 
reverse 112-115. The flattening in CHD mortality trends have occurred in spite of 
the increasing use of evidence-based therapies, suggesting that unfavourable 
recent trends in risk factors in young adults may explain these changes, specifi-
cally increases in obesity and diabetes compounded by stable cholesterol levels 
and blood pressure. Additionally, the deterioration of the economical situation 
in some European countries, may contribute to the flattening in the CHD mor-
tality rates trends in the near future, since the most deprived groups are those 
with higher CHD mortality rates 116. These facts suggest that the cardiovascular 
disease epidemic could not be fully controlled and the trends in risk factors and 
CHD mortality in the next decades need to be monitored for best support of 
decisions and health plans. 
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5. Conclusions
The last decades of the 20th century witnessed a dramatic decrease in cardio-
vascular disease mortality and years of life lost in Portugal, along with a recent 
transition towards a higher burden of cancer. 
As for the contribution of risk factors for the decline, these studies focused on 
the trends of hypertension and diabetes. Between 1990 and 2005, the preva-
lence of objectively defined hypertension remained stable in younger adults and 
decreased in middle-aged and older adults, whereas self-reported hypertension 
increased in both sexes and all age groups. Between 1975 and 2005, mean sys-
tolic blood pressure decreased in men after middle-aged and women at all ages. 
These results suggest an increasing awareness of hypertension that translates 
into a higher treatment proportion, resulting in a decrease in blood pressure level. 
Adverse trends were observed for diabetes mellitus, between 1987 and 2009, with 
an increase in the prevalence of self-reported diabetes in middle-aged and older 
adults, and in mean fasting glucose in all adult ages, both in women and men.
There was an improvement in the use of the recommended pharmacological ther-
apy for secondary prevention after an acute coronary syndrome, with the vast 
majority of patients currently receiving antiplatelet therapy, statins, beta-block-
ers and angiotensin-converting-enzyme inhibitor inhibitors. Of note, there was 
also a change towards earlier start of therapy before discharge. In 2009, the vast 
majority of patients received evidence-based pharmacological treatment, but only 
half were discharged with the combination of the recommended 5 drugs (aspi-
rin, clopidogrel, beta-blockers, angiotensin-converting-enzyme inhibitor inhibitors 
and statins). Further improvements are necessary, especially in elderly patients.
When modeling the 25% decrease in coronary heart disease mortality in Portugal 
between 1995 and 2008, we observed that the reductions attributable to evi-
dence-based medical therapies accounted for approximately 50% fewer deaths, 
and approximately 42% of the fall was due to the trends in major risk factors. 
The decrease in mean blood pressure and increase in hypertension treatment 
contributed most to the coronary heart disease mortality decline. The rise in 
diabetes and body mass index in both sexes and in smoking among women gen-
erated additional deaths. 
This thesis helped to clarify the contribution of primary and secondary CHD pre-
vention to mortality trends in Portugal. The high treatment uptake after disease 
suggests that the quality of health care in CHD secondary prevention is good. 
Healthier lifestyles have the potential to be further implemented, particularly 
since some of the observed decline in main risk factors was due to pharmaco-
logical treatment. On the one hand, this thesis supports the need for a greater 
investment in primary prevention, mainly through whole population strategies; 
on the other hand, it also provides objective evidence for the importance of med-
ical treatments, particularly to fight against age-related inequalities.
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